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Abstract
Oxytocin is synthesised within the brain mainly in the neurones of the supraoptic
nucleus and the paraventricular nucleus in the hypothalamus. Oxytocin is involved in the
regulation of several physiological functions and behaviours including male sexual
behaviour. Alpha-melanocyte-stimulating hormone (a-MSH) is produced in the brain
mainly in the neurones of the arcuate nucleus. a-MSH acts centrally in behaviours
including male sexual behaviour via MC3 and MC4 receptors. These central actions are
remarkably similar to those mediated by central oxytocin. They both induce penile
erection and enhance copulatory behaviours when given centrally. Projections between
the arcuate nucleus and the supraoptic nucleus (SON) have been described and MC4
receptor mRNA is expressed in the SON and in the PVN. Oxytocin and a-MSH are both
secreted from the pituitary gland into the blood, and peripheral injection of oxytocin or
a-MSH enhances male sexual behaviour. Taken together these observations suggest that
their actions are not independent and that oxytocin and a-MSH could interact to regulate
male sexual behaviour.
Firstly, changes in peripheral secretion of oxytocin and a-MSH, and oxytocin
and a-MSH neuronal activity were studied during copulation. Intromission increased
plasma concentration of both oxytocin and a-MSH and Fos expression in neurones in
the SON, in the PVN and in the arcuate nucleus was increased.
The putative interaction between oxytocin and a-MSH was then investigated by
probing at which central or peripheral level this interaction would occur.
Oxytocin antagonist iv-injection had no effect on the intromission -induced
secretion of oxytocin and a-MSH, suggesting that peripheral oxytocin does not regulate
peripheral a-MSH secretion. However, central administration of oxytocin to non-mating
conscious rats decreased plasma a-MSH concentration, suggesting that central oxytocin
may regulate the peripheral secretion of a-MSH. These studies therefore confirm an
interaction between central oxytocin and a-MSH.
iii
Then, the effects of central a-MSH on oxytocin secretion and neuronal activity
were investigated. Intracerebroventricular administration of a-MSH induced Fos
expression in magnocellular oxytocin neurones in the SON and in the PVN but had little
effect on parvocellular oxytocin neurones. a-MSH directly administered onto the SON
induced a strong increase in Fos expression in oxytocin neurones in the SON. These
studies indicate that a-MSH modulates directly the activity of selected oxytocin
neurones and that consequently, a-MSH may regulate some specific oxytocin effects
and not others. However, central administration of a-MSH decreased oxytocin secretion
from the pituitary gland. This illustrates that Fos induction is independent from the axon
terminal secretion and therefore that it does not necessarily reflect electrical excitation
of the neurones. Finally, MC4R antagonist centrally administered reduced the Fos
expression induced at intromission in magnocellular oxytocin neurones but had no effect
on the Fos expression in the parvocellular neurones. These studies confirm the direct
modulatory effect of a-MSH on magnocellular oxytocin neurones via MC4 receptors.
Thus, oxytocin and a-MSH interact centrally to enhance male sexual behaviour.
Some a-MSH behavioral effects in male sexual behaviour are mediated by
magnocellular oxytocin neurones rather than parvocellular neurones. The activation of
magnocellular oxytocin neurones by a-MSH via MC4R may result in a central release
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General introduction Chapter 1
PART 1: Central regulation ofmale sexual behaviour
1.1. Description of Male Sexual Behaviour:
In rats, mating is orchestrated in bouts where sequences of ordered sexual
behaviours alternate with periods of no sexual activity. When a male rat is presented to a
receptive female, he follows her and sniffs at her anogenital region (Fig. 1.1). He then
starts to mount her, and she responds by adopting the lordosis posture (arched-back
posture) (Fig 1.2). After several mounts, the male achieves intromission, during which
he palpates the female's flanks with his forepaws and stops pelvic thrusting (Fig. 1.3A).
The male may then dismount and display genital grooming behaviour (Fig. 1.3B), and
may repeat the sequence several times before he reaches ejaculation. Before and after
copulation, the male rat emits vocalizations at frequencies of ~ 20-22 kHz. After
ejaculation, the male falls back and displays genital grooming behaviour followed by a
period of sexual inactivity. Another bout of sexual activity may begin after a varied
length of time.
Sexual activity in the male rat can be divided into two distinct phases: an
appetitive phase, and a consummatory phase, a dichotomy first described by Beach and
colleagues in 1956 (Beach, 1967). The first phase is a pre-copulatory or non-
consummatory period during which the male seeks sexual contact by investigating the
female and presents penile erection. This first period, reflecting sexual motivation,
prepares for and leads to the second phase. If during the first phase the stimulation
received and given by both male and female are inadequate to maintain sexual
excitement, copulation may not occur. The second period is the copulatory phase, or
consummatory period, during which the male performs a series ofmounts (first without
intromission and then with intromission) that lead to ejaculation. The period of sexual
inactivity following ejaculation comprises two phases: an absolute refractory period
1
Figure 1.1: Video-extracted pictures illustrating rats sniffing
behaviour during the pre-copulatory phase.
Sniffing behaviour is one of the behaviours reflecting rat's sexual
motivation. When a male and a receptive female rats are paired, they both
investigate each other anogenital regions.
Figure 1.2: Video-extracted pictures illustrating male mounting behaviour (A)
and male mounting behaviour with intromission (B) on female in Lordosis
posture.
Figure 1.3: Video-extracted pictures illustrating male mounting behaviour
with pelvic thrust and putative ejaculation (A) and male grooming
behaviour after copulation (B).
The arched-back male posture indicates a deeper thrust leading to a putative ejaculation,
(ejaculation can only be confirmed by vaginal samples).
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during which the male is insensitive to any sexual stimulation, and a relative refractory
period.
Thus male sexual behaviour is a complex behaviour constituted by numerous
different components such as partner preference, sexual motivation, erection and non-
contact penile erection, performance (copulation and ejaculation), sexual reward and
sexual satiety. It can be difficult to distinguish between these components; so, to
investigate the neural pathways mediating each of these behaviours, it is important to
use appropriate methodological tools (see review Meisel & Sachs, 1994; Agmo, 1997)
and to use behavioral terms and parameters consistently to avoid misleading
interpretations (Appendix 1 regroups a list of definitions of all major behavioral terms
and parameters used throughout this thesis).
1.2 Neural regulation of male sexual behaviour:
Numerous areas of the brain have been reported to be involved in the regulation
of male sexual behaviour based on evidence from lesion studies, electrical stimulation,
local administration of hormones and peptides or by immunocytochemical staining for
Fos, a protein product of the immediate early gene c-fos that is used as an indicator of
neuronal activation (Meisel & Sachs, 1994; Pfaus & Heeb, 1997). Due to the many areas
and the complexity of the pathways, this introduction describes examples of some of the
major brain structures involved in neuronal pathways that regulate male sexual
behaviour in rats. Table 1.1 summarizes the central nervous system (CNS) areas
reported to be involved in the regulation of male sexual behaviour.
Brain areas involved in the regulation of male sexual behaviour play different roles:
some recognize sensory cues from the female, some areas convey the olfactory
information to other brain areas, and some areas control the motor performance. The
specificity of each brain area involved in the regulation of sexual activity is illustrated
by one major pathway originating from the olfactory system, where sensory cues are
o
Behavioral phases regulated
Motivation (detection olfactory cues)
Motivation (detection olfactory cues)























BNST (Bed Nucleus of the Stria Terminalis)
Nucleus accumbens
VTA (Ventral tegmental area)
MPOA (Medial preoptic area)














Table 1.1: CNS areas involved in the regulation of male sexual behaviour.
PE: Penile erection.
Adapted from Meisel & Sachs, 1994; Pfaus & Heeb, 1997; Hamson & Watson, 2004; McKenna,
2004.
Figure 1.4: The rat olfactory system. Adapted from Meredith M. website
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collected, to the limbic system and hypothalamus, where motor copulatory patterns are
regulated (Fig. 1.4):
1.2.1 The olfactory system:
The olfactory system is especially important in the regulation of sexual
behaviour in rodents. It is comprised of the olfactory bulbs (main and accessory) and the
vomeronasal organ. Two different pathways perceive olfactory information:
i. Olfactory information travels through the nasopalatine duct to reach the
vomeronasal organ (VNO). The vomeronasal nerves project to the
accessory olfactory bulbs (AOB).
ii. Olfactory information reaches the main olfactory bulbs (MOB) by the
olfactory nerves originating from the olfactory epithelium.
The AOB and MOB project to central structures that include the medial amygdala, the
bed nucleus of the stria terminalis (BNST) and the medial preoptic area.
In male hamsters, a selective cutting of the vomeronasal nerve has been reported
to disrupt copulation in some studies but not in others (Meredith, 1986; Powers &
Winans, 1975; Winans & Powers, 1977). Destruction of receptors in the olfactory
epithelium induces similar contradictory effects: it has been reported to disturb
copulation in some studies but not in others (Devor, 1973; Lisk et al., 1972; Powers &
Winans, 1975; Winans & Powers, 1977). However, interfering simultaneously with the
VNO and the olfactory epithelium or bilateral olfactory bulbectomy eliminates
copulation (Meisel & Sachs, 1994).
In male rats, Saito et al. (1986) described that surgical removal of the VNO does
not block copulation in sexually experienced rats, nor impair the non-contact penile
erection (NCE) induced by cues from a receptive female, suggesting that desafferrenting
the AOB does not block sexual behaviours. By contrast, Kondo et al. (1999) reported
that lesions of the olfactory epithelium inhibited NCE. This suggests that the
3
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vomeronasal organ is not critical to the development of copulation in male rats, and
indicates that the main olfactory bulbs/ olfactory epithelium system is important in the
establishment of sexual arousal. Olfactory bulbectomy has been reported to reduce the
number of rats copulating to ejaculation (Meisel et al, 1980), and bulbectomized rats
that did mate had longer intromission latencies, suggesting a reduction of sexual arousal.
It is not clear why some olfactory bulbectomized rats still copulate and achieve
ejaculation. No evidence of direct projections from the VNO and from the olfactory
epithelium to central structures involved in the regulation of male sexual behavior has
been reported. This suggests that rats that have lost olfaction have deficits in sexual
behaviour but still have the ability to copulate, illustrating the multi-sensory regulation
ofmale sexual behaviours: although olfaction is predominant in rodent species, other
sensory stimuli (e.g.: visual, auditory, tactile and imaginative) can initiate copulation
using different neural pathways.
1.2.2. The amygdala:
Manipulations of the amygdala disrupt normal display of sexual activity. The
amygdala is comprised of two main regions: the corticomedial amygdala (medial
amygdala), and the basolateral amygdala. The major inputs to the medial amygdala
derive from the olfactory bulbs. Lesions of the basolateral amygdala do not disrupt
copulation and even tend to decrease the onset time to copulation (Harris & Sachs,
1975). By contrast, lesions of the medial amygdala increase ejaculation latencies
(Giantonio et al., 1970).
In the medial amygdala (MeA), Fos expression is increased during sexual
activity, suggesting that the MeA is not only a relay of information to other brain areas
but also that neurones in the MeA are activated to process the information. This increase
in neuronal activity follows two distinct patterns: Firstly, Fos expression in the medial
MeA is induced by sex-related odours, and secondly, Fos expression in the dorsolateral
MeA is increased by ejaculation (Pfaus & Heeb, 1997). This gives evidence that sub¬
divisions in the amygdala have distinct roles in the regulation of male sexual behaviour.
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Thus the MeA receives information from the vomeronasal organ and the
olfactory bulbs, processes it and relays it to other brain areas such as the BNST and the
medial preoptic area.
1.2.3. The bed nucleus of the stria terminalis:
Lesions of the BNST disrupt the male's ability to copulate to ejaculation by
increasing inter-intromission intervals and ejaculation latencies (Emery & Sachs, 1976;
Claro et al., 1995). Coolen et al. (1996) have shown that Fos expression in the
posteromedial part of the BNST (BNSTpm) is increased following sexual activity, and
they also described the existence of clusters of Fos immunoreactivity in specific sub-
regions of the BNSTpm only after ejaculation. They concluded that specific sub-regions
of the BNSTpm were involved in different aspects of sexual activation since different
sexual behaviours induced different patterns of Fos expression. Liu et al. (1997)
reported that, while lesions of the BNST moderately impaired copulation (ejaculation
latencies increased), it severely affected non-contact penile erection. Liu and colleagues
proposed that BNST lesions might impair penile erection by interfering with the
processing of olfactory cues from the receptive female. Pfaus & Heeb (1997) proposed
that the role of the BNST cannot be only the relay of chemosensory information from
the MeA to the medial preoptic area as suggested by Meisel & Sachs (1994), because
lesions of the MeA in sexually experienced rats do not reduce the Fos expression in the
BNST induced by sex-related odors.
Thus the BNST plays an important role in penile erection and in copulation. Its role
appears to be to process chemosensory information as well as to relay this information to
other brain area to maintain sexual motivation and to stimulate copulation.
1.2.4.The medial preoptic area:
The effects of lesions of the MPOA on copulation in rats were first studied by
Heimer and Larsson (1964), they reported that rats with MPOA lesions did not copulate
5
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or display any mounting behaviour when paired with a receptive female. Hansen &
Gummesson (1982) investigated whether the loss of copulatory behaviours after lesions
of MPOA was consequential to interruption of nerve fibres passing through this area to
"deliver" information to another brain area, or due to the destruction of neurones that
process information that is then passed on to other brain areas. They reported similar
effects of electrolytic and neurotoxic lesions, suggesting that neurones within the MPOA
play a role in the processing of sensory information leading to copulatory behaviour.
This suggestion has been supported by Fos studies revealing that sexual activity
increased Fos expression in the MPOA (Pfaus & Heeb, 1997).
It was initially believed that the MPOA was critical in the initiation of sexual
activity because lesions in the MPOA eliminated copulation in sexually experienced
males. Early studies explained the failure of copulation by a reduction of sexual arousal
or motivation (Ginton & Merari, 1977; Edwards & Einhorn, 1986), but Hansen et al.
(1984) described that MPOA-lesioned male rats still investigated the female and even
sometimes mounted her. Everitt et al. (1990) suggested that, in MPOA-lesioned rats, the
failure to copulate did not result from a reduction of sexual arousal but from a failure to
translate signals induced by sexual arousal into copulatory motor patterns.
Thus the MPOA has a critical role in processing the sensory information derived
from sexual motivation during the pre-copulatory period to induce sexual performance
during the consummatory period. The MPOA also has a role in the regulation of penile
erection since MPOA efferents project to the midbrain (Periaqueductal gray) and to the
medulla, two areas that project to the spinal cord to regulate penile reflexes (McKenna,
2000). Thus the MPOA is a key area for the regulation of male sexual behaviour,
involved in both motivation and regulation of sexual performance.
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1.2.5.The paraventricular nucleus:
The paraventricular nucleus of the hypothalamus (PVN) is a very heterogeneous
nucleus consisting of several subdivisions where different cell types are located (Fig.
1.6). In the PVN, a large number of neuropeptides are contained in neurones that project
to many intra and extra -hypothalamic brain areas, to the brainstem and the spinal cord
(Buijs, 1978; Swanson & Sawchenko, 1983; Hallbeck, 2001). Due to this extended
network of neuronal projections and the variety of neurotransmitters identified, the PVN
is considered as an integration centre involved in the control of numerous functions,
including male sexual behaviour. During copulation, Fos expression is increased in the
PVN (Pfaus & Heeb, 1997; Coolen et al, 1996) and lesions of the PVN impair
copulation by increasing mount and intromission latencies (Hughes, 1987). The
identification of projections from the PVN to the lower lumbar regions of the spinal cord
involved in penile reflexes suggests an important role for the PVN in the modulation of
penile erection. Chen et al. (1997) reported that electrical stimulation or chemical
stimulation (by glutamate) of the PVN increased the intracavernous pressure (ICP) along
with visible erection and ejaculation. The PVN has been recognized to be the site of
action of many peptides and neurotransmitters involved in the regulation of male sexual
behaviour. Indeed, penile erection can be induced by injection of oxytocin, or
apomorphine, or NO donors into the PVN (Melis & Argiolas, 1997).
Thus the PVN is mainly involved in the regulation of sexual performance.
However, its role in the regulation of sexual motivation should not be excluded, as,
during copulation, the establishment of penile erection also reflects the rat's aroused
state. Due to the presence of many neurotransmitters within the nucleus, the PVN is a
site of crucial interactions between different systems that modulate copulatory
behaviour. To understand the role of the PVN in the regulation of copulatory behaviour
in a more detailed manner, the investigation of the role of each of these peptides and
neurotransmitters is required. The mechanisms of action of dopamine, oxytocin and
nitric oxide and their interactions are described section 1.3 and in section 2.
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Taken together, these few examples of brain areas illustrate the high organization
of the complex neuronal network involved in the regulation of male sexual behaviour.
While some brain areas are more specialized in the detection and the integration of
chemosensory cues (e.g.: medial amygdala, BNST), others regulate the motor patterns
crucial to sexual performance (e.g.: MPOA, PVN, Brainstem). However, a clear
dichotomy is hard to draw as several of these brain areas have roles in both sexual
motivation and performance, and even some of these brain areas are also themselves
organized in subdivisions that regulate specific aspects of the male sexual behaviour.
1.3. Peripheral regulation of penile erection:
Penile erection is one component of a series of complex physiological events
constituting male sexual behaviour and is regulated via both central and peripheral
neural pathways (see reviews Steers, 2000); Guiliano & Rampin, 2004). Penile erection
depends upon adequate blood inflow to erectile tissues, coordinated dilatation of the
penile arteries and relaxation of erectile tissues. As a vascular event, penile erection is
therefore controlled by the autonomic nervous system. Parasympathetic and
thoracolumbar sympathetic pathways innervate the penis, and while parasympathetic
pathways are pro-erectile, sympathetic pathways are anti-erectile and related to
detumescence. The penis also receives somatic innervations via the dorsal nerve of the
penis, facilitating penile rigidity.
Fig 1.5 represents a schematic illustration of the autonomic pathways controlling penile
erection.
1.4 Neurochemical and hormonal regulation of male sexual behaviour:
Numerous neuromodulatory factors including peptides and hormones have been




Figure 1. 5: Peripheral and central neural pathways controlling penile
erection.
The penis receives innervations from sacral parasympathetic (pelvic), thoracolumbar
sympathetic (hypogastric & lumbar sympathetic chain) and somatic (pudental) nerves.
The parasympathetic nervous system is the major excitatory input to the penis,
inducing vasodilatation of the penile vasculature and therefore erection. Descending
brain pathways control lumbar sympathetic and sacral parasympathetic outflow to the
penis. The brain also receives sensory information from the penis via ascending spinal
pathways.
Adapted from Steers W.D. Neurosc. Biobehav. Rev. (2000)
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see Meisel & Sachs 1994; Argiolas, 1999). Table 1.2 summarizes the central effects of
some of these neuromodulators. The present introduction mainly focuses on selected
factors that have been most studied. The role of oxytocin and ACTH -related peptides
such as a-MSH is described in the following parts of the introduction (see Part 2 & 3,
Chapter 1).
1.4.1 Dopamine:
Dopamine is the factor that is the most studied in the regulation of male sexual
behaviour. In brief, dopamine facilitates male sexual behaviour. In one of the first
studies on dopamine and sexual behaviour, Tagliamonte & Gessa (1974) reported that
systemic injection of L-DOPA (dopamine precursor) combined with an inhibitor of
DOPA carboxylase increased by 50% the number of sluggish male rats that reached
ejaculation. However, the role of dopamine in male sexual behaviour is complex:
systemic injection of apomorphine (a dopamine agonist) has a biphasic effect on male
sexual behaviour as a function of the dose injected. While low doses of apomorphine are
facilitative of copulation, high doses tend to inhibit copulation in male rats (Clark &
Smith, 1987; Paglietti et al., 1978).
i. Dopamine systems involved in the central regulation ofmale sexual behaviour:
Dopamine acts on different aspects of the male sexual behaviour via three different
dopamine systems:
The mesolimbic dopamine system:
The mesolimbic system originates in the ventral tegmental area (VTA) and projects
to several terminal fields including the nucleus accumbens. The mesolimbic system is
critical for appetitive behaviours and plays a major role in the anticipatory, pre-
copulatory phase of sexual behaviour (Everitt, 1990; Hull et al., 1999; Argiolas, 1999).
In the nucleus accumbens, the concentration of extracellular dopamine is increased in
males when they are stimulated by cues from a receptive female (Damsma et al., 1992)
but not when they are presented to a non-receptive female (Wenkstern et al., 1993).
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Chemical messengers Effect on sexual behaviour
Dopamine Facilitatory
Serotonin Inhibitory/ Facilitatory
Prolactin Inhibitory (Hyperprolactinemia) ?
ACTH/ MSH peptides Facilitatory














Table 1.2: Central effects of chemical messengers on male sexual behaviour.
Adapted from Meisel & Sachs, 1994; Argiolas, 1999; Hull, 1999; Guiliano & Rampin, 2001.
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Injections into the nucleus accumbens of D-amphetamine (that acts by releasing
dopamine) reduce mount- and intromission- latencies (Everitt, 1990). Hull et al. (1986)
reported that injection of apomorphine into the nucleus accumbens slightly decreased
intromission latency whereas the injection of apomorphine into the VTA increased
intromission latency. Taken together, these results show that the mesolimbic dopamine
system is involved in the anticipatory and motivational phase of male sexual behaviour
as well as being part of the rewarding process of sexual behaviour, since the VTA and
the nucleus accumbens are part of the 'rewarding -related behaviours' pathways.
The nigrostriatal dopamine system:
The nigrostriatal dopamine system originates in the substantia nigra and projects to
the striatum, and is important in the coordination between sensory stimuli and motor
performance. Dopamine is released in the striatum during the consummatory phase of
sexual behaviour (Damsma et al., 1992), suggesting that the nigrostriatal dopamine
system is involved in motor processes related to consummatory behaviours rather than
the motivational aspects of copulation (Everitt, 1990; Hull et al., 1999).
The incertohypothalamic dopamine system:
The two structures the most studied in the incertohypothalamic dopamine system are
the medial preoptic area (MPOA) and the paraventricular nucleus (PVN). Injection of
apomorphine into the MPOA (0.5pg) decreases the mount latency, the numbers of
intromissions required to reach ejaculation and increases the number of ejaculations
(Hull et al., 1986). Microdialysis studies revealed that concentrations of dopamine and
dopamine metabolites in the MPOA are increased during copulation and decline after
ejaculation (Hull et al., 1993). Similar observations have been made for the role of
dopamine in the PVN. Injections of apomorphine in the PVN decreased the mount
latency and the number of intromission required to reach ejaculation (Melis and
Argiolas, 1995). The PVN is also thought to be the site of action of dopamine in
regulation of penile reflexes. Melis et al. (2003) reported that, during erection,
extracellular concentrations of dopamine are increased in the PVN. Moreover, injection
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of apomorphine into the PVN stimulates spontaneous erection (Melis et al, 1987) while
lesions of the PVN reduce apomorphine-induced erection (Argiolas et al., 1987).
Nevertheless, the role of dopamine in the regulation of penile erection is not yet clearly
defined.
Undoubtedly the incertohypothalamic dopamine system plays a role in the
regulation of consummatory behaviours, but there is growing evidence that dopamine in
the MPOA facilitates the anticipatory phase as well as copulatory performance. The
MPOA receives sensory inputs from the mesolimbic system (from VTA) and from the
olfactory system. Hull et al. (1995) found that concentrations of extracellular dopamine
in the MPOA in males were increased during pre-copulatory exposure to a receptive
female while non-sexual social stimuli did not induce any significant increase,
suggesting that the dopamine released in the MPOA could influence sexual motivation.
ii. Dopamine receptors involved in the regulation ofmale sexual behavior:
Two types of G-protein coupled receptors, distributed throughout the brain, have
been identified as mediating the effects of dopamine: D1 and D2 receptors. While the
role of D1 receptors is not clearly defined, D2 receptors appear to play a major role in
the regulation of copulatory behaviours. Hull et al. (1989) reported that in the MPOA,
D1 and D2 receptors have opposite roles in copulation: injection in the MPOA of the
selective D2 agonist (LY 163502) had the same effect as an injection of a D1 antagonist
(SCH 23390): both increased the mount and intromission latencies. In the PVN, D1
receptors have also been reported to be functionally antagonistic to D2 receptor -
mediated facilitative actions on penile responses (Eaton et al., 1991).
Through three different dopamine systems and by interacting with other
hormones or neuropeptides systems such as testosterone, oxytocin, opioids and nitric
oxide (for review see Melis & Argiolas, 1995; Hull et al., 1999), dopamine plays an
important role in all aspects of male sexual behaviour during both pre-copulatory
11
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(arousal) and copulatory (performance, erection, seminal emission) phases and possibly
in reward too.
1.4.2 Opioids:
Endogenous opioids and opioid receptors are distributed throughout the CNS
(Mansour et al., 1988), including in central structures involved in the regulation of male
sexual behaviour. Although opioid effects on male sexual behaviour have been
generalized as inhibitory, opioids have a dual effect: they facilitate appetitive behaviours
but inhibit consummatory behaviours.
Endogenous opioids have been reported to facilitate on sexual motivation (Band
& Hull, 1990; Meisel & Sachs, 1994; Argiolas, 1999). However, systemic injection of
morphine decreases the number of rats that copulate, and increases the mount and
intromission latencies (Agmo & Parades, 1988). Central administration of (3-endorphin
or met-enkephalin also has inhibitory effects on copulatory behaviours (Argiolas, 1999).
When injected systemically or centrally, naloxone, an opioid antagonist, facilitates
copulation by reducing mount, intromission, and ejaculation latencies, and by decreasing
the number of intromissions to achieve ejaculation (Van Furth et al., 1994); but injection
of naloxone also increases the post-ejaculatory interval (Szechtman et al., 1981; Miller
& Baum, 1987). This illustrates the complex dual effects of opioids on sexual behaviour
and indicates that opioids might be involved in the initiation of a new mating sequence
after an ejaculation has occurred.
The different effects of opioids on sexual behaviour might be explained by the
numerous sites of action that opioids have in the brain. Opioids have been reported to act
in the MPOA, in the MeA, in the ventral tegmental area (VTA), in the nucleus
accumbens, and in the PVN. During sexual behaviours, the MPOA has been reported to
be the main site of inhibitory opioid actions, which are probably mediated via p -opioid
receptors (Coolen et al., 2004). The p -opioid agonists, morphine, (3-endorphin and met-
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enkephalin injected into the MPOA inhibit copulation in a dose-dependent manner
(Leyton & Stewart, 1992; Hughes, 1987, 1990). Injection of (3-endorphin into the MeA
delays copulatory behaviour (McGregor & Herbert, 1992), suggesting that opioids
interfere with the processing of the olfactory cues in the MeA. Injection of morphine or
dynorphin into the VTA facilitates copulation and repeated injections of morphine
increase dopamine transmission in the nucleus accumbens, which has a stimulatory
effect on sexual motivation (Mitchell & Stewart, 1990). Injection of morphine into the
PVN prevents penile erection induced by oxytocin (Melis et al. 1992) or by the
proerectile peptide hexarelin (Succu et al., 2003). Finally, opioids, through the VTA and
the nucleus accumbens, might also participate to the stimulation of sexual motivation
and sexual reward by acting on the mesolimbic dopaminergic system (Van Furth & Van
Ree, 1996).
1.4.3 Nitric oxide:
Nitric oxide (NO) has a well-known role in the peripheral mediation of penile
erection (Rajfer et al., 1992) but is also implicated in the central regulation of penile
erection. NO synthase (NOS) is highly concentrated within the CNS in areas involved in
the regulation of sexual behaviours such as the MPOA, the PVN and the spinal cord
(Bredt et al., 1990), and NOS mRNA expression in the PVN is twice as abundant in
sexually potent rats as in impotent rats (Benelli et al., 1995). Melis et al. (1993) showed
that i.c.v injection of NOS inhibitors inhibited penile erection induced by dopamine, by
oxytocin, or by ACTH. NO donors such as nitroglycerin or isoamyl nitrite injected i.c.v.
induced penile erection in a dose-dependent manner (Argiolas, 1994). Melis & Argiolas
(1997) suggested that the main site of action of NO in the regulation of penile erection
was the PVN. Indeed, injection of NOS inhibitors into the PVN can prevent penile
erection induced by oxytocin or by apomorphine, and NO donors injected into the PVN
induce penile erection similarly as to when injected i.c.v. To support this hypothesis they
reported that injection of oxytocin, or apomorphine at doses that initiate penile erection,
increased NO production in the PVN. To clarify the mechanisms of action of NO, they
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suggested that NO induces penile erection by activation of central oxytocin transmission
as i.c.v. injection of oxytocin antagonists has the same effects as i.e.v. injection of NOS
inhibitors: both prevents penile erection induced by oxytocin, apomorphine and by the
NO donors nitroglycerin and isoamyl nitrite. Melis & Argiolas (1997) attested that,
unlike at the peripheral level, NO does not activate the guanylate cyclase (GC) pathway
in the central regulation of penile erection in the PVN. Indeed, i.c.v. injection of a GC
inhibitor (methylene blue) at low doses failed to prevent penile erection induced by
oxytocin, apomorphine or NO donors.
These results suggest that central NO might be the final mediator of the actions
of several neurotransmitters that are involved in the central regulation of penile erection.
Nevertheless the mechanisms by which NO interacts with other neural systems remain
to be understood. Finally, it is expected that NO facilitates penile erection throughout
copulation. Therefore, studying the regulatory role of NO on penile erection in the
context of copulation rather than during drug-induced penile erection could give
precious information on the real impact of central NO during male sexual activity.
1.4.4 Testosterone:
That normal male sexual behaviour requires testosterone is well-known. Early
studies in the 1800s reported that castrated rats were not able to copulate. Davidson et al.
(1966) described progressive loss of copulatory behaviours within days of castration:
castrated rats first lost the ability to ejaculate, then the ability to mount the female with
intromission, and, finally, castrated rats lost all mounting behaviour. They also described
that the effects of castration could be reversed by s.c. injection of testosterone,
confirming that the depletion of testosterone was inducing the disruption in copulation.
Davidson et al. (1966) also investigated the effect of testosterone implants in different
brain areas in castrated rats. They were the first to suggest that the brain was the
"primary target" for testosterone action in the regulation of copulation, and reported that
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the MPOA and the anterior hypothalamus were the two brain areas most sensitive to
testosterone action in the regulation of male sexual behaviour.
In various tissues including the brain, testosterone can be converted into
estradiol (by aromatization) or into dihydrotestosterone (DHT) (by reduction). Androgen
and estrogen receptors are distributed throughout the brain in areas involved in the
regulation of male sexual behaviour (review Meisel & Sachs, 1994). Implants of
estradiol in the MPOA restored copulation in castrated rats (Christensen & Clemens,
1974). Injection of an estrogen antagonist or injection of steroids blocking aromatization
inhibited the restorative effects of testosterone, confirming that estradiol was necessary
to restore copulation in castrated rats (Beyer et al., 1976). Putman et al. (2003) studied
the effectiveness of the two testosterone metabolites, estradiol and DHT in maintaining
copulation in castrated rats. Rats treated with both estradiol and DHT or with
testosterone (s.c.) copulated normally, but although rats treated with estradiol-alone or
DHT-alone presented intromission behaviours, they failed to ejaculate. This indicates
that both androgens and estrogens are required for normal copulation.
The difference between androgens and estrogens in capacity to maintain sexual
behaviour may be explained by their different ability to interact with other neural
systems or neuropeptides that regulate male sexual behaviour. One major role of
testosterone in male sexual behaviour is to facilitate dopamine release in the MPOA
during copulation. As described in section 1.4.1, dopamine is important for sexual
behaviour, and activation of dopamine receptors in the MPOA facilitates copulation,
sexual motivation and genital reflexes (Hull et al., 1995, 1999). Hull et al. (1995)
showed that the depletion of testosterone by castration inhibited extracellular dopamine
release in the MPOA, which is normally induced when a male is presented to a receptive
female. Putman et al. (2003) reported that s.c. injection of testosterone, or estradiol and
DHT, or injection of each metabolite alone, had different effects on basal concentrations
of dopamine and on dopamine release within the MPOA during sexual behaviour. While
estradiol maintained normal basal concentrations of dopamine in the MPOA that allow
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some copulation, androgens were required for the increase in dopamine release, before
and during copulation, that facilitates ejaculation. This confirmed the complementary
role of testosterone metabolites in the maintenance of copulation, although their
mechanisms of action are yet to be understood. Thus, testosterone, by interacting with
neuronal systems such as the dopamine system, plays a critical role in the normal
mediation of male sexual behaviour.
Taken together, these examples of neuromodulatory factors illustrate the
complexity of interactions between different systems involved in the regulation of male
sexual behaviour. The following two sections of the general introduction focus on the
role of two key peptides involved in the regulation of male sexual behaviour: Oxytocin
and a-MSH.
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PART 2: Oxytocin and male sexual behaviour
2.1. Oxytocin system:
2.1.1. Structure, localization and oxytocin efferents:
Oxytocin is a nonapeptide whose structure was identified in 1953 by Du Vigneaud
and colleagues. Oxytocin is a neurohormone synthesized in the hypothalamus primarily
by neurones in the supraoptic nucleus (SON) and in the paraventricular nucleus (PVN):
i. The SON is a nucleus located at the ventral surface of the brain lateral to the
optic chiasm. Magnocellular oxytocin neurones are distributed throughout the
SON from a ventro-dorsal distribution (anterior SON) to a dorsal distribution
(posterior SON). Supraoptic magnocellular oxytocin neurones project to the
neural lobe of the pituitary via the median eminence.
ii. The PVN is a heterogeneous nucleus located adjacent to the third ventricle.
The PVN is subdivided into several areas where magnocellular and
parvocellular oxytocin neurones are distributed (Fig. 1.6). Axons from
magnocellular oxytocin neurones project to the posterior pituitary, via the
median eminence. Axons from parvocellular oxytocin neurones project to
numerous areas within the CNS such as the limbic system, the hypothalamus,
the brainstem and the spinal cord (Fig 1.6).
iii. Oxytocin cell bodies have also been reported in the accessory nuclei, in the
anterior commissure nuclei, in the anterior and posterior fornical nuclei, in the nucleus
circularis and in the nucleus of medial forebrain bundle (Peterson, 1966; Sofroniew,
1983).
Buijs and colleagues (1978, 1979, 1980, 1985) have extensively described the
network of oxytocin fibres in the CNS of the rat. They detailed oxytocin pathways
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Figure 1. 6: Sub-divisions of the PVN, oxytocin cells distribution and
oxytocin neuronal projections within the CNS.
Parvocellular oxytocin neurones also project to areas within the brain.
ap Anterior parvocellular PVN; pm Posterior magnoceilular PVN; dp Dorsal
parvocellular PVN; vp Ventral parvocellular PVN; Ip Lateral posterior
parvocellular PVN ; 3V Third ventricle. Adapted from Swanson & Kuypers, 1980, J.
Comp. Neurol., 194, 555-570.
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within the hypothalamus but also extra-hypothalamic oxytocin pathways leading to the
olfactory bulbs, the limbic system, the brainstem and the spinal cord. The distribution of
oxytocin fibers is summarized in Table 1.3.
2.1.2. Oxytocin systemic secretion and central release:
At the posterior pituitary, oxytocin is secreted from the magnocellular neurones
into the general circulation and blood-borne oxytocin acts at specific high -affinity
receptors at distant targets including the uterus, mammary glands, testis and kidneys.
Oxytocin is also produced by the Leydig cells in the testis, providing a small additional
source of systemic oxytocin.
The blood-brain barrier prevents the oxytocin secreted into the blood from
penetrating into the brain, but oxytocin is also released within the CNS from the
parvocellular neurones. Although, the secretion of oxytocin from axon terminals is
dependent on the neuronal electrical activity, oxytocin can also be released centrally
from the soma and dendrites of magnocellular neurones independently from the
electrical activity (Pow & Morris, 1989; Ludwig, 1998).
2.1.3. Oxytocin receptors:
Rozen and colleagues (1995) have identified the rat oxytocin receptor gene. The
oxytocin receptor is a member of the G- Protein Coupled Receptor family, it has a seven
transmembrane a-helices with two potential glycosylation sites. Oxytocin receptors are
coupled to Gq/n class GTP binding protein that stimulates the activity of phospholipase
C to initiate a cascade of intracellular events (For review on gene structure and
regulation, receptor characteristics and signal transduction see Barberis & Tribollet,
1996; Gimpl & Fahrenholz, 2001).
OT receptors are widely distributed. In the periphery, oxytocin receptors mRNA
or oxytocin binding sites have been identified in a variety of tissues such as the uterus,
the Leydig cells in the testis, the mammary glands, the kidney, the heart, the thymus, the
adipocytes, the pancreas and the adrenal gland. In the CNS, the distribution of oxytocin
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Table 1.3: Distribution of oxytocin receptor mRNA and oxytocin fibres in the
central nervous system.
Brain Regions OT R OT OT
mRNA binding Fibres
Olfactory system
Olfactory bulb + ? +
Anterior olfactory nucleus +++ ++ +
Olfactory tubercle +++ ++ +
Island of Calleja ND +++ ?
Piriform cortex ++ ? 9
Entorhinal / perirhinal area + + +
Cortical areas
Peduncular cortex ? +++ ?
Insular cortex ? + ?
Cingulate cortex + ND ?
Retrosplenial cortex ? ND ?
Frontal cortex ++ (+) ?
Temporal cortex (+) + 7
Taenia tecta +++ (+) ?
Diagonal band of Broca + ? 7
Basal nucleus of Meynert ND ND 7
Basal ganglia
Caudoputamen +++ ++ ?
Ventral pallidum cell groups ++ +++ ?
Globus pallidus ND ND 7
Nucleus accumbens + + ?
Limbic system
Lateral septal nucleus + + +
Medial septal nucleus ? ? +
Ventral hippocampus + ? +E
Dorsal hippocampus + ? +E
Bed nucleus of stria terminalis +++ +++ +
Amygdaloid-hippocampal area +++ + ?
Central amygdala +++ +++ +E
Medial amygdala ++ + +E
Basolateral amygdala +++ + +E
Parasubiculum and presubiculum ND ++ ?
Dorsal subiculum +++ (+) +
Ventral subiculum +++ +++ +
Circumventricular organs
OVLT + ? +E
Subfornical organ + ? +E
Thalamus & Hypothalamus
Anteroventral thalamic nucleus ND ND +
Paraventricular thalamic nucleus ++ + +
Ventromedial hypothalamic nucleus +++ ++ +
Anterior medial preoptic area +++ ND +E
Suprachiasmatic nucleus + ? +
Supraoptic nucleus +++ (+) +
Paraventricular nucleus ++ (+) +
Dorsomedial hypothalamic nucleus ? 9 +E
Arcuate nucleus + ? +E
Medial tuberal nucleus ND ++ +
Posterior hypothalamic area + ND +
Supramammillary nucleus ++ + +
Lateral mammillary nucleus ND + +
Medial mammillary nucleus ND ND +
Brain stem
Locus ceruleus ? 7 +
Substantia nigra pars compacta ++ ND ++
Medial pars compacta + 7 7
Ventral and Dorsal tegmental area ++ ND 7
Central gray + ND +
Dorsal raphe nucleus + ND +
Reticular nuclei + ND +E
Medial vestibular nucleus + ND 7
Hypoglossus nucleus ++ ND 7
Nucleus of the solitary tract + ND ++E
Nucleus ambiguus +E
Dorsal motor nucleus of the vagus nerve +++ ND +E
Inferior olive nucleus + ND ?
Spinal cord + ND +E
Pituitary gland ND ND +E
Expression: +++ strong; ++ moderate; + weak; (+) at the detection limit; ND Not Detectable;
? Not reported; E Axonal endings.
adaptedfrom Buijs et al., 1979, 1980, 1985; Gimpl G. & Fahrenholz F., (2001).
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receptor mRNA or oxytocin binding sites extends from the olfactory system to the
cortex, hypothalamus, limbic system, brainstem and spinal cord, and is summarized in
Table 1.3.
2.2. Roles of oxytocin:
Oxytocin has been implicated in a variety of physiological functions and behaviours
including regulation of salt and water balance, parturition, milk-ejection reflex,
nociception, regulation of cardiovascular functions, thermoregulation, memory, feeding
behaviour, maternal behaviour, grooming, yawning and sexual behaviour (see review
Richard, 1991). Some of the most well known functions are briefly described below:
2.2.1 Osmolarity:
The structural similarities between oxytocin and the antidiuretic hormone
vasopressin, led to the study of the role oxytocin in the regulation of salt and water
balance. In response to changes in extracellular fluid osmolarity, oxytocin acts centrally
and peripherally to induce physiological and behavioral changes that will restore an
adequate osmolarity. Oxytocin actions include the regulation of sodium appetite and
thirst (behavioral changes) and the regulation of sodium excretion from the kidneys
(physiological changes). In response to osmotic stimulation, such as hypovolemia or
hyperosmolarity, magnocellular neurones are activated in the SON and in the PVN,
modifying oxytocin and vasopressin secretion. For example, i.p. injection of hypertonic
saline increases magnocellular oxytocin neurone activity in the SON (Brimble & Dyball,
1977). Magnocellular neurones from the SON are osmosensitive, as direct
administration of hypertonic saline onto the SON induced an increase in neuronal
activity (Leng, 1980). Magnocellular neurones also receive afferents from other
osmosensitive brain areas including the subfornical organ and the organum vasculosum
of the lamina terminalis (OVLT), and from cardiovascular and visceral inputs.
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2.2.2 Parturition:
In the rat, oxytocin has two important roles in parturition. Oxytocin plays a role
in the expulsive phase and in the timing of parturition. The last days of pregnancy, the
local production of prostaglandins by the uterus is increased, leading to a fall in the
production of ovarian progesterone. As a result, the expression of oxytocin receptors is
increased (Lefebvre et al., 1992). A positive feedback loop between the uterus and the
oxytocin cells exits: There are afferent inputs from the cervix and uterus to the
brainstem. From the NTS, A2 noradrenegic cells project to oxytocin cells, whose
activation, leads to an increase in oxytocin secretion (Douglas et al., 2001). This results
in more uterine contractions directly via oxytocin-receptors located in the myometrium
and indirectly via stimulation of prostaglandins production in other tissues. During
parturition, oxytocin secretion is pulsatile. Each birth is associated with a pulse of
oxytocin secretion triggered by a burst of high electrical activity of the oxytocin cells.
Neumann et al. (1996) showed that centrally released oxytocin stimulates its own release
during parturition by a receptor-mediated positive feedback, and suggested that once
released, oxytocin might be involved in the coordinated activation of oxytocin neurones.
2.2.3 Lactation and the milk-ejection reflex:
Oxytocin stimulates the contraction of myoepithelial cells surrounding the
alveoli and the mammary duct in the mammary gland, inducing milk let down. During
lactation, the pups' suckling stimulates pressure receptors in the skin overlying the
mammary gland. The suckling stimulus triggers synchronized bursts of activity of
oxytocin neurones (Wakerley & Lincoln, 1973). Each burst is sufficient to release
oxytocin, which in turns induces the milk-ejection. The milk-ejection reflex involves
simultaneous activation of the SON and the PVN (Belin & Moos, 1986). This
coordination is under the regulatory influences of other brain areas including the limbic
system (Ingram et al., 1995) but is also under the influences of interaction between each
oxytocin neurones (Neumann et al., 1996).
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The role of oxytocin in lactation is essential. Indeed, in transgenic oxytocin
knockout mice, pups will starve although milk is available. In absence of oxytocin, the
milk-ejection reflex does not occur, inhibiting the milk expulsion from the mammary
gland (Nishimori et al., 1996)
2,2,4, Social behaviours:
Oxytocin is implicated in social behaviours and social recognition mechanisms (see
reviews Insel & Young, 2001; Ferguson, 2003; Carter, 2003). Oxytocin plays an
important role in two selective social behaviours, the maternal behaviour and the less
ubiquitous adult-adult pair bond. Both behaviours require overcoming any avoidance
behaviour and stimulating the motivational attraction to a specific individual (infant or
partner).
2.2.4.1. Oxytocin & maternal behaviour:
Oxytocin has a dual role in the establishment of maternal care, as it stimulates
maternal motivation towards the offspring, and also facilitates the attachment of the
infant towards its mother. In rats and sheep, the maternal behaviour is not spontaneous,
but is initiated by the process of parturition itself. In rats, oxytocin facilitates the onset of
maternal care by overcoming the mother's avoidance behaviours towards the neonates
and by stimulating nurturing behaviours (Pedersen et al., 1985). In sheep, the maternal
behaviour is selective: an ewe will reject any alien lamb; and oxytocin is responsible for
the selectivity of the maternal care that an ewe develops towards her own lamb
(Kendrick et al, 1987; Keverne & Kendrick, 1992). In mice, the role of oxytocin in
developing maternal care is likely to be less critical than in rats and sheep, as oxytocin
knockout mice present normal nurturing behaviour; this might be explained by the fact,
as the difference of rats and sheep that mice present spontaneous maternal behaviour.
Oxytocin also plays a role in the infant-mother attachment. Oxytocin facilitates the
learning processes that allow the pups to recognize its mother olfactory cues, and
influences the vocalization frequencies that a pup produces to signal its isolation to its
mother.
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2.2A.2. Partner preference formation. Pair-bonding:
One model used to investigate the involvement of oxytocin in the pair-bond
formation is the prairie voles and the montane voles. Prairie voles are monogamous and
forms pair bonds after mating. In female prairie voles, central oxytocin facilitates the
development of partner preference formation even in absence ofmating (Williams,
1994; Insel & Hulihan, 1995). By contrast, montane voles are polygamous, and central
oxytocin fails to induce pair bonding (Winslow et al., 1993). In male prairie voles,
oxytocin has no effect on social bonding whereas vasopressin is critical for pair bonds as
central injection of vasopressin antagonist blocks partner preference formation (Winslow
et al., 1993). The species difference can be explained by the difference in receptors
expression. Although the two species share the same oxytocin and vasopressin receptors,
their distribution throughout the brain is different. While oxytocin and vasopressin
receptors are highly expressed in the prairie voles' brain in regions associated with
reward (oxytocin receptors in the nucleus accumbens and the Via receptor in the ventral
pallidum), oxytocin and vasopressin receptors are almost virtually absent from the same
areas in the montane vole brain (Lim et al., 2004).
2.3. Oxytocin and sexual behaviour:
2.3.1. Oxytocin and female sexual behaviour:
Central oxytocin facilitates female sexual behaviour. Injection of oxytocin in the
MPOA increases sexual receptivity (Cadwell, 1992) and oxytocin injection in the VMN
facilitates lordosis behaviour. The effect of oxytocin has been reported to depend on
some estrogen and progesterone as infusions of oxytocin in the VMN induces increase in
lordosis behaviour in females treated with estrogen and progesterone but not in females
treated with estrogen alone (Schumacher et al., 1989).
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2.3.2. Oxytocin and male sexual behaviour:
2.3.2.1. Systemic oxytocin and male sexual behaviour:
Melin and Kihlstrom, in 1963, were the first to mention that oxytocin had facilitative
effects on male sexual behaviour, reporting that i.v. injection of oxytocin reduced the
ejaculation latency in rabbits. In rats, i.v. injection of oxytocin reduces the number of
intromissions required to reach ejaculation (Stoneham et al., 1985), and i.p. injection of
oxytocin shortens the ejaculation latency and the post-ejaculatory interval (Arletti et al.,
1985). Hillegaart et al. (1998) reported an increase in plasma oxytocin concentration
during copulation in sexually nai've rats and there is good evidence for a pulse of
oxytocin secretion at ejaculation (Ivell et al. 1997). Although oxytocin receptors have
been localized in the male reproductive tract including in the testis and in the prostate
(Gimpl & Farenholz, 2001), the mechanisms by which systemic oxytocin acts to
facilitate sexual behaviour remain to be identified. Stoneham et al. (1985) suggested that
systemic oxytocin could 'prime' the male genitalia to respond to subsequent sexual
stimuli and therefore facilitate sexual performance.
2.3.2.2. Central oxytocin and male sexual behaviour:
Oxytocin cells are activated during penile erection. Electrical stimulation of the
dorsal penile nerve excites 50% of oxytocin cells in the PVN (Yanagimoto et al., 1996)
and 60% of oxytocin cells in the SON (Honda et al., 1999), and high concentrations of
oxytocin have been measured in the cerebrospinal fluid at ejaculation (Hughes et
al., 1987). Jirikowski (1992) investigated the effects of three -weeks of sexual activity on
oxytocin immunoreactivity in the hypothalamus in male mice. He described that in
repeatedly-mated males, oxytocin immunoreactivity was increased in many brain areas
including the MPOA, the anterior hypothalamic nucleus, the SON, the PVN and the
median eminence. Jirikowski suggested that this increase in oxytocin immunoreactivity
was likely to reflect stimulation of synthetic activity in oxytocin neurones, and that
sexual behaviour was activating oxytocin production.
23
General introduction Chapter 1
Early studies on the central effects of oxytocin on male sexual behaviour had
contradictory results. Stoneham et al. (1985) reported that i.e.v. injection of oxytocin
increased both mount and intromission latencies, suggesting that central oxytocin
inhibited copulation. In the other hand, Arletti et al. (1985) reported that i.e.v. injection
of oxytocin improved copulation by shortening the ejaculation latency and the post-
ejaculatory interval. A series of studies by Argiolas and coworkers provided additional
information confirming the facilitative role of central oxytocin in the regulation of male
sexual behaviour. In 1986, Argiolas et al. described oxytocin as "the most potent agent
able to induce penile erection so far" in rats, rabbits and monkeys. In rats, they showed
that i.c.v. injection of oxytocin (5-90 ng) induced penile erection and yawning
behaviour. They also reported that i.c.v. injection of the oxytocin antagonist d(CH2)s-
o
Tyr(Me)-Orn -vasotocin inhibited male copulatory behaviour by decreasing the mount
and intromission frequencies and by abolishing ejaculation (Argiolas et al., 1988). Thus,
these results illustrate the facilitative role of oxytocin in the central regulation of male
sexual behaviour.
It is difficult to say whether oxytocin acts on the anticipatory phase as well as on
sexual performance. Most of the studies investigating the role of oxytocin in male sexual
behaviour have focused on the ability of oxytocin to induce penile erection. However,
penile erection reflects the capacity to copulate, but might not consistently reflect
motivation to copulate (Appendix 1). Nevertheless, as described previously, oxytocin
plays an important role in socio-sexual behaviour such as partner preference and pair
bonding. Melis et al. (1999) investigated the effects of oxytocin on sexual arousal. Male
rats were injected i.c.v. with the oxytocin antagonist d(CH2)5-Tyr(Me)-Orn -vasotocin
and then placed in an apparatus where the access to a receptive female was blocked. The
number of non-contact penile erections (NCE, reflecting sexual arousal) was counted.
The oxytocin antagonist reduced the number of NCE, suggesting that oxytocin also
plays a role in sexual motivation as well as sexual performance. However, more studies
clarifying the involvement of oxytocin in the anticipatory phase need to be performed.
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2.3.2.3. Central sites of action of oxytocin:
Melis et al. (1986) reported that the most sensitive brain area for oxytocin
injection to induce penile erection was the PVN. Injection of low dose of oxytocin (3 ng)
into the PVN induced penile erection in 60% of the injected -rats; and lesions of the
PVN impaired oxytocin -induced penile erection (Argiolas et al., 1987). Witt and Insel
(1994) reported that Fos expression was increased in oxytocin neurones in all the
parvocellular subdivisions of the PVN during increasing levels of sexual contact.
Parvocellular oxytocin neurones project from the PVN to many intra- and extra-
hypothalamic areas, including the brainstem and the spinal cord (Fig 1.6), so the sites
where oxytocin can act on sexual behaviour might be widely distributed throughout the
CNS from the hypothalamus to the spinal cord.
Melis et al. (1986) reported that bilateral injections of oxytocin (9 ng) into the
CA1 field of the hippocampus induced penile erection. This was supported by a study by
Chen & Chang (2001) in which they showed that injection of oxytocin into the
hippocampus of male rats increased the intracavernous pressure (ICP: an experimental
parameter used to assess penile erection) and that injection of both oxytocin antagonist
o
(d(CH2)5-Tyr(Me)-Orn -vasotocin) and oxytocin into the hippocampus had no effect on
the ICP. Thus, these results suggest that oxytocin actions in both the PVN and the
hippocampus are involved in the central regulation of penile erection.
A second oxytocin pathway from the PVN has been identified; oxytocin
neurones from the PVN project to the spinal cord. Veronneau-Longueville et al. (1999)
reported the presence of oxytocin binding sites in the thoracolumbar and lumbosacral
segments of the spinal cord, areas already described in the 1890s as the "erection -
generating center". They showed evidence of synaptic contacts between oxytocin
varicosities and lumbosacral parasympathetic pre-ganglionic neurones controlling penile
erection.
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These studies illustrate that the PVN is at the core of the central actions of
oxytocin. Oxytocin is involved in the regulation of copulatory behaviours in different
areas within the CNS via oxytocin projections originating from the PVN. For instance,
oxytocin regulates penile erection via two pathways originating from the PVN, one
reaching the hippocampus, the second one reaching the spinal cord via the ventral
medulla.
2.3.2.4. Mechanisms of action of oxytocin:
The mechanisms of action of oxytocin are poorly understood. Oxytocin is part of
a complex network of neural systems regulating male sexual behaviour, and while
oxytocin mediates the effects of some of these neural systems, some of them regulate the
effects of oxytocin.
i. Oxytocin and dopamine incertohypothalamic system:
When injected i.e.v., oxytocin and apomorphine have similar effects on male
sexual behaviour: both induce repeated episodes of penile erection and yawning
(Argiolas et al., 1986; Melis et al., 1987). Argiolas et al. (1987) reported that i.e.v.
injection of an oxytocin antagonist prevented penile erection induced by oxytocin and by
apomorphine. Although blockade of dopamine receptors impairs penile erection induced
by dopamine agonists, it does not disrupt oxytocin -induced penile erection (Argiolas et
al., 1988). Melis et al. (1989) also studied the effect of concomitant i.e.v. injection of
oxytocin and apomorphine on the induction of penile erection; co-injection of oxytocin
and apomorphine failed to increase the number of penile erection compared to the
number of penile erection induced by the substances given independently. Taken
together, these results led Argiolas and colleagues to suggest that dopamine agonists
induce penile erection by stimulating the release of oxytocin in the PVN and
surrounding structures.
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ii. Oxytocin and nitric oxide.
As mentioned in section 1.4.3, the increase in oxytocin transmission facilitating
the induction of penile erection is accompanied by an increase in NO production in the
PVN and the spinal cord. Indeed, i.e.v. injection of NOS inhibitors inhibit penile
erection induced by oxytocin or by apomorphine (Melis & Argiolas, 1993). Melis and
Argiolas (1997) measured NO production in the PVN after i.e.v. injection of oxytocin by
measuring the concentration of NO2 and NO3", the reaction products of newly -formed
NO with O2 and H2O. They found that i.e.v. injection of oxytocin, at doses that initiate
penile erection, increased NO production They also reported that i.e.v. injection of
oxytocin antagonists has the same inhibitory effects as i.e.v. injection of NOS inhibitors:
both prevent penile erection. Thus, they suggested that NO induces penile erection by
activation of central oxytocin transmission.
Hi. Oxytocin and testosterone
Melis et al. (1994) reported that the facilitative effects of oxytocin on penile
erection were prevented by castration and were restored by testosterone replacement or
by its metabolites (DHT and estradiol). Tribollet et al. (1990) showed that testosterone
increased oxytocin binding in the brain in male rats and that castration reduced it. Arletti
et al. (1992) suggested that a threshold of testosterone was required for oxytocin to
improve male sexual behaviour. Although testosterone restored the effects of oxytocin in
castrated rats, an increased dose of testosterone did not enhance the effects of oxytocin.
iv. Oxytocin and opioids
As mentioned in section 1.4.2, opioids have inhibitory effects on copulatory
behaviours, and hence on penile erection. Melis et al. (1992) reported that in the PVN,
opioids interacted with oxytocin neurones mediating the penile erection. They suggested
that opioids prevented penile erection by inhibiting the oxytocin transmission possibly
through (i-receptors located on oxytocin neurones.
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Thus, oxytocin has a facilitative role in male sexual behaviour. Although, the
effects of oxytocin on copulatory behaviours, especially on penile erection, are well
documented, the role of oxytocin in sexual motivation needs further investigation. In the
regulation of sexual performance, oxytocin has a crucial role, as it acts as a central
mediator of some neurotransmitter-mediated effects (e.g.: dopamine). Oxytocin
transmission is controlled by inhibitors (e.g.: opioids), activators (nitric oxide) and
permissive compounds (e.g.: gonadal steroids) whose interactions can influence each
other's effects.
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PART 3. oc-MSH and male sexual behaviour:
3.1. a-MSH system:
3.1.1. Structure, secretion and distribution:
The peptide alpha -melanocyte-stimulating-hormone (a-MSH) is part of the
melanocortin system, which consists of two subgroups of peptides with structural
similarities: melanotropins (a-, (3-, y- MSH), and corticotropin (ACTH). The
melanocortins derives from the proopiomelanocortin (POMC) prohormone. Depending
of the expression of different cell-specific enzymes, the POMC prohormone is
processed by enzymatic cleavage in different melanocortin peptides and in the opiate¬
like peptide (3-endorphin (Fig 1.7). The melanocortins and opiate-like peptides have
been detected in a variety of peripheral tissues (e.g.: pituitary gland, blood circulation,
kidney, intestine, adrenal glands, pancreas, ovaries, testis, placenta and skin) and in the
central nervous system.
a-MSH is produced in the melanotrophs cells in the intermediate lobe of the
pituitary gland from which it can be secreted into the general circulation. The secretion
of a-MSH from the intermediate lobe is under the influence of intra and extra -
hypothalamic regulatory factors such as for instance dopamine or serotonin, which
respectively inhibits or stimulates the exocytosis of a-MSH secretory vesicles. Once
secreted, a-MSH then behaves as a classic hormone.
a-MSH is also produced within the brain in neurones in the dorsomedial hypothalamus
and in the arcuate nucleus of the hypothalamus. a-MSH released within the brain can
then act as a neuromodulator. Nerves fibres containing a-MSH project from the arcuate
nucleus to numerous areas within the CNS including the hypothalamus, the thalamus,
the mesencephalon, the amygdala, the hippocampus, the cortex, the medulla and the
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Figure 1.7: Post-translational products of the prohormone proopiomelanocortin.
A first proteolytic cleavage of POMC by enzyme proconvertase 1 (PC1) generates ACTH and
b-lipoproteic hormone. The cleavage of ACTH by enzyme proconvertase 2 (PC2) generates
a-MSH. The processing of POMC in a tissue dependent manner. Adapted from Textbook "An
introduction to neuroendocrinoiogy" by R E. Brown. Cambridge University Press.
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3.1.2. Melanocortin receptors:
Five sub-types of melanocortin receptors (MCI to MC5) have been identified
(Adan & Gipsen, 1997; Hadley et al., 1999; Gantz & Fong, 2003) and each sub-type
derives from a separate gene (Abdel-Malek, 2001). Melanocortin receptors (MCR) are
G-protein coupled receptors. They have seven transmembrane domains with several N-
glycosylation sites in their N-terminal domains. MCR are coupled to the Gs protein and
adenylate cyclase and therefore mediate their effects by activating the cAMP-dependent
signaling pathway. However, the MC3 receptor has also been associated with increases
in intracellular Ca2+via the inositol triphosphate pathway and the MC5 receptor has also
been associated with the JAK/STAT pathway. MCR may be regulated by
phosphorylation as all subtypes contain recognition sites for protein kinase C and protein
kinase A. The five subtypes of MCR have different affinities for the melanocortins and
the endogenous antagonists agouti and AGRP. The MCR affinities and the MCR
distribution and principal identified functions are summarized in Table 1.4.
3.2. Functions of q-MSH;
a-MSH is involved in a variety of physiological functions and behaviours
including hair and skin coloration, inflammation, immunomodulation, nociception,
nerve regeneration, regulation of cardiovascular functions, energy homeostasis,
thermoregulation, avoidance behavior (learning and memory), grooming, yawning and
sexual behaviour (see review Hadleyet al, 1999; Gantz & Fong, 2003; Starowicz &
Przewlocka, 2003). Some of the most well -known functions are briefly described
below:
3.2.1. a-MSH and pigmentation:
a-MSH is involved in skin and hair coloration. In lower vertebrates, a-
MSH regulates the rapid color changes. In mammalian species, a-MSH, via MC1R,
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Conversely, the antagonist agouti peptide induces the synthesis of the yellow pigment
phaeomelanin. The final coloration is the result in the competition amongst a-MSH/
ACTH and agouti peptides.
3.2.2. a-MSH and inflammation:
Central and peripheral a-MSH has anti-inflammatory properties. It reduces
different types of inflammatory responses such as acute and chronic inflammation and
contact hypersensitivity (Starowicz & Przewlocka, 2003). a-MSH injected centrally
reduces brain inflammation but also inflammation in peripheral tissues (Rajora et al.,
1997; Lotti et al., 2002). The anti- inflammatory effects of a-MSH are though to be
mediated via MC1R and via MC3R as these two sub-types are expressed in many cells
involved in the regulation of inflammatory processes (macrophages, monocytes,
neutrophils, fibroblasts and endothelial cells).
3.2.3. a-MSH and energy homeostasis:
Centrally acting melanocortins are involved in the regulation of food intake and
body weight. a-MSH injected i.c.v inhibits food intake (Pogglioli et al., 1986, McMinn
et al., 2000), and compared to the other POMC-peptides, a-MSH is the most potent
regulator of feeding. Over-expression of agouti peptide in the hypothalamus leads to
hyperphagia, reduced energy expenditure and obesity (Lu et al., 1994). The hypotrophic
effects of a-MSH are thought to be mainly mediated by MC4R. Injection of the MC4R
antagonist, SHU-9119, blocks the inhibitory effect of the melanocortin agonist
Melanotan-II (Fan et al., 1997), and mutation in the MC4R gene lead to obesity
associated with hyperphagia (Huszar et al., 1997) as described for the over-expression of
the MCR antagonist agouti. MC3R knockout mice are obese but with reduced food
intake (Chen et al., 2000), MC3R may be implied in the regulation of feeding behaviour
too. a-MSH and interact with other systems regulating the energy homeostasis. Indeed,
melanocortins have been reported to mediate the effects of leptin and to control the
expression of the neuropeptide Y (Vergoni & Bertolini, 2000).
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3.3. a-MSH and sexual behaviour:
3.3.1. a-MSH and female sexual behaviour:
In rats, a-MSH injected into the VMN, into the MPOA, or at the median
eminence, stimulates sexual activity and lordosis behaviour (Gonzalez et al, 1993;
Scimonelli et al., 2000). Gonzalez et al. (1993) showed that injection of a-MSH into the
VMN induced noradrenaline release while enhancing sexual activity. Scimonelli et al.
(2000) suggested that a-MSH effects were mediated by noradrenaline acting on (3-
adrenergic receptors. Indeed, injection of a (3- adrenergic antagonist into the median
eminence eliminated the facilitative effects of a-MSH. The effects of a-MSH on sexual
behaviour are mediated by the central MC3R and/or MC4R, as injection of a MCR
antagonist into the VMN eliminates the effects of a-MSH on lordosis in a dose -
dependent manner (Cragnolini et al., 2000). Nonetheless, whether it is the MC3R or the
MC4R that mediate the central effects of a-MSH in the regulation of female behaviour
is still not known.
3.3.2. a-MSH and male sexual behaviour:
3.3.2.1 Systemic a-MSH and male sexual behaviour:
No studies have reported a modification of a-MSH secretion during male sexual
behaviour, as no studies have measured plasma a-MSH concentration in males during
copulation. However, Wessells et al. (1998) reported that s.c injection of the a-MSH
analogue melanotan-II induces penile erection in normal men and in men with
psychogenic erectile dysfunction, even at very low doses (0.025mg/k.g). Melanocortin
receptors have been identified in the male genital tract: MC1R and MC5R can be found
in the testis (Abdel-Malek, 2001), and MC4R mRNA has been localized in the penis
(Van der Ploeg et al, 2002). The role ofMC4R in the peripheral regulation of male
sexual behaviour has been investigated by studying the effects of the MC4R agonist
THIQ (tetrahydroisoquinoline). Martin et al. (2002) reported that i.v injection of THIQ
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increased the number of erection in a dose-dependent manner, and that these effects
were blocked by the iv injection of a MC4R antagonist. Thus, systemic a-MSH
facilitates male sexual behaviour but more investigation is required to clarify the role of
a-MSH in the peripheral regulation of male sexual behaviour.
3.3.2.2. Central a-MSH and male sexual behaviour:
The involvement of the melanocortin system in the central regulation of the male
sexual function has been known since the study by Ferrari and colleagues in 1963. They
found that i.c.v injection of ACTH, a-MSH and related peptides in common laboratory
animals including rats, induced the "stretching-yawning syndrome" associated with
repeated episodes of penile erection and ejaculation, i.c.v injection of a-MSH and
ACTH have been since reported to reduce ejaculation latencies and the number of
mounts and intromissions required to achieve ejaculation in sexually -experienced rats
(Argiolas,1999).
The central mechanisms of action of a-MSH in the regulation of sexual
behaviour have yet to be clarified. The effects of a-MSH are likely to be mediated by
the MC3R and/ or the MC4R, as they are the MCR the most abundantly expressed
within the CNS. Most evidence implicates the MC4R in the regulation of penile
erection. Martin et al. (2002) reported that central administration of the selective MC4R
agonist THIQ increased the intracavernosal pressure and the number of reflexive penile
erections in rats, but some contradictory data refute the MC4R involvement in favor of
the MC3R. Vergoni et al. (1998) showed that injection of the putative specific MC4R
antagonist HS014 into the hypothalamus failed to block penile erection induced by a-
MSH at doses that impaired the stretching and yawning reflex.
Although these discrepancies are still not resolved, it is clear that a-MSH effects
on male sexual behaviour are modulated by other systems. Indeed, the facilitative effects
of ACTH and a-MSH are eliminated by castration but restored by testosterone,
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confirming that testosterone has a permissive role in the expression of sexual behaviour
(Bertolini, 1975). A pre-treatment with moiphine blocks penile erection induced by
ACTH, suggesting that opioids interfere with the melanocortins system (Melis &
Argiolas, 1995). Finally, NO is likely to be the final mediator of a-MSH effects as NOS
inhibitors prevent a-MSH induced penile erection (Benelli et al., 1995; Melis &
Argiolas, 1995).
So far, it is difficult to say whether a-MSH plays a role in the regulation of
sexual motivation as well as in the modulation of sexual performance. As a-MSH
injections have not been reported to facilitate socio-sexual interaction in rats and to
stimulate sexual activity in sluggish rats (Argiolas, 1999), it has been assumed that a-
MSH and related peptides were involved in the regulation of sexual copulatory
performance rather than in sexual motivation. However, Wessells et al. (2000) showed
that in men, s.c injection of melanotan-II increased sexual desire, suggesting that a-
MSH does stimulate sexual motivation. Therefore, additional studies specially designed
to investigate the role of a-MSH in sexual motivation are required to clarify these
discrepancies.
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What is the hypothesis of this PhD thesis?
Oxytocin and a-MSH are involved in the central regulation of a variety of
physiological functions and behaviours. Remarkably, the central effects of a-MSH and
oxytocin in the regulation of these behaviours are very similar: Oxytocin and a-MSH
both reduce food intake when injected centrally (Vergoni et al., 1986; Arletti et al.,
1989); they both induce grooming and yawning behaviours (Richard et al., 1991,
Argiolas, 2000); and in the regulation of sexual behaviour, oxytocin and a-MSH have
similar facilitative effects (sections 2.3.2 & 3.3.2): They enhance female sexual
behaviour, induce penile erection, and stimulate sexual performance in males. They both
induce penile erection when injected into the PVN, which indicates that the PVN is a
shared site of action for both oxytocin and a-MSH in the regulation ofmale sexual
behaviour. Both oxytocin and a-MSH actions are inhibited by opioids and by NOS
inhibitors, suggesting that NO is the key mediator of oxytocin and a-MSH effects in the
regulation of penile erection. Thus, these observations are persuasive evidence that
central actions of oxytocin and a-MSH in the regulation of male sexual behaviour are
not independent.
Anatomical evidence also supports the idea of an interaction between oxytocin
and a-MSH. a-MSH fibres innervate the SON and the PVN where oxytocin is produced
(O'Donohue, 1979); and MC3 receptors and MC4 receptors mRNA expression have
been localized in the hypothalamus and high levels ofmRNA expression for the MC4R
have been found in the SON and in the PVN (Mountjoy, 1994; Adan, 1997).
Finally, previous studies have reported that a-MSH has modulatory effects on
oxytocin neuronal activity, as i.c.v injection of a-MSH induces Fos expression in
oxytocin neurones in the SON and in the PVN (McMinn, 2000; Olszewski, 2001).
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Taken together, these observations lead to the hypothesis that oxytocin and a-
MSH interact to enhance male sexual behaviour; in particular,that some effects of
oxytocin are mediated by a-MSH, or alternatively, some effects of a-MSH are mediated
by oxytocin.
What are the objectives of this PhD thesis?
The objectives of this thesis are to complete the knowledge of the actions of
oxytocin and a-MSH in the regulation of male sexual behaviour, and to test whether
their actions are not independent. To do so the following questions were asked:
1. Do both peripheral and central a-MSH play a role in the regulation of male
sexual behaviour?
(Although a-MSH given centrally or systemically enhances male sexual
behaviour, no studies have yet investigated the changes in a-MSH systemic secretion
and in neuronal activity of a-MSH -containing neurones during male sexual
behaviour.)
2. At which level (central and/or peripheral) do oxytocin and a-MSH interact?
3. Does oxytocin that modulates the actions of a-MSH or alternatively, does a-
MSH modulate the effects of oxytocin? Does blocking the effects of one
influence the actions of the other?
4. Does the interaction between oxytocin and a-MSH occur during male sexual
behaviour?
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5. What is the influence of this interaction on the regulation of male sexual
behaviour? Does blocking this interaction impair the behaviour?
What is the interest in studying interactions between oxytocin and a-MSH in the
regulation ofmale sexual behaviour?
Male sexual behaviour is a complex behaviour, whose regulation mechanisms
involve numerous systems that are likely to interact to enable the behaviour to occur
normally, and most of these regulatory mechanisms remain unclear. Investigating the
interaction between oxytocin and a-MSH will allow a better understanding of the
physiological role of two of the most potent peptides identified so far to induce penile
erection and enhance male sexual behaviour. The clarification of their mechanisms of
action could give new ideas and tools to develop new pharmaceutical strategies to solve
male sexual disorders such as psychogenic erectile dysfunction.
To a larger extent, if the interaction between oxytocin and a-MSH is underlined,
this interaction could be transposed to other behaviours in which oxytocin and a-MSH
have similar effects, and could open new areas of research in the comprehension of
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2.1. Animals
Sprague-Dawley adult male (350-450g body weight) and female (250g body
weight) rats from Bantin & Kingman were used. Following ethical guidance and
regulations (Animals (Scientific procedures) Act 1986), animals were housed in the
Medical Faculty animal facility at Edinburgh University (MFAA) in stock cages of a
maximum of 5 rats. Rats were kept in ambient temperature (22°C) with relative
humidity at 55%(± 10%) and with food and water ad libitum on a 12 hour light -dark
cycle (light: 7:00h - 19:00h). From their day of arrival, rats were allowed a minimum
of one week of acclimatisation before any experimental use.
2.2. Non -surgical procedures
2.2.1. Sub-cutaneous injection (s.c.)
The rat was laid on its stomach. The injection was made using a sterile 23-gauge
needle inserted into the skin at back of its neck parallel to the body wall.
2.2. Intraperitonal injection (i.p.)
The rat was restrained on its back with the low abdomen extended. The abdominal
muscles were gently pushed up. A sterile 23-gauge needle was inserted through these
muscles to reach the peritoneal cavity. The needle was slightly withdrawn, without
exiting the peritoneal cavity before the drug was injected.
2.3. Anaesthesia & analgesia
In non-recovery experiments, rats were given an i.p. injection of 25% urethane
solution (ethyl carbamate, 1.25 mg/ kg rat; Sigma, UK). Urethane induces an increase
in Fos expression in the brain, including the hypothalamus (Takayama et al., 1994).
Therefore, rats were anaesthetised with an i.p. injection of sodium pentobarbitone
(Sagatal, Rhone Merieux, 60mg/kg, 1ml/ kg rat) in all the experiments including Fos
expression studies.
In recovery experiments, rats were anaesthetised under halothane (Fluothane,
Merial, UK) inhalation: they were first placed in a box with 5% halothane in
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600ml/min both oxygen and nitrous oxide and then maintained anaesthetised
throughout the surgery with 3% halothane in 1200ml/ min both oxygen and nitrous
oxide.
To minimise post-surgery pain, rats were given 0.05ml s.c. of the analgesic
Zenecarp (C-Vet/ Products, Grampan Pharmaceuticals Ltd, UK) before surgery.
2.4. Surgery
All procedures were carried out under sterile conditions using autoclaved
instruments. The fur was shaved over the incision sites and the skin was disinfected.
After each recovery surgery, rats were given 1 ml i.p. or i.v. of 0.9% physiological
saline to compensate for any fluid loss. Rats were allowed up to 20 min in a recovery
box at 35°C then placed in a clean single cage for a minimum of 3 days to recover
before experiment.
2.4.1. Jugular vein cannulation (performed by Dr A.J. Douglas)
To withdraw blood samples and to administer drugs intravenously, anaesthetised
rats were fitted with a cannula into the jugular vein.
A 1cm incision was made through the skin from the right mandible to the right
clavicle to expose the right jugular vein. Two ligatures (5-0 size silk thread, F.S.T.,
UK) were placed around the vein. The cranial ligature was tightened to avoid blood
loss. A silastic catheter (Bore: 0.5mm; Wall: 0.25mm; Altec, UK) containing heparin
saline (0.9% saline with heparin 5000 Units/ ml; Sigma, UK) was inserted into the
vein for 3 cm reaching the right atrium of the heart. A small amount of blood was
withdrawn and then re-infused with heparin saline to check that the blood could be
easily withdrawn. The cannula was then secured by tightening the second ligature.
Finally, the cannula was exteriorised at the back of the neck, sealed with a blocker
(half cut 23-gauge needle sealed with glue), fixed in place with adhesive tape (1 cm
width) sutured to the skin with two stitches (2-0 size silk thread) and the ventral
incision was sutured closed.
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2.4.2. Intracerebroventricular (i.c.v.) cannulation
To infuse drugs into the brain, rats were fitted with an i.c.v. cannula.
The anaesthetised rat was placed in a stereotaxic frame (ASI instruments); two ear
bars fixed to the frame restrained the rat in position. An incision was made through
the scalp to expose the dorsal surface of the skull. Skin and connective tissues were
moved apart. To make sure that the brain was horizontal, level of Bregma and
Lambda was checked and adjusted if necessary. A hole was drilled in the skull at
0.6mm posterior and 1.6mm lateral to Bregma ("The rat brain in stereotaxic
coordinates" G. Paxinos & C. Watson, Academic Press). An i.c.v. guide cannula (22-
gauge, 4.5mm length, Bilaney Consultants Lts, USA) was inserted into this hole
reaching a depth of 4.5mm from the surface of the skull. Its position was secured onto
the surface with two jeweller screws and dental cement (Kemdent, Associated Dental
Products Ltd, UK). The skin was replaced above the hard cement and two sutures
with 2-0 size silk thread were made around the guide cannula. Finally, a cap rinsed
with saline was inserted into the guide cannula.
2.4.3. Preparation & placement of a microdialysis probe onto the supraoptic
nucleus (SON)
To infuse drugs onto the SON and to collect dialysates from the same area,
sagatal-anaesthetised rats were fitted with a microdialysis probe (membrane 1 mm
length, 0.5 mm diameter; CMA-12, CMA/Microdialysis, Stockholm, Sweden)
adjacent to the right supraoptic nucleus.
2.4.3.1. Preparation of the microdialysis probe
The probe was placed in a vial filled with artificial cerebrospinal fluid (aCSF:
124mM NaCl, 26mM NaHC03, 3mM KCL, 1.24mM KH2P04, 2.1mM CaCl2 in
distilled water). A 1-ml glass microsyringe (Hamilton, Aldrich) gas-tight and filled
with degassed aCSF, was mounted onto an automatic microinjection pump (Stoelting
Co, USA) and was connected to a liquid switch with 25 cm of FEP tubing (CMA/
Microdialysis) containing 3pl aCSF. The inlet cannula of the probe was connected to
the same liquid switch with 25 cm FEP tubing containing aCSF.
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Ten cm of empty FEP tubing were connected to the outlet cannula of the probe in
order to facilitate the sample collection into a lOOpl eppendorf tube.
The probe contains glycerol while packaged; so to flush out the glycerol, the probe
was perfused with ethanol at 40pl/min, in a vial filled with 70% ethanol for 4-5 min.
Back in a vial filled with aCSF, the probe was perfused at 40p,l/min another 5 min
with aCSF to wash out the ethanol and air. To make sure that no air bubbles were
trapped inside the membrane, the probe was checked under a microscope.
The probe was then perfused at a 1.5pl /min during the surgery and the experiment.
2.4.3.2. Surgery
Using the same surgical approach as for i.e.v. cannulation (see section 2.4.2.),
a perfused microdialysis probe supported by stereotaxic manipulator was inserted into
the brain at 0 mm rostrocaudal to Bregma, 1.5mm lateral to Bregma and to a depth of
9.5mm from the surface of the skull.
2.5. Drug administration procedures via surgically fitted cannulae
2.5.1. Intravenous injection (i.v.)
The i.v. cannula was connected to a 1-ml graduated plastic syringe by a silastic
tubing filled with 100/rl heparin saline. The blood was withdrawn to the tip of the
needle; the drug was injected using a second syringe followed by further heparin
saline to flush the drug into the bloodstream.
2.5.2. Intracerebroventricular injection (i.c.v.) & injection site examination
2.5.2.1. i.c.v. injection
The tubing containing the drug was connected to the i.c.v. injection cannula
inserted into the guide cannula. Using a I0p\ Hamilton syringe, the drug was injected
at \pM 30 s. A maximum volume of 5/xl was injected.
2.5.2.2. Injection site examination
For hormone secretion studies, the injection site was checked by injecting
i.c.v. 2p\ of a blue dye (5% alcian blue) after the rat was dead. The brain was then
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removed and cut with a scalpel blade to check the presence of blue dye in one of the
lateral ventricles. For immunocytochemistry studies, the dye was not used, the
presence of a cannula tract through the brain to one lateral ventricle was checked
under a microscope after the brain had been sectioned with the freezing microtome.
Only brains with confirmed correct injection site were analysed.
2.5.3. Drugs infusion onto the SON & infusion site examination
Microdialysis probes were used to deliver drug onto the SON. The drug was
chronically infused at 0.75/xl/ 30 s. The correct infusion site was checked by looking
for a tract through the brain to the vicinity of one SON (anterior) after preparation of
brain sections.
2.6. Blood sample collection:
An hour before the first blood sample was collected; the jugular vein cannula
was connected to 50cm silastic tubing (Bore: 0.50mm, Wall: 0.50mm; Altec, UK)
joined to a 1 ml plastic syringe containing heparin saline. When taking each sample,
blood was withdrawn to the tip of this syringe. The blood sample was then collected
with a second syringe and placed in a 1.5-ml eppendorf tube containing 10pl of a
solution of protease inhibitor (aprotinin 0.039TIU, Sigma, UK) and 60pl of EDTA
5% (anti-coagulant calcium chelating agent, Sigma, UK). Unless specified otherwise,
0.4 ml of blood was withdrawn and, then replaced with the same volume of 0.9%
saline to retain a constant volume of blood. Samples were stored in ice (- 4°C) until
centrifugation. Plasma was separated from red cells by centrifugation (13,000 r.p.m.
for 2-3min) and stored at -20°C until the day of the radioimmunoassays.
2.7. Radioimmunoassays:
2.7.1. General principles
Radioimmunoassay was used to obtain accurate measurements of plasma
125
peptide concentrations. Radioimmunoassay is based upon the competition of I-
peptide and peptide (in either standard or unknown samples) binding to a limited
quantity of antibodies specific against the peptide. As the quantity of peptide in
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standards or in unknown samples in the reaction increases, the amount of I25I-peptide
able to bind to the antibody is decreased. The complex antibody-bound 125I- peptide
can be separated from the free fraction using two different methods:
i. Second antibody method: a second antibody is used to bind the primary
antibody to form a high molecular weight complex that can be separated
from the free fraction by centrifugation.
ii. Double antibody -polyethylene glycol precipitation method: The
polyethylene glycol induces the precipitation of the high molecular weight
1 95
complex antibodies (primary + secondary)-bound I- peptide, which can
be separated from the free fraction by centrigugation.
After centrifugation and aspiration of the supernatants, the radioactivity of the
125
precipitates ( I-peptide bound) is measured using an Auto-Gamma Counter (LKB
Wallac, Finland). By measuring the amount of ,25I-peptide bound as a function of the
peptide concentration in the standards, it is possible to construct a standard curve from
which the concentration of peptide in unknown samples can be determined using an
Ultraterm 2 software programme.
2,7,2. Precision and sensitivity of an assay
Intra-assay coefficient ofvariation:
To assess variations between samples within an assay, stock solutions of known
hormone concentration were measured in duplicated at the beginning and end of each
assay. Intra-assay coefficient was calculated using results of one specific standard
from the assay using the following equation:
Intra-assay coefficient of variation= SD X 100
X
Where X is the mean of hormone concentration from all intra-assay tubes of a specific
standard and SD is the standard deviation around that mean.
Inter-assay coefficient ofvariation:
To assess variations between different assays from comparable experiments, stock
solutions of known hormone concentrations from previous assay were placed into the
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new assay. The variation was calculated using results from one specific standard for
all the assays and using the following equation:
Inter-assay coefficient of variation = SD X 100
X
where X is the mean of hormone concentration from all inter-assay tubes of a specific
standard for all the assays and SD is the standard deviation around that mean.
Assay sensitivity:
To assess the assay sensitivity, the amount of radioactivity bound by each
standard (B) was expressed as a percentage of the maximum binding in the assay
(Bmax) using the following equation (A):
Equation(A):
%B/Bmax = (Mean com of std- mean cpm of NSB)
(Mean cpm of Bmax- Mean of NSB)
X 100
where NBS is the average number of counts for the non-specific binding tubes.
A graph is created by plotting %B/Bmax against the log of the hormone concentration
of each standard. The sensitivity of the assay is the concentration of the peptide for
which the %B/Bmax obtained is the closest to the sensitivity calculated with the
following equation (B):
Equation (B):





Using the graph, the percentage of sensitivity of the assay is converted a hormone
concentration.
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2.7.3. Oxytocin radioimmunoassay
The assay procedure was adapted from one elaborated by Prof. T. Higuchi
(Higuchi et al., 1985). They developed a sensitive and specific radioimmunoassay to
measure oxytocin concentration in the blood. They raised an antibody specific against
oxytocin after several injections of an oxytocin -bovine serum albumin conjugate into
two female rabbits. They tested the specificity of the antibody and the crossreactivity:
The anti oxytocin serum used showed no crossreactivity with arginine-vasopressin,
arginine-vasotocin or with any of the products from the degradation of oxytocin.
2.7.3.1 .Reagents:
Assay buffer
0.125g sodium phosphate (monobasic)
0.594g sodium phosphate (dibasic)




Normal rabbit serum diluted at 1:400 in assay buffer. (SAPU)
Rabbit anti-rat oxytocin, THF3
(Provided by Prof. Higuchi.)
Primary antibody diluted at 1:200,000 in antibody buffer.
Standard oxytocin (4th international standard,
National Institute for Biological Standards and Control)
Standards were diluted in assay buffer from an oxytocin stock solution of 50ng/ml.
Eleven concentrations of standard were used: 2.4, 4.8, 9.7, 19.5, 39.1, 78.1, 156, 312,
625, 1250 and 2500 pg/ml.
125-
-I-oxytocin (NEN Life Science Products)
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Donkey anti-rabbit IsG serum
Secondary antibody diluted at 1:25-50 in assay buffer
(IDS Ltd)
Pansorbin cells (Novabiochem Ltd)
Diluted at 1:25-50 in assay buffer.
Controls
Inter/intra-assay standards were made from the oxytocin stock solution of 50ng/ml
and diluted in assay buffer at 1000, 500, 250, 50 and lOpg/ml.
2.13.2. Methods:
Day one
1. 50pl of standards and inter-assay standards were added in triplicates to their
respective assay tubes (0.75ml polypropylene tubes, Luckman LP2). 50pl of unknown
samples were added in duplicates to their respective assay tubes.
2. 50pl of rabbit anti- oxytocin serum was added to all tubes. To measure non-specific
binding, three tubes received 50pl of normal rabbit serum instead of anti-oxytocin
serum (NSB tubes).
3.Tubes were vortex-mixed and incubated at 4°C for 24 h.
Day two/ three
1. 50 pi of 12 -I-oxytocin were added to each tube. To measure total counts, three
tubes only received 12 -I-oxytocin (TC tubes).
2. Tubes were vortex-mixed and incubated at 4°C for 48 h.
Day four/ five
1. 50pl of the anti rabbit IgG serum were added to all the tubes except the TC tubes.
2. Tubes were vortex-mixed and incubated at 4°C for 48 h.
Day six
1. 50pl of pansorbin cells were added to all tubes to facilitate the visualisation of the
pellet.
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2. Tubes were centrifuged at 1700g (3,000 r.p.m.) at 4°C for 30 min.
3. Supernatants were removed by aspiration immediately after centrifugation.
4.Radioactivity in each tube was counted using a Gamma Counter.
A standard curve and a binding curve obtained from an oxytocin radioimmunoassay
are shown in Figure 2.1.
2.7.4. a-MSH radioimmunoassays
a-MSH plasma concentrations were determined using two different commercially
available kits. The first one (Phoenix pharmaceuticals, INC, Belmont, USA) required
extraction of the peptide from the plasma before the radioimmunoassay procedure.
The extraction procedure increased the number of manipulations of the samples and
therefore the risk of mistakes, to avoid this; a second kit (Euro-diagnostica, Malmo,
Sweden) was used to measure the concentration of a-MSH from un-extracted plasma
samples.
2.7.4.1. Determination of a-MSH concentration from extracted plasma samples:
i) Extraction of a-MSH from plasma:
Elution solvents:
Buffer A: 1% trifluoroacetic acetic (TFA) in H20.
Buffer B: 60% acetonitrile in 1% TFA.
Methods:
Plasma samples were acidified with an equal amount of buffer A and loaded
onto a C-18 SEP-COLUMN (Lida, NY, USA). The column was slowly washed with
3ml of buffer A (twice), the wash was discarded. a-MSH peptide was eluted with 3ml
of buffer B. The eluant was collected into a tube and evaporated to dryness in a
centrifugal concentrator. The final residue was dissolved in 250ql of RIA buffer for
radioimmunoassay.
ii) Assay protocol:
Reagents: (Phoenix Pharmaceuticals kit)
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Figure 2.1: Standard curve (A) and binding curve (B) from an example
of oxytocin radioimmunoassay.
The sensitivity of the assay is calculated using the equation (B) described in section
2.7.2. The sensitivity of this example of radioimmunoassay is found to be around
5.5pg/ml.
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RIA buffer
19nM monobasic sodium phosphate
81nM Bibasic sodium phosphate
0.05 NaCl




Eight concentrations of standard were used: 1, 2, 4, 8,16, 32, 64 and 128pg/tube.
Rabbit anti a-MSH serum
Rabbit antiserum raised against a-MSH conjugated to bovine serum albumine and
reconstituted in 13ml RIA buffer.
The anti a-MSH serum used in this kit is directed to the C-terminal part of the a-




I-a-MSH was reconstituted with 13ml of RIA buffer to obtain a concentration
between 8,000 and 10,000 cpm / 100pl solution.
Goat anti-rabbit IgG serum
Reconstituted with 13ml of RIA buffer.
Normal rabbit serum
Reconstituted with 13ml of RIA buffer.
Methodology:
Day one
1. To measure non-specific binding, 200|al RIA buffer was added to two tubes (NSB
tubes). To measure total counts, lOOpl RIA buffer was added to two tubes (TC tubes).
2. 100|al of standards and samples were added in duplicates in their respective tubes.
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3. 100p,l of primary antibody rabbit anti-oc-MSH serum was added to all tubes except
the TC tubes and the NSB tubes.
4. Tubes were vortex-mixed and incubated at 4°C for 24 h.
Day two
1. lOOjul of I25I-a-MSH was added to all tubes.
2. Tubes were vortex-mixed and incubated at 4°C for 24 h.
Day three
1.100(xl of goat anti-rabbit IgG serum and lOOjil of normal rabbit serum were added
to all tubes except the TC tubes.
2.Tubes were vortex-mixed and incubated at room temperature for 90 min.
3.500p,l RIA buffer was added to all tubes except the TC tubes.
4. Tubes were vortex-mixed.
5. All the tubes except TC tubes were centrifuged at 1700g (3,000 r.p.m.) at 4°C for
20 min.
6. Supernatants from all the tubes except TC tubes were aspirated immediately after
centrifugation.
7. Radioactivity of the precipitates was counted using a gamma counter.
Although, we obtained exploitable results using this a-MSH radioimmunoassay kit,
we found the step of peptide extraction limiting the accuracy of the results. To
facilitate the reproducibility of assays and comparison between assay, we used a
second kit were the extraction of the peptide was not required to determine the
concentration of a-MSH in the samples.
2.7.4.2 Determination of a-MSH concentration from un-extracted plasma samples.
i) Reagents: (Euro-diagnostica kit)
Anti-g-MSH serum
Rabbit antiserum raised against a-MSH conjugated to bovine serum albumine in 24ml
0.04M Phosphate buffer.
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125I-g -MSH
Reconstituted with 25ml distilled water to obtain a concentration between 9,000 and
11,000 cpm/200pl solution.
Double antibody -PEG
Diluted goat anti-rabbit-Ig antiserum and 5.0% w/v polyethylene glycol 6000.
q-MSH Standards
Seven concentrations were used: 0, 4, 7, 9, 18.8, 37.5, 75 and 150 pmol/1
Controls
Two controls with known concentrations from each assay kit.
ii) Methodology
Day one
1. 100 pi of standards and controls were added in duplicates to their respective assay
tubes. 100 pi of samples were added to their respective assay tubes.
2. 200 pi of anti-a-MSH were added to the tubes. Non-specific binding of the
antiserum was calculated from two tubes that received antiserum buffer but no
antiserum (NSB tubes).
3. Tubes were vortex-mixed and incubated for 24 h at 4°C.
Day two
1. 200 pi 125I-a -MSH were added to all the tubes. The total radioactivity added (total
counts) was determined from two tubes (TC tubes) that only received iodinated a-
MSH.
2. Tubes were vortex-mixed and incubated for 24 h at 4°C.
Day three
1. 500 pi double antibody-PEG were added to all the tubes except TC-tubes.
2. Tubes were vortex-mixed and incubated for 60 min at 4°C.
3. Tubes were centrifuged at 1700g (3,000 r.p.m.) for 15 min at 4°C.
4. Supernatants were removed by aspiration immediately after centrifugation.
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Figure 2.2 : Standard curve (A) and Binding curve (B) of an example of a -
MSH radioimmunoassay.
The sensitivity of the assay was then calculated using the equation (B) described in section
2.7.2. The sensitivity of this example of radioimmunoassay was found to be less than
4.7pg/ml.
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5. Radioactivity of the precipitates was counted using a gamma counter.
An example of a standard curve and a binding curve obtained from a a-MSH
radioimmunoassay are shown in Figure 2.2.
2.8. Brain processing
2.8.1. Transcardial perfusion
Rats, from which the brain was used for immunocytochemistry studies, were
transcardially perfused to fix the brain quickly and therefore to stabilise any potential
antigens and avoid their degradation.
The rat was deeply anaesthetised with sodium pentobarbitone (Sagatal, 1 ml i.p. or 0.4
ml i.v.) and then placed on its back. An incision in the skin was made to expose the
thoracic cage. The chest was opened up and the diaphragm carefully cut to expose the
beating heart. After removing the pericardium, a 19-gauge needle was inserted into
the apex of the left ventricle and the perfusion started with a rinsing solution of
heparin saline (5000 units /ml, 100 ml). A cut into the right atrium was made to allow
drainage of the perfusion solutions and body fluids. After 5 min or when the blood
had run clear, the rinsing solution was replaced with the fixative solution (4%
paraformaldehyde in phosphate buffer (PB) 0.1M, pH=7.4) for another 10 to 15 min
(typically 300 ml). Spontaneous movements and stiffening of the limbs should have
been observed to indicate a correct perfusion. Upon completion of the perfusion,
brains were removed and placed in a post-fix solution (half fixative solution, half 15%
sucrose in 0.1M PB) overnight in the fridge at 4°C. Tissues were then placed in a
cryoprotective solution of 30% sucrose in 0.1M PB at 4°C and left until they had sunk
(typically 48 h). The brain tissues were frozen in dry- ice and stored at -70°C until
processing.
2.8.2. Brain sectioning
Brains were cut at 44pm using a freezing microtome. Brains sections were placed
in PB 0.1M if used the same day, or stored in cryoprotectant (50% 0.2M PBS, 30%
Ethylene glycol, 20% Glycerol, Sigma, UK) at -20°C.
51
General methods Chapter 2
2.8.3. Immunocytochemistry
Immunocytochemistry is a combination of immunology and microscopy. Firstly
described by Coons et al. (1941), this technique relies upon the specific binding of an
antibody to its antigen in a tissue, and the reaction to localise the antigen-antibody
complex. Antigens can be proteins, carbohydrates, lipids, nucleic acids and many
other compounds. Antibodies need to have high specificity, affinity and avidity for the
antigen. Two types of antibodies can be distinguished: Polyclonal or monoclonal
antibodies. Polyclonal antiserum is a mixture of highly specific antibodies, each
active against different epitopes on the antigen. Monoclonal antibodies are specific to
only one epitope on the antigen. Polyclonal antisera are more sensitive and specific
than monoclonal antibodies because they have more paratopes active against the same
antigen. Moreover, if the paratope of the monoclonal antibody is destroyed all
sensitivity towards the antigen will be lost.
The antigen-antibody complex is then localised using a microscopically dense marker
that will highlight the antigen-antibody reaction. This marker possesses an intrinsic
property to change a colourless substrate (chromogen) into a coloured product. For
light microscopy, the marker can be an enzyme (peroxidase or alkaline phosphatase)
or a fluorescent dye.
There are numerous immunolabelling techniques; one of them is the 'three steps'
indirect technique where a secondary biotinylated antibody is used between the
primary antibody and the dense marker. Flere, the avidin-biotin peroxidase complex
has been used as the dense marker. The avidin has four high -affinity binding sites for
biotin and therefore a preformed avidin-biotin peroxidase complex can bind to the
biotinylated secondary antibody, thus amplifying the signal (Fig 2.3). Then, to
visualise peroxidase, the chromogen Diaminobenzidine (DAB) is used as substrate for
the enzyme reaction during which it turns brown or black when enhanced by nickel
ammonium sulfate.
2.8.3.1. Fos immunocytochemistry :
Fos is the protein product of the gene c-fos that belongs to the immediate early
genes family (IEGs) and is present in many cells including neurones. Once produced,
Fos forms a heterodimer with another EEG protein product (Jun for instance), creating
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Figure 2.3: Schematic illustration of the "3 steps" indirect technique.
A secondary biotinylated antibody binds to the primary antibody. A preformed avidin-
biotin peroxidase complex (ABC) binds to the secondary antibody, thus amplifying the
signal. The peroxidase induces the chromagen DAB to turn black. A: Avidin, B: Biotin,
P: Peroxidase.
Adapted from Beesley (1993)
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a transcription factor AP-1 (activatory protein-1). The binding of AP-1 to DNA
regulates the expression of other genes. The mechanisms of activation of c-fos
transcription remain yet to be clarified.
Fos protein and c-fos mRNA levels are very low in basal conditions in many brain
regions including the hypothalamus but numerous stimuli can increase these levels.
Fos protein and c-fos mRNA accumulation within the cell nucleus can be visualised
by immunocytochemistry and in situ hybridisation. Therefore, Fos is widely used as a
marker of neuronal activation.
i) Reagents
Phosphate Buffer 1M (PB), pH-7.4
1 L distilled water
115g Disodium hydrogen orthophosphate (BDH)
27.2g Sodium dihydrogen orthophosphate (BDH)
Phosphate buffer 0.1M with 0.2% Triton X-100 (PB-T), pH-7.4
1 L Phosphate buffer 0.1M (100ml 1M PB + 900ml dH20)
2ml Triton X-100 (BDH)
0.3% Hydrogen peroxide in 0.1M PB
99ml 0.1MPB
lml 30% H2O2 (Sigma)
Primary antibody: c-fos Ab-2 polyclonal antiserum (Oncogene)
Rabbit antibody raised against the N-terminal amino-acids 4-17 of the protein product
of human c-fos.
Normal sheep serum (SAPU)
Secondary antibody (Vector Labs PK6101 kit)
Biotinylated anti-rabbit IgG.
Normal goat serum (Vector Labs PK6101 kit)
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Sodium acetate buffer 0.2M, pH=6
16.4g sodium acetate
1L distilled water
The pH was adjusted to 6.0 using a couple of drops of acetic acid.
(BDH)
ABC solution (Vector Labs PK6101 kit)
For lmlO.lMPB-T:
20[x\ Avidin DH
20/xl Biotinylated horseradish peroxidase
This solution was left for 30 min before to use to allow the complex avidin -biotin
peroxidase to be formed.
Nickel-DAB solution
i. 25mg DAB (Diaminobenzidine tetrachloride) (Sigma)
50ml distilled water
ii. 2.5g nickel ammonium sulphate (BDH)
50ml 0.2M acetate buffer
When the nickel ammonium was dissolved, 0.4g of glucose (Sigma) and 0.08g of
ammonium chloride (BDH) were added to the solution (ii).
The two solutions were then mixed and filtered (filter papers 185 mm diameter;




To remove the fixative and the cryoprotectant, and to make the cell
membrane permeable, sections were rinsed in PB-T 0.1M for 15 min at room
temperature (4 times), and then washed 5 min in 0.1M PB.
To block the action of any endogenous peroxidase, sections were placed in a 0.3%
H202 in 0.1M PB solution for 15 min and then rinsed with PB-T 0.1M for 10 min (3
times). To reduce non- specific staining, sections were placed in a 1% normal sheep
serum (NSS) solution for 30 min. Sections were incubated for 24 to 48 h with a rabbit
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Ab-2 Fos polyclonal antibody (Oncongene science) diluted at 1:1000 in PB-T + 1%
NSS at 4°C.
Second step:
To remove the excess of the primary antibody, sections were washed in PB-T
0.1M for 10 min (3 times). To localise the primary antibody, sections were incubated
for one hour at room temperature with a secondary antibody, a biotinylated anti-rabbit
immunoglobulin diluted at 1:100 in PB-T 0.1M + 3% Normal goat serum (NGS).
Sections were then rinsed in PB-T 0.1M for 10 min (3 times).
Third step
To amplify any immunoreactive signal, sections were put in an ABC solution
(Avidin DH and Biotinylated horseradish peroxidase in PB- T) for one hour at room
temperature. Sections were washed in PB-T for 10 min (twice) and then rinsed with
0.1M acetate buffer for 5 min to be prepared for the visualisation stage.
Visualisation: The glucose oxidase-Ni-DAB solution was poured onto the drained
sections. After 30 s, sections were checked under a microscope to detect any
immunoreactive signal. To stop the DAB reaction, sections were rinsed in 0.1M
acetate buffer for 5 min.
Finally, sections were rinsed in PB 0.1M.
2.8.3.2. Oxytocin immunocytochemistry
The immunocytochemistry procedure for oxytocin labelling was the same as
previously described for Fos (section 2.8.3.1.). The primary antibody used was a
rabbit Ab-1 oxytocin polyclonal antibody (Oncogene science) diluted at 1:1000. The
secondary antibody, the dense marker, the chromagen and the incubation times were
the same as for the Fos immunocytochemistry.
2.8.3.3. a-MSH immunocytochemistry
The immunocytochemistry procedure for a-MSH labelling was the same as
previously described for Fos (see section 2.8.3.1.). The primary antibody used was a
rabbit anti a-MSH polyclonal antibody (Peninsula Lds, USA) diluted at 1:2000 in
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0.1M PB-T in 2% NSS. The secondary antibody, the dense marker, the chromagen
and the incubation times were as previously described for Fos immunocytochemistry.
8.3.4. Specificity of immunocytochemistry reactions & antibody controls
The immunocytochemistry reaction must be specific for the antigen under
investigation. Non-specific immunologic reactions are a major critical point that can
invalidate any immunocytochemistry studies. Many factors can lead to non-specific
immunologic localization. For instance, if the antigen used during immunization
hasn't been highly purified, the antiserum obtained will have contained a small
percentage of antibodies not related to the antigen under investigation. The cross
reactivity is a second factor. Cross-reactions are immunologic reactions between the
antibody and unknown tissue constituents due to stereological configuration
similarities between these constituents and the immunizing antigen. These cross-
reactions result in an immunolocalisation of wrong antigens/ compounds.
Therefore, the specificity of the antibody used needs to be checked to confirm that the
results obtained are not due to non-specific immunological reactions (Stemberger,
1979; Beesley, 1993).
i) Rabbit Ab- 2 c-fos polyclonal antiserum (Oncogene)
The specificity against the Fos protein of the rabbit Ab-2 c-fos polyclonal
antiserum is well established. This polyclonal antiserum specifically recognises the
residues 4 to 17 of the protein product of the human c-fos, a sequence that is
immunogenic to human, mouse and rat species. This antibody has been extensively
used in our laboratory with results described in many publications, e.g.: Srisawat et
al., 2000; Douglas et al., 2000; Johnstone et al., 2000.
ii) Antibody controls in the indirect method:
The antibody controls were as follow:
Control A: Sections were incubated with the primary antiserum to be tested, as
previously described.
Control B: A preimmune serum substituted the primary antiserum.
Control C: The primary antiserum was blocked by absorption (it was bound to an
excess of the specific antigen before use with the sections)
Control D: Sections were incubated with no antibody.
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No immunolabelling should be seen for the controls B, C and D. Control A should
present an immunoreactive signal where the cells containing the antigen against
which the antibody specificity is tested, are located.
iii) Test of rabbit Ab-1 oxytocin polyclonal antiserum specificity
Using standard immunocytochemistry procedure (see section 2.8.3.2.) a few brain
sections throughout the hypothalamus were processed following the 4 controls:
Control A: Sections were incubated with 3/xl rabbit anti oxytocin polyclonal
antiserum diluted at 1:1000 in 0.1M PB-T + 1% NSS.
Control B: Sections were incubated with neat preimmune serum (normal rabbit
serum; 3/xl in 3ml of 0.1M PB-T + 1% NSS).
Control C: The antiserum was mixed with 40 or 330/xg of oxytocin (control CI and
control C2 respectively) in 0.1M PB-T + 1% NSS for 24 h at 4°C. Then, sections were
incubated in the antiserum-oxytocin solution.
Control D: Sections were incubated with 3ml 0.1M PB-T + 1%NSS.
Sections were analysed under the microscope. Sections from control A showed an
expected and distinctive labelling from cells in the SON and PVN where oxytocin
cells are located (Fig 2.4). Fibres emerging from the PVN and SON and projecting to
the median eminence (where numerous oxytocin fibres are located) were detected
(results not shown). Sections from controls B and D did not present any labelling.
Sections from control CI presented a pale immumoreactive signal in the SON and
PVN. An increase in the quantity of oxytocin peptide in the absorption complex C2
significantly reduced the staining in the nuclei (Fig 2.4)
The distribution of the cells labelled as oxytocin cells with the tested antibody
corresponded to the correct distribution of oxytocin cells, no inadequate staining was
noticed. The absorption complex significantly suppressed the action of the antibody,




Figure 2.4: Photomicrographs illustrating the specificity test of rabbit Ab-1
oxytocin polyclonal antibody
44 jam coronal sections through the PVN and SON were treated for single
immunocytochemistry for oxytocin following 4 antibody controls: Control A: rabbit oxytocin
polyclonal serum (A, B); Control B: rabbit pre-immune serum (C, D); Control C1: Absorption
complex with 40 pg oxytocin peptide (E, F); Control C2: Absorption complex with 330 jag
oxytocin peptide (G, H). Black arrow: Oxytocin cells. 3V: Third ventricle. OC: Optic chiasm.
Scale bar: 100 pm.
Figure 2.5: Photomicrographs illustrating the specificity test of a-MSH
polyclonal antiserum.
44 urn coronal sections through the arcuate nucleus were treated for single
immuncytochemistry with A, B: rabbit a-MSH polyclonal antiserum, C, D:
rabbit preimmune serum, E, F: absorption complex. Black arrow: a-MSH
cells. Scale bar: 100pm
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iv) Test of rabbit anti a-MSH polyclonal antiserum specificity
Using standard immunocytochemistry procedure (see section 2.8.3.3.) a few brain
sections were processed following the 4 controls:
Control A: Sections were incubated with 3/xl rabbit anti a-MSH polyclonal antiserum
diluted at 1:1000 in 0.1M PB-T + 1% NSS.
Control B: Sections were incubated with neat preimmune serum (normal rabbit
serum; 3/rl in 3ml of 0.1M PB-T + 1% NSS).
Control C: The antiserum was mixed with 60p,g of a-MSH in 0.1M PB-T + 1% NSS
for 24 h at 4°C. Then, sections were incubated in the antiserum a-MSH solution.
Control D: Sections were incubated with 3ml 0.1M PB-T + 1%NSS.
Sections were analysed under the microscope. Sections from control A showed a
distinctive labelling from cells in the arcuate nucleus where a-MSH containing cells
are expected to be located (Fig 2.5). Sections from controls B, C and D did not
present any labelling. No unspecific labelling was observed. Thus, the rabbit anti a-
MSH polyclonal antiserum used is therefore specific against the a-MSH peptide.
2.8.3.5 Double immunocytochemistry
To study co-localisation of Fos in individual neurones (e.g.: oxytocin neurones
or a-MSH neurones), brain sections were processed for Fos/oxytocin and Fos/a-MSH
by double immunocytochemistry. To distinguish between the two immunoreactive
signals (Fos protein and peptide), the visualisation step had to be modified during the
second immunocytochemistry (peptide labelling). The chromagen DAB was used
without the nickel ammonium sulfate in the second immunocytochemistry, and turned
brown after the enzyme reaction. Thus, Fos protein was visualised by a black nucleus
signal and oxytocin or a-MSH - containing neurones were identified by a brown
cytoplasm signal (Fig 2.6.C).
i) Fos/oxytocin double immunocytochemistry
Brain sections were firstly processed for Fos labelling (see section 2.8.3.1.) and
then for oxytocin (see section 2.8.3.2.).
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ii) Fos/ a-MSH Double immunocytochemistry
Troubleshooting:
We adapted the Fos/ oxytocin double immunocytochemistry procedure for
Fos/ a-MSH double immunocytochemistry. Initially, unsatisfactory results were
obtained: The background labelling of the sections was high, the immunoreactive
signal was weak and the sections were difficult to mount (sticky and easily
breakable). To overcome these problems, the protocol was modified:
(1) The number of washes of the sections in 0.1M PB-T was increased.
(2) To make sure that none of endogenous peroxidase was left active, sections were
placed again in a 0.3% hydrogen peroxidase solution during the a-MSH
immunolabelling process.
(3) To reduce the non-specific staining, the concentration of the normal sheep serum
and the time of incubation were increased in the first step of the labelling process of
a-MSH (From 30 min in 1% NSS to 90 min in 2% NSS).
(4) To minimise the background staining, the concentration of the biotinylated
secondary antibody was decreased (from 1:100 to 1:200 dilution). (Second step)
(5) 100pl hydrogen peroxide was added to the DAB solution. (Third step)
(6) The DAB reaction was stop by a wash in PB 0.1M instead of a wash of acetate
buffer to improve the aspect of the sections.
Final protocol:
First step
After labelling for Fos, brain sections were washed in 0.1M PB-T and were
then placed in a 0.3% H2O2 solution for 15 min. After being rinsed in 0.1M PB-T,
sections were placed in a solution of 2% normal sheep serum for 90 min. Finally,
sections were incubated with a rabbit anti a-MSH polyclonal antibody diluted at
1:2000 in 0.1M PB-T + 2% NSS, for 24 - 48 h at 4°C.
Second step
After being rinsed in 0.1M PB-T, sections were incubated with the second
antibody, a biotinylated anti-rabbit IgG diluted at 1:200 in 0.1M PB-T + 1% normal
goat serum for 1 h at room temperature.
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Third step
After being rinsed in 0.1M PB-T, sections were placed in the ABC solution
diluted at 1:100 in 0.1M PB-T for one hour at room temperature. Sections were rinsed
again in PB-T followed by a wash in 0.1M PB for 5min.
Visualisation: 100 p\ of 30% H202, was added to the DAB solution. This solution was
then poured onto the sections. When the immunoreactive signal had appeared, usually
60 sec later, the peroxidase-chromagen reaction was stopped by washing the sections
in 0.1MPB.
2.8.4. Mounting, dehydratating & coverslipping
After any immunocytochemistry, brain sections were mounted onto
gelatinised slides (Super premium microscope slides, 1.0-1.2 mm thick, BDH)
following a rostro-causal anatomical order. Slides were cleaned and dehydrated into a
series of 70, 90, 95 and 2 x 100 % alcohol baths for respectively 5, 5, 5 and 2x10
min. Alcohol was then removed from the sections by dipping the slides for 2x10 min
into xylene baths. Slides were immediately coverslipped with DPX mounting agent
(BDH) and left to dry overnight.
2.8.5. Analysis
All the analysis was done "blind": the identity of each slide was unknown
during the counting procedure.
For single immunocytochemistry, sections were analysed using a Wang microscope
(Wang Biomedical, UK) with x 20 objective.
For double immunocytochemistry, sections were analysed using a Leica DMR
microscope with x 20 and x 40 objectives.
For each brain areas, the same number of sections was counted for each rat and only
undamaged sections at the same anatomical level were analysed.
In Fos immunocytochemistry studies, only cells with a black or dark grey nucleus
were considered as Fos-positive cells (Fig 2.6.A).
In double immunocytochemistry studies, only cells with a visible nucleus (Fos-
negative or positive) were counted (Fig 2.6.B, 2.6.C).
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Figure 2.6: Photomicrographs illustrating the controls used for the
analysis of the immunocytochemistry.
A: Fos immunocytochemistry: Black arrow: example of Fos-positive cell.
B, C: Double immunocytochemistry Fos / oxytocin. B: Fos -negative oxytocin
cell; C: Fos -positive oxytocin cell.
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In all experiments studying the Fos distribution, the following whole brain areas were
counted:
Analysis of the SON
SON within brain sections from rostro-caudal -1.30 mm to -1.40mm to Bregma
(Figures 23, 24; Paxinos & Watson, 1996) were analysed for Fos distribution.
Analysis of the PVN
The subdivisions of the PVN were analysed following the description of the PVN
by Swanson and Kuypers, (1980). (Fig 1.5).
Analysis of the Arcuate nucleus
Arcuate nucleus within brain sections from rostro-caudal -2.30 mm to -3.30 mm
to Bregma (Figures 27, 31; "The rat brain atlas", Paxinos G. & Watson C.) were
analysed for Fos distribution.
2.9. Sexual behaviour experiments
Because rats mate during the night, all sexual behaviour experiments were
performed under reverse light cycle (dark: 7:00h -19:00h, light: 19:00h-7:00h) to
facilitate the timing of the experiments. At least one week was left before any use to
acclimatize the rats to the reverse light cycle. Rats were kept in plastic cages with see-
through lids, at 22°C, in a quiet room only designated to the sexual behaviour studies,
with food and water ad libitum.
2.9.1. Female sexual receptivity
As for all female mammals, female rat reproductive processes are cyclic with
fluctuations of sex hormones (e.g. estrogen and progesterone secreted from the
ovary). During the cycle, functional and morphological changes occur in the
reproductive tract and in sexual receptivity. The period of receptivity or "heat" is
called Estrus; the receptive female presents a characteristic posture called Lordosis,
when mounted by a vigorous male. Rats are polyestrus mammals, they complete











Figure 2.7: Rat estrus cycle.
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pregnancy, pseudo-pregnancy or disease) (Fig 2.7). The rat estrus cycle is dependent
on diurnal rhythms, with a beginning of the estrus period just after midnight.
2.9.1.1. Estrus cycle study
To establish the sexual status of the female rat, smears prepared from the
vaginal fluid were examined every morning at the same time for two weeks before the
experiment.
The presence of characteristic cells indicates the stage of the cycle (Fig 2.8; Table
2.1).
STAGES CHARACTERISTIC CELLS
DI-ESTRUS Many polymorphonuclear leucocytes.
Few nucleated intermediate epithelial cells.
PRO-ESTRUS Loads of intermediate epithelial cells. Few cornified cells
lacking nuclei appear.
Leucocytes almost completely absent.
ESTRUS Hundreds of large cornified superficial cells with degenerate
nuclei. Few epithelial intermediate cells.
METESTRUSI End of the Estrus, masses of adherent cornified cells.
METESTRUS II
Few cornified superficial epithelial cells are left.
Loads of polymorphonulear leucocytes.
Table 2.1: Stages of the estrus cycle and characteristic cell types.
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Figure 2.8: Photomicrographs illustrating Estrus cycle smears
A: Diestrus, B: Pro-estrus, C: Estrus, D: Metestrus I, E: Metestrus II
Red arrow: Leucocyte, Black arrow: Intermediate epithelial cell, Green arrow: Cornified
cell. Scale bar: 100pm.
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During the stages of Estrus and Metestrus I, the female rats are receptive and the
mating is permitted, therefore only female rats in these sexual stages were used on the
day of experiment.
2.9.1.2 Hormonal induction of receptivity
We noticed several factors limiting the effectiveness of the "smears" technique to
study the estrus cycle: Keeping females in groups tended to result in a synchronisation
of their estrus cycle; the stress of daily vaginal smearing induced delays in the cycle;
and additionally, a couple of females presented a pseudo-pregnancy state (sterile
mating). Therefore, to avoid these limiting factors and to be sure to have enough
receptive females for each experimental day, sexual receptivity was induced in
ovariectomised rats with injection of estrogen and progesterone. Indeed, estrogen is
responsible for the onset of the estrus state: 48 h before showing estrus behaviour, the
rat is under the influence of a high level of estrogen as well as an increased level of
progesterone (Rao and Mahesh, 1986).
i) Ovariectomy:
From a dorsal approach at the lumbar level, two incisions were made through the
skin and through the abdominal wall. Some of the adipose tissues were withdrawn to
expose the fallopian tubes and the ovaries. A thread was strongly tied at the top of
each fallopian tube. The ovaries were cut off and discarded. The fallopian tubes and
the adipose tissues were placed back in the abdominal cavity. Finally, the abdominal
walls and the skin were sutured with two stitches of 5-0 and 2-0 silk threads.
ii) Flormonal induction:
After being ovariectomised (at least 3 weeks before the experiment) and 48 h
before the day of experiment, female rats were injected s.c. with 30jig of 3-beta -
estradiol-benzoate (ICN Biomedicals Inc, USA) diluted in 300|iL of sesame oil. Six
hours before the beginning of the test, lmg of progesterone (Sigma, UK) diluted in
100|iL of sesame oil were injected s.c. into the female rats.
The sexual receptivity of the "induced " female was tested a few minutes before the
beginning of the experiment: a vigorous sexually experienced male was placed in the
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female cage; only females responding with lordosis posture (within 10 min) were used
during the experiment.
2.9.2. Preliminary sexual behaviour study
It was necessary to know, first, whether the rats would mate in our laboratory
conditions; and then, whether they would behave following the same range of
behavioural parameters and timing that is described in the literature (e.g.: Stoneham et
al. 1985; Vergoni et al. 2000; Ratnasooriya & Jayakody J. 2000). Indeed, slightly
different conditions could result in changes in the display and in the timing of the
behaviours that could lead to a difficult interpretation of our results. Therefore a
preliminary study of mating behaviours of one pair of rats was performed. A receptive
female and male were placed in a clean cage. The test started when a short period of
exploration of the new cage ended (tO). Both rats showed sexual interest in their
partner, they displayed sniffing behaviour. The first mount of the female by the male
appeared at +120 s whereas the first lordosis happened at +240 s. The first
intromission occurred at +250 s. A series of mounts with pelvic thrusts & dismounts
followed by a prolonged session of cleaning of the genitals indicated a putative
ejaculation (+ 319 s). The sexual activity was then suspended for 6 min before a new
series of mounts started again. The test ended when the mount latency was above
15min. The results obtained were in the range of what was expected from the
literature (Table 2.2) and they indicated sufficient laboratory conditions to study
mating behaviours.
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Preliminary Vergoni et Ratnasooriya Stoneham




120 39.7-122 15-195 120
Intromission
latency (s)
250 48.7-225.5 15-260 -
Ejaculation
latency (s)




600 325-387.2 - 341-514.26
Table 2.2: Time range of sexual behaviour parameters.
Mount latency: Time to the first mount; Intromission latency: Time to first intromission;
Ejaculation latency: Time between the first intromission and ejaculation; Post-ejaculatory
interval: Time between the first ejaculation and the next intromission.
2.9.3. Experimental parameters for the study of the male sexual behaviour
To keep constancy between experimental parameters for all the experiments, the
following parameters were used:
2.9.3.1. Time limit to onset of mating:
We used a time limit of 15 min for the male to present a mounting behaviour after
being paired with a receptive female. Above this time limit, the male was considered
as non-mated male.
2.9.3.2. Determination of the intromission behaviour, the reference behaviour:
The mechanisms during the behaviour "intromission" were studied in all the
'sexual behaviour' experiments. Intromission can be recognised when the male
performs a series of intensive mounts with slow pelvic thrusts on a female in lordosis,
usually followed by a grooming behaviour (Fig 2.9). The third time this behaviour
was observed, was considered as our behaviour reference "Intromission". In a series
of intensive mounts, several mounts will lead to intromission, but the first mounts do
not necessarily mean that a successful intromission happened (male and female can be
not perfectly positioned or the female can manage to escape), therefore we used the
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Figure 2.9: Video -extracted photomicrographs illustrating the
Intromission Reference behaviour
A: Intromission: Male mounting female (in lordosis) with pelvic thrust. B: Male
grooming behaviour indicating a successful intromission.
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third time we observed this behaviour to be sure that a intromission had occurred
during the mounts.
2.9.4. General experimental design of sexual behaviour experiments
2.9.4.1. For hormone secretion studies:
Two hours before beginning the test, the receptivity of each female was checked
using a sexually -experienced male. Only females responding to the male with
lordosis postures were used for the experiment. Their cage was removed from the rack
onto a table near a red lamp to facilitate behavioural observations.
One hour before beginning the test, catheters for blood sampling and/ or drug
injection were connected to the previously implanted cannulae (see section 2.4.1,
2.4.4). Rats were then watched to make sure none of the cannulae or tubes were
pulled out.
Thirty minutes before the test, a first basal blood sample was taken, followed by a
second sample 30 min later.
At the start of the test, one male was gently removed from its cage and placed in the
cage of one of the pre-selected females. This was designated as tO.
If no mounts occurred within 15 min, the male was put back in its own cage and
considered as non-mated male. Blood samples were then taken every 10 min.
If mounts occurred within 15 min, behaviours were recorded until the display of the
reference behaviour Intromission (tl). Blood samples were taken for each sexual
behaviour observed. Five minutes after the reference behaviour occurred (tl +5mins)
the male was placed back in its own cage. A last blood sample was taken between tl +
60 and tl +120 min. At the end of the test, rats were killed by an i.v. injection of a
lethal dose of Sagatal.
2.9.4.2. For immunocytochemistry studies:
The receptive females were selected as mentioned earlier. At tO, a male was
placed in the cage of one of the receptive females and the recording of each behaviour
was started. Ninety minutes after the reference behaviour had occurred, the rat was
given an overdose of Sagatal (i.p.) and transcardially perfused.
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2.9.4.3.Experiments with drug injection:
Tubing for the drug injection was connected to the i.e.v. cannula 1 h before the
beginning of the experiment.




Systemic oxytocin and oc-MSH secretion during
male sexual behaviour
Oxytocin and Ot-MSH secretion during male sexual behaviour Chapter 3
3.1. Introduction:
Both oxytocin and a-MSH enhance male sexual behaviour, and both oxytocin
and a-MSH are secreted from the pituitary gland into the blood. Although oxytocin is
secreted peripherally during male sexual behaviour, no study has yet measured a-MSH
secretion (Chapter 1). The present study investigates changes in systemic oxytocin and
a-MSH secretion during male sexual behaviour, by studying the effects of copulation on
plasma oxytocin and a-MSH concentrations in male rats. As oxytocin and a-MSH have
similar effects on male sexual behaviour, we hypothesised that systemic a-MSH
secretion would increase during male sexual behaviour; and that this increase would be
stimulated by systemic and/or central oxytocin.
In a first experiment, we investigated whether peripheral oxytocin stimulates a-
MSH secretion to drive sexual behaviour. To do so, rats were injected i.v. with oxytocin
antagonist before being paired with a receptive female, and plasma oxytocin and a-MSH
concentrations were measured during male sexual behaviour.
In a parallel experiment, we investigated whether central oxytocin stimulates
systemic a-MSH secretion to drive male sexual behaviour. To mimic the central release
of oxytocin occurring during male sexual behaviour, conscious rats were injected i.c.v
with oxytocin. Plasma a-MSH concentration was then measured over time.
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3.2. Methods:
3.2.1. Experiment 1: Changes in plasma oxytocin and oc-MSH concentration during
male sexual behaviour. Influence of iv-injection ofoxytocin antagonist:
3.2.1.1. Reverse light cycle:
Three weeks before the beginning of the experiment, rats were placed in reverse
light cycle (dark from 7:00h to 19:00h). The following experiment was performed in the
dark under red light.
3.2.1.2. Female receptivity:
To predict the sexual receptivity of each female each day of the experiment, the
estrus cycle of each female was studied using smears performed every morning at the
same time for three weeks before the experiment. In the morning of the experiment,
females in estrus and metestrus I stages were paired with a vigorous stud male to check
their receptivity. Only females that responded with lordosis behaviour were used for the
experiment.
3.2.1.3. Surgery:
Each male was briefly anaesthetized using halothane in the 'reverse-light' room
(dark at the time) under red light. Once anaesthetized, the rat was transported to the
surgery room where it was fitted with an i.v. cannula while maintained under halothane
anaesthesia (for description of the surgery procedure see sections 2.4.1; 2.4.4). The rat
was then placed back in the 'reverse-light' room in individual cage for four days of
recovery.
3.2.1.4. Experimental design:
i. Oxytocin antagonist injection:
The oxytocin antagonist 'F382' (Ferring Pharmaceuticals inc.) was used. F382, when
injected i.v., has been reported to be effective to delay the onset of birth at dose of 60
pg/kg BW (Antonijevic et ah, 1995). To ensure the blockade of the oxytocin receptors,
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F382 was used at the two doses of 100 jLtg/kg and 300 M-g/kg. 400 p.1 of the antagonist
solutions were therefore injected at the concentration of 40(ig/ rat (OTA-40) and at
120p,g/ rat (OTA-120).
Even injected i.v. at high doses, it is very unlikely that F382 can cross the blood -
brain barrier, since it differs by only one amino acid (Cys to Gly) from the other
oxytocin antagonist peptide F792, which has been shown not to cross the blood -brain
barrier(Opstad et al., 1996; personal communication from Prof. G. Leng). Thus, the use
of this specific antagonist of peripheral oxytocin receptors, guarantees that any effect
observed after i.v. injection of F382 are consequential to the blockade of peripheral
mechanisms and not central ones.
Because F382 has long-lasting effects that occur rapidly after injection, male rats
were injected 2 min before being paired with a receptive female.
ii. Protocol:
Sixty minutes after each i.v cannula was connected to a blood-sampling tube, a
first basal blood sample was taken, followed by a second sample 30 min later. Rats were
then injected i.v. with 400jul of either vehicle (physiological saline), or OTA-40 or OTA-
120. Two minutes after the drug injection, each male was placed into a receptive
female's cage and the sexual behaviours were recorded. A blood sample was then taken
during the first intense ano-urogenital investigation ('Sniffing' sample) and at
intromission (reference behaviour); 5 min after the reference behaviour occurred, the rat
was placed back into its own cage, and 60 min later, a final blood sample was taken
('Back cage' sample) before a lethal dose of pentobarbitone (Sagatal, 50mg/kg s.c.) was
injected to kill the rat at the end of the test (For description of the blood sample
collection procedure see section 2.6). Blood samples were then prepared for
radioimmunoassays as described in section 2.6. Plasma samples were processed by
radioimmunoassays for determination of plasma oxytocin and plasma a-MSH as
described in sections 2.7.3 (oxytocin RIA) and 2.7.4.2 (a-MSH RIA). The percentage of
binding and sensitivity of these assays are summarized in Table 3.1:
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RIA % Binding % Sensitivity Detection limit
of assay
Oxytocin 31 95.8% Less than 5.5pg/ml
a-MSH 48.14 98.7% Less than 4.7pg/ml
Table 3.1: Sensitivity of the oxytocin and a-MSH radioimmunoassays for experiment 1.
3.2.2 Experiment 2: Changes in plasma a-MSH concentration after i.c.v injection of
oxytocin or oxytocin agonist in conscious rats:
3.2.2.1. Surgery:
A week before the experiment, male rats were fitted with i.v. and i.c.v. cannulae
under brief halothane anaesthesia (for description of the surgery procedures see section
2.4.1, 2.4.4). Rats were then placed in single cages for recovery.
3.2.2.2. Experimental design:
i. Oxytocin and oxytocin agonist solutions:
Two concentrations of oxytocin were used: OT-IO: 10ng/ 2pl and OT-lOO:
100ng/2pl. The oxytocin agonist Thr4-Gly7-OXT (Sigma, UK) was used at the
concentration of 10ng/2pl (OTago-lO).
ii. Protocol:
Sixty minutes after each i.v and i.c.v cannulae were connected to blood-sampling
and drug-administration catheters, a first basal blood sample was taken followed by a
second sample 30 min later. Rats were then injected i.c.v with 2 pi of vehicle (aCSF),
OT-IO, OT-lOO or OT ago-10 at lpl/ 30s. Blood samples were withdrawn 5, 10, 15, 30,
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45 and 60 min after the drug injection. At the end of the test, rats were killed by a lethal
injection of Sagatal. Data from rats with a misplaced i.c.v site of injection were
discarded (see section 2.5.2 for procedure of injection site checking). Blood samples
were then prepared for radioimmunoassay as described in section 2.6. Plasma samples
were processed by radioimmunoassay for determination of plasma a-MSH following the
procedure described in section 2.7.4.2 (a-MSH RIA; percentage of binding: 48%; assay
sensitivity: 98% and sensitivity less than 4.7pg/ml)
3.3. Statistics:
All data were normalised into percentages with basal values equalling 100%.
Data presented in the graphs are means ± S.E.M. To compare the effect of i.v. injections
of oxytocin antagonist on the onset to sexual behaviour, a one -way ANOYA followed
by a pairwise multiple comparison procedure (Student-Newmann-Keuls method) was
used. For the two experiments, a two -way repeated measures ANOVA test was used to
compare oxytocin and a-MSH secretion during different phases of sexual behaviour,
followed by a pairwise multiple comparison procedure (Student-Newmann-Keuls
method). A P value < 0.05 was considered as statistically significant.
3.4. Results:
3.4.1 Experiment 1:
i.) Effects of i.v. injection ofoxytocin antagonist on the display ofmale sexual
behaviour:
While all rats injected with vehicle mated when paired with a receptive female, 2
out of 6 rats and 1 out of 7 rats injected with respectively 40 mg and 120 mg of oxytocin
antagonist did not mate. In rats that did mate, the injection of oxytocin antagonist slowed
down the sexual performance since the intromission latency significantly increased in
rats injected with 120 mg of oxytocin antagonist (P=0.002, one -way ANOVA; Fig 3.1).
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ii.) Changes in plasma oxytocin and a-MSH concentration during sexual behaviour:
During sexual behaviour, in all the three groups, plasma oxytocin increased to a
maximal level at intromission (Fig 3.2). In the vehicle-treated rats, the plasma
concentration of oxytocin rose by 65% at intromission compared to basal. In each of the
OTA-injected groups, the plasma concentration of oxytocin was significantly higher at
intromission than at basal (OTA-40: P=0.009; OTA-120: P=0.003; Two -way RM
ANOVA). At intromission, the plasma concentration of oxytocin in the OTA-40 -treated
group was also significantly higher compared to vehicle-treated animals fP=0.038, Two
-way RM ANOVA), but there was no significant difference in the increase in plasma
oxytocin concentration seen at intromission between the OTA-120 -treated group and
the vehicle -treated group (P=0.058) and between the two OTA-treated groups
(P=0.938).
During sexual behaviour, in all the three groups, the plasma concentration of a-
MSH increased to a maximal level at intromission and decreased to values similar to
basal values when the rat was returned to its own cage (Fig 3.3). In each of the three
groups, the plasma concentration of a-MSH was significantly higher at intromission
than at basal (Vehicle: P=0.006; OTA-100: P=0.048; OTA-300: P=0.015; Two -way
RM ANOVA). However, there was no significant difference in the increase in plasma a-
MSH concentration seen at intromission between the oxytocin antagonist -treated
groups and the vehicle -treated group. In the vehicle -treated group, the plasma



















Figure 3.1: Effects of i.v. injection of oxytocin antagonist on
intromission latency.
Injection of 40pg (OTA-40) or 120pg (OTA-120) of oxytocin antagonist. *P<0.05





Figure 3.2: Effects of i.v.-injection of oxytocin antagonist on plasma
oxytocin concentration during male sexual behaviour.
Injection of 40pg (OTA-40) or 120jag (OTA-120) of oxytocin antagonist. *P<0.05
versus Basal within each treatment (Two-way RM ANOVA). #P<0.05 versus









Figure 3.3: Effects of i.v.-injection of oxytocin antagonist on plasma a-
MSH concentration during male sexual behaviour.
Injection of 40|ig (OTA-40), or 120pg (OTA-120) of oxytocin antagonist. *P<0.05
versus Basal, +P<0.05 versus Sniffing, #P<0.05 versus Back cage within each




Basal +5min +10min +15min +30min +45min +60min
Figure 3.4: Changes in plasma a-MSH concentration after i.c.v injection
of vehicle, oxytocin or oxytocin agonist in conscious male rats.
OT-10: oxytocin 10ng/2|nl; OT-100: oxytocin 100ng/2j.il; OTago-10: oxytocin















Figure 3.5: Decrease in systemic oxytocin secretion after i.c.v injection
of MC4 receptor agonist.
One -way RM ANOVA followed by post- hoc t test. *P<0.05 versus basal within
MC4 R antagonist treatment. The number of rats per group is in parentheses. HS:
hypertonic saline.
Experimentperformed by Dr P.Bull; Figure adaptedfrom Sabatier et
al., (2003) J. Neuroscience 23(32): 10351-10358.
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3.4.2. Experiment 2:
The injection of 10 or 100 ng of oxytocin i.c.v had no significant effect on
plasma a-MSH concentration at any time point (Fig 3.4). A reduction of 44 % in plasma
a-MSH concentration can be noticed 10 min after the i.c.v injection of lOng of oxytocin
agonist, but this reduction was not statistically significant (Two -way RM ANOVA,
P=0.051).
3.5. Discussion:
Systemic oxytocin and the display ofmale sexual behaviour:
Only one behavioral parameter, the intromission latency, was recorded in the
present study and therefore the interpretation of the effects of the i.v. injection of
oxytocin antagonist on sexual behaviour is limited. Nonetheless, we found that an i.v
injection of oxytocin antagonist slowed down sexual performance: Some rats injected
with oxytocin antagonist did not mate when presented with a receptive female within the
observation period and within the rats that did mate the intromission latency was
significantly increased when the higher dose of oxytocin antagonist was given. These
results suggest that systemic oxytocin is important in copulatory behaviour: when
peripheral actions of oxytocin are blocked, copulation is delayed. Systemic oxytocin
could be involved in the motor and physical aspects of the stimulation of penile erection
although no oxytocin receptors have yet been localized in the penis and on corpora
cavernosa smooth muscles.
Systemic oxytocin and a-MSH secretions are increased at intromission:
The present results show for the first time, that plasma a-MSH concentration is
increased during male sexual behaviour, especially at intromission. We also noticed an
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increase in plasma oxytocin concentration at intromission, this increase was not
significantly different from basal values in the vehicle-treated rats, but this observation
is consistent with the study of Hillegaart et al. (1998), in which they reported that
oxytocin secretion is increased during copulation in male rats. Thus, these studies
illustrate that both oxytocin and a-MSH are peripherally secreted during male sexual
behaviour. However, how systemic oxytocin and a-MSH are involved in the mediation
of male sexual behaviour remains to be understood. There are indications about how
systemic oxytocin and a-MSH could intervene: Oxytocin receptors have been identified
in the testis and prostate (Gimpl & Fahrenholz, 2001), and evidences report a role of
systemic oxytocin in the spermatogenesis by influencing stereoidogenesis and the
contractibility of the seminiferous tubuli (Nicholson, 1991). Systemic oxytocin could
also act on the release of prostate secretion during ejaculation as suggested by Lippert et
al, (2003). MC1R and MC5R have been identified in the testis, and MC4R have been
localized in the penis. Martin et al, (2002) have reported the importance of the
peripheral MC4R in male sexual behaviour as an i.v -injection ofMC4R agonist
increased the number of penile erection in rats. Thus, once secreted into the blood, both
oxytocin and a-MSH may act on distant targets (e.g.: testis and penis) to maintain sexual
performance and facilitate ejaculation, but they may also act on other physiological
systems (e.g.: cardiovascular system) that require modulations to answer the
physiological demands of sexual exercise.
Peripheral oxytocin does not modulate peripheral a-MSH secretion during male
sexual behaviour:
In the first experiment, we found that i.v. injection of two doses of the oxytocin
antagonist 'F382' had no effect on the increases in plasma a-MSH concentration
observed at intromission. 'F382', which even injected i.v at high doses does not cross
the blood-brain barrier, only acts by blocking the peripheral oxytocin receptors.
Therefore, these results suggest that peripheral oxytocin has no modulatory effects on a-
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MSH secretion. This is supported by the lack of evidence of oxytocin receptors in the
intermediate lobe of the pituitary gland from where a-MSH is secreted into the blood.
It is difficult to interprete the significant increase in oxytocin plasma concentration
observed at intromission in the rats injected with the lower dose of oxytocin antagonist
compared to vehicle-injected rats. As mentioned previously, the oxytocin antagonist
injection disrupted the display of male sexual behaviour: Intromission was delayed in
OTA-injected rats compared to vehicle injected rats. The increase of plasma oxytocin
concentration seen once intromission had occured could be related to stress mechanisms
(induced by male's impossibility to perform) or could reflect a negative retrocontrole of
oxytocin on its own secretion.
These results suggest that oxytocin and a-MSH do not interact peripherally to
facilitate male sexual behaviour. If an interaction between oxytocin and a-MSH exists, it
must occur centrally rather than peripherally.
Central oxytocin does not stimulate peripheral a-MSH secretion:
We have hypothesized that oxytocin released centrally during male sexual
behaviour stimulates peripheral a-MSH secretion to facilitate male sexual behaviour. In
the second experiment, to mimic the central release of oxytocin during male sexual
behaviour, conscious rats were injected i.c.v with oxytocin (or oxytocin agonist). We
found that i.c.v. injection of oxytocin did not increase plasma a-MSH concentration,
suggesting that central oxytocin does not stimulate systemic a-MSH secretion. These
results illustrate that central oxytocin is unlikely to control systemic a-MSH secretion
during male sexual behaviour.
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Taken together, these results illustrate a new similarity between oxytocin and a-
MSH involvement in male sexual behaviour, as both systemic oxytocin and a-MSH
secretion are stimulated to facilitate copulation. Although systemic oxytocin is likely to
be involved in the regulation of sexual performance, as a systemic injection of oxytocin
antagonist delayed intromission, the mechanisms by which systemic oxytocin acts to
facilitate copulation remain unclear.
Systemic oxytocin does not regulate a-MSH secretion, as systemic injection of oxytocin
antagonist had no effect on a-MSH secretion. This suggests that the interaction between
oxytocin and a-MSH during male sexual behaviour must occur centrally rather than
peripherally.
The putative interaction between central oxytocin and a-MSH during male sexual
behaviour needs further investigation. Although we found that central oxytocin did not
stimulate systemic a-MSH secretion, central a-MSH might modulate oxytocin secretion
during male sexual behaviour. This is supported by findings from our laboratory. Dr P.
Bull investigated the effects of an i.e.v. injection of MC4 receptor agonist on the
systemic secretion of oxytocin. He measured the plasma oxytocin concentration in
anaesthetized rats after i.c.v injection of 400 ng of MC4 receptor agonist. In a first
experiment, i.ev. injection of MC4 receptor agonist did not stimulate plasma oxytocin
concentration (results not shown). In a second experiment, he investigated whether the
i.c.v. injection of MC4 receptor agonist could induce an decrease in plasma oxytocin
concentration. Because oxytocin concentration is low in basal conditions, oxytocin
secretion was pre-stimulated with i.p injection of hypertonic saline to obtain plasma
level on which an eventual inhibition by i.c.v. injection of MC4 receptor agonist could
be distinguishable. He found that i.c.v. injection ofMC4 receptor agonist did
significantly decreased plasma oxytocin concentration, suggesting that central a-MSH
can inhibit systemic oxytocin secretion (Fig 3.5). These results illustrate that central a-
MSH can interact with the oxytocin system to modulate systemic oxytocin secretion and
therefore, that this interaction could occur during male sexual behaviour.
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Neuronal activation in the paraventricular
nucleus, supraoptic nucleus and arcuate
nucleus at intromission:
Influence of previous sexual experience.
Neuronal activity in the PVN. SON & arcuate nucleus at intromission Chapter 4
4.1. Introduction:
Oxytocin is secreted into the general circulation from magnocellular neurones
projecting from the PVN and the SON to the posterior pituitary. In Chapter 3, we
confirmed that oxytocin was secreted into the blood during male sexual behaviour,
especially at intromission. Witt & Insel (1994) reported that the number of cells
activated in the magnocellular regions of the PVN increased following intromission and
ejaculation. Ex copula electrophysiological recordings of the activity of magnocellular
oxytocin neurones in the SON and in the PVN reported that electrical stimulation of the
dorsal penile nerve excitated oxytocin cells in the PVN (Yanagimoto, 1996) and in the
SON (Honda, 1999). Thus, these studies suggest that magnocellular oxytocin neurones
in the PVN and in the SON are activated during copulatory behaviour. Using Fos as an
indicator of neuronal activation, we investigated whether magnocellular oxytocin
neurones are activated during male sexual behaviour by studying Fos expression in
oxytocin neurones in the SON and in the PVN at intromission.
Both a-MSH and oxytocin are involved in the central regulation of male sexual
behaviour since they both facilitate sexual behaviours when given centrally (see Chapter
1 sections 2.3.2.2 & 3.3.2.2) Centrally -projecting parvocellular oxytocin neurones in the
PVN are activated during male sexual behaviour (Witt & Insel, 1994). However, the
activation of a-MSH -containing cells in the arcuate nucleus during male sexual
behaviour has not been described yet. In the present study, we investigated whether a-
MSH -containing cells are activated during male sexual behaviour by studying the Fos
expression in a-MSH -containing cells in the arcuate nucleus at intromission. As a
positive control, we also studied the Fos expression in parvocellular oxytocin neurones
in the PVN to check that the experimental conditions used were adequate to investigate
neuronal activity related to male sexual behaviour.
Sexually -experienced rats are usually used in any study investigating
mechanisms related to sexual behaviour to ensure that the rats used are physically able
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to mate. We hypothesized that a previous sexual experience could induce long-term
changes in the neuronal activity involved in the regulation of male sexual behaviour,
thus facilitating the copulation process. Investigating changes in the neuronal activity
after one copulation or after several, could give an indication of the role of different
brain areas involved in the regulation of the sexual behaviour. Therefore, in the present
study, we also compared Fos expression observed at intromission in the PVN, the SON
and the arcuate nucleus between sexually -naive and sexually -experienced rats.
4.2. Methods:
4.2.1. Preparation of the males:
Sexually -naive and sexually -experienced rats were used. Two weeks before the
experiment, male rats gained sexual experience by being placed twice with a female for
a period of four days (length of one estrus cycle) until a plug was found. Only males that
successfully mated were considered as sexually experienced rats.
4.2.2. Reverse light cycle:
Two weeks before the beginning of the experiment, male and female rats were
placed in reverse light cycle (dark from 7:00h to 19:00h). The following experiment was
performed in the dark under red light.
4.2.3. Female receptivity:
To predict the sexual receptivity of each female each day of the experiment, the
estrus cycle of each female was studied using smears performed every morning at the
same time for two weeks before the experiment. In the morning of the experiment,
females in estrus and metestrus I stages were paired with a vigorous stud male to test
their receptivity. Only females that responded with lordosis behaviour were used for the
experiment.
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4.2.4. Experimental design:
Four groups of animals were used: Sexually -naive control or mated and
sexually -experienced control or mated. Two males were removed from their own cages
at the same time and either placed in an empty cage (control group) or in a receptive
female's cage (experimental group). Sexual behaviour was recorded until the reference
behaviour (intromission) occurred, and 10 min later, each rat was returned into its cage.
Ninety minutes after the reference behaviour, rats received a lethal dose of
pentobarbitone (Sagatal, 50mg/kg, s.c.), and were then perfused transcardially with
heparinised physiological saline (0.9%) followed by 4% paraformaldehyde in 0.1M
phosphate buffer (see section 2.8.1). The brains were removed, post-fixed overnight,
cryoprotected in 30% sucrose and stored at -70°C until processed for
immunocytochemistry. Coronal sections of the hypothalamus were cut at 44/rm using a
freezing microtome. Free-floating sections were processed for single
immunocytochemistry for Fos (see section 2.8.3.1), and for double
immunocytochemistry for Fos and oxytocin (see section 2.8.3.2) or for Fos and a-MSH
(see section 2.8.3.3). Fos-positive nuclei and the percentage of Fos positive oxytocin or
a -MSH cells were counted blind throughout the PVN and the SON or throughout the
arcuate. Six SON/ rat were counted for the dorsal SON; two profiles/ rat were counted
for each subdivisions of the PVN and Fos-positive nuclei in six arcuate nuclei/ rat were
analysed throughout the arcuate nucleus. To establish the percentage of oxytocin or a-
MSH cells activated, only cells with a clear positive or negative nucleus were counted,
and between 20 and 30 oxytocin cells were counted per SON or PVN and between 20
and 35 a-MSFI cells were counted per arcuate nucleus.
4.3. Statistics:
A t-test was used to compare behavioral parameters (success of mating and
intromission latency) between sexually -naive and sexually -experienced rats.
A two -way ANOVA followed by a pairwise multiple comparison procedure (Student -
Newmann -Keuls method) was used to compare Fos expression between the four groups
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of rats (sexually -naive/ control, sexually -naive/ intromission and sexually -experienced/
control, sexually -experienced/ intromission). When only data for the sexually
experienced group were available, a t-test was used to compare Fos expression at




Previous sexual experience facilitated the display of sexual performance, as it
increased the percentage of rats that successfully mated and reduced the intromission
latency. While 88% of sexually experienced rats (7 out of 8) mated when presented to a
receptive female, only 71% of naive rats (5 out of 7) mated in the same conditions. The
intromission latency was 324 ± 30s in naive rats (n= 5) significantly greater than in
experienced rats (180 ± 18s, n= 7; P=0.002, t-test) (Fig 4.1).
ii) Changes in Fos expression in the SON at intromission:
While the level of Fos expression in the SON at intromission was not
significantly different from control level in sexually -naive rats, Fos expression was
significantly greater in the SON at intromission in sexually -experienced rats. In sexually
-experienced rats, the number of Fos -positive cells increased from 1 ± 1 cell in control
rats to 8 ± 3 cells in mated rats (P=0.040, t-test) (Fig 4.2, Fig 4.3). Of these five rats, two
rats showed a mean of 2 Fos -positive cells/ section, a mean that overlaps the levels of
Fos expression in the control group, and three rats had between 9 and 15 Fos -positive
cells /section.
Sections from all rats were processed for double immunocytochemistry for Fos and
oxytocin. Within the sexually -experienced group, in the three mated rats in which clear
elevated levels of Fos expression existed (Fig 4.4), we estimated what proportion of
oxytocin cells were activated. Estimates in the three rats were 7, 8 and 22% of oxytocin
cells activated during male sexual behaviour. Those may be underestimates because of
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the method of analysis. Sections were analyzed by only counting oxytocin cells with a
distinct nucleus Fos-positive or Fos-negative; as the SON is packed with oxytocin cells,
the high density of cells made difficult to be able to distinguish individual cells.
Therefore, from the double immunocytochemistry it was very difficult to be sure that
any cells in which Fos was expressed were oxytocin negative, but equally it was not
possible to be certain that all Fos -positive cells were oxytocin positive.
iii) Changes in Fos expression in oxytocin neurones in the PVN at intromission:
Due to technical problems, brain sections processed for Fos single
immunocytochemistry were damaged and therefore not analyzable. A few sections were
processed for Fos and oxytocin double immunocytochemistry and analyzed, but no
sections of the anterior parvocellular PVN or lateral posterior PVN from sexually naive
rats were usable.
In the parvocellular PVN subdivisions:
In all the parvocellular subdivisions of the PVN except in the lateral posterior
PVN, a higher percentage of oxytocin neurones that were Fos -positive at intromission
was observed in both sexually -naive and -experienced rats. However, these increases
were not statistically significant (Fig 4.5)
In the magnocellular PVN subdivisions:
In the PVN, in both sexually -nai've and sexually -experienced rats, the
percentage of magnocellular oxytocin neurones that were Fos -positive increased at
intromission (Fig 4.6). Indeed, in sexually -experienced rats, no oxytocin cells were Fos
-positive in control rats but 3 ± 1 % of oxytocin cells were Fos -positive at intromission
(n= 5, P=0.025, Two -way ANOVA followed by Student -Newman -Keuls method). In
nai've rats, the increase in the percentage of magnocellular oxytocin neurones Fos -
positive at intromission was not statistically significant (P= 0.079). In control conditions
or at intromission, there was no statistical difference in the percentage of magnocellular
oxytocin neurones Fos -positive between sexually -nai've and -experienced rats.
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iv) Chanties in Fos expression in the arcuate nucleus at intromission:
Fos expression was significantly increased in the arcuate nucleus at intromission
in both sexually -naive and sexually -experienced rats (Fig, 4.7, 4.8A). Indeed, in
sexually -nai've rats, the number of Fos -positive cells rose from 20 ± 2 cells in the
control group to 28 ± 2 cells in the mated group (n= 5, P- 0.006, Two -way ANOVA,
followed by Student -Newman -Keuls method). In sexually -experienced rats, the
number of Fos -positive cells was 23 ± 2 cells in the control group, not significantly
different from the naive rats, and 30 ± 2 cells in the mated group (n=5, P= 0.013, Two -
way ANOVA, followed by Student -Newman -Keuls method). However, there was no
significant difference in the Fos expression at intromission between the sexually -naive
and the sexually -experienced rats, suggesting that previous sexual experience had no
influence on the Fos expression in the arcuate nucleus observed at intromission.
After double immunocytochemistry for Fos and a-MSH, no significant
difference in the percentage of a-MSH-containing cells that were Fos -positive was
noticed between intromission and control group for either sexually -nai've rats or
sexually -experienced rats (Fig 4.7, 4.8B).
v) Observations concerning the morphological arrangement of a-MSH fibres:
During the analysis of brain sections processed for Fos and a-MSH double
immunocytochemistry, the a-MSH fibres distribution throughout the hypothalamus
especially in the PVN could clearly be seen. Remarkably, in the PVN of rats that mated,
numerous Fos-positive cells were surrounded by a-MSH fibres (Fig 4.9). Although this
observation needs to be confirmed by further detailed analysis, this nonetheless indicates
that a-MSH fibres projecting from the arcuate nucleus to the PVN could have contacts
with cells involved in the regulation of male sexual behaviour. This anatomical evidence
could therefore support the hypothesis that a-MSH can be released within the PVN and
SON, and then can interact with the oxytocin system to regulate male sexual behaviour.
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Figure 4.1: Intromission latency in sexually naive and
experienced rats.
Values are mean ± SEM. *p= 0.002, t-test. The number of rats per
group is in parentheses.
Figure 4.2: Photomicrographs illustrating Fos immunoreactivity
(arrow) in the SON of sexually -experienced rats in control
conditions (A) or at intromission (B).







































Figure 4.3: Fos expression at intromission in the SON (A) and in
oxytocin cells in the SON (B).
Values are mean Fos-positive/ section ± SEM (A) or mean % of oxytocin cells
Fos -positive / section ± SEM (B). *p=0.02 versus control (2 way ANOVA ,
Student-Newmann-Keuls method). The number of rats per group is in
parentheses.
Figure 4.4: Photomicrographs illustrating Fos immunoreactivity in
oxytocin neurones (arrow) in the SON of sexually -experienced rats in
control conditions (A) and at intromission (B).
OC: Optic chiasm. Scale bar: lOOpm.


















































































Figure 4.5: Fos expression in oxytocin neurones in the
parvocellular subdivisions of the PVN at intromission in sexually -
naive and -experienced rats.
Values are mean of percentage of oxytocin neurones Fos -positive/ section ±
SEM. The number of rat per group is in parentheses. A: apPVN: anterior
parvocellular PVN. B: vpPVN: ventral parvocellular PVN. C: dpPVN: dorsal

























Figure 4.6: Fos expression in oxytocin neurones in the
magnocellular subdivisions of the PVN at intromission in sexually
naive and -experienced rats.
Values are mean of percentage of oxytocin neurones Fos -positive/ section ±
SEM. *P= 0.025, Two -way ANOVA followed by Student- Newman- Keuls
method. The number of rat per group is in parentheses.
Figure 4.7: Photomicrographs illustrating Fos immunoreactivity (black
arrow) in a-MSH -containing cells (blue arrow) in the arcuate nucleus
of sexually -experienced rats in control conditions (A, C) and at
intromission (B, D,E).





Figure 4.8: Fos expression at intromission in the arcuate nucleus (A)
and in a-MSH containing cells in the arcuate nucleus (B).
Values are mean Fos-positive/ section ± SEM (A) or mean % of a-MSH cells Fos
-positive / section ± SEM (B). *P<0.05 versus control (Two -way ANOVA ,








Figure 4.9: Photomicrographs illustrating a-MSH -containing
fibres (blue arrow) at the vicinity of Fos -positive nuclei (black
arrow) in the PVN at intromission.
Scale bar: 50j_im.
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4.5. Discussion:
Chapter 4
Methodology and experimental design limits:
The control group chosen was male rats placed in a new cage when experimental
rats were placed with a receptive female. Control rats had no sexual stimulation and no
physical contact with a receptive female, and the Fos expression at intromission was
compared with the Fos expression at the same time point in control rats. By using the
control group chosen here, we cannot distinguish the Fos expression induced by
intromission itself as the Fos expression observed at intromission results from other
physical aspects occurring at the same time including mounting behaviour and penile
erection and results as well from sexual motivation. Therefore, we investigated Fos
expression induced by male sexual behaviour as a whole and not just induced by
intromission. To investigate the effect of intromission itself on Fos expression, the
control group should have physical or at least chemosensory contacts with a receptive
female but without being able to display intromission behaviour.
Within the same experiment, the influence of previous sexual experience on Fos
expression during male sexual behaviour was investigated, and to do so rats were
divided into sexually -naive and sexually -experienced rats, reducing the number of rats
per group. Technical problems with the brain sections and immunocytochemistry
procedures reduced the number of section available for analysis, and at the end, the
volume of data available was considerably reduced to just two rats in some groups.
Consequently, the data was not sufficient to compensate for the variability amongst rats
in each group and thus in some cases, a statistical difference between groups could not
be perceived.
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Parvocellular oxytocin neurones are activated during male sexual behaviour:
Intromission increased the percentage of oxytocin neurones activated in all the
parvocellular subdivisions of the PVN except in the lateral posterior PVN. The number
of sections available for analysis was low and high variability between rats could be
seen. Nonetheless, overall these results suggest that parvocellular oxytocin neurones are
activated during sexual behaviour, supporting the study ofWitt & Insel (1994) who
reported that oxytocin neurones in all parvocellular subdivisions are activated following
intromission and ejaculation.
Are magnocellular oxytocin neurones activated during male sexual behaviour?
We investigated whether magnocellular oxytocin neurones were activated during
male sexual behaviour by studying Fos expression in magnocellular oxytocin neurones
in the PVN and in the SON at intromission. In the PVN, we found that magnocellular
oxytocin neurones were activated during male sexual behaviour and that the activation
was significantly increased compared to control, supporting the study by Witt & Insel
(1994) who reported an increase in neuronal activity in the magnocellular subdivisions
of the PVN during male sexual behaviour.
In the SON, the neuronal activity was increased during male sexual behaviour
since the levels of Fos expression in the SON significantly increased at intromission.
This result importantly shows that the magnocellular system from the SON is activated
during male sexual behaviour. After double immunocytochemistry for Fos and oxytocin,
we also found magnocellular oxytocin neurones activated during male sexual behaviour.
However, whether this activation concerned exclusively magnocellular oxytocin
neurones or also involved magnocellular vasopressin neurones requires further
investigation.
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The arcuate nucleus is activated during male sexual behaviour, are a-MSH -
containing cells activated?
When injected i.c.v a-MSH modulates male sexual behaviour, suggesting that
during male sexual behaviour a-MSH is released centrally. Once released a-MSH,
might act in different brain areas including the SON and the PVN, and interact with
different neuronal populations to regulate copulation. We hypothesized that during male
sexual behaviour, a-MSH is centrally released from axonal projections from neurones
located in the arcuate nucleus. We showed for the first time that the neuronal activity in
the arcuate nucleus was increased during male sexual behaviour since Fos expression in
the arcuate nucleus significantly increased at intromission. Using double
immunocytochemistry for Fos and a-MSH, we found many a-MSH -containing cells
activated during male sexual behaviour. However, the neuronal activity of a-MSH -
containing cells at intromission was not significantly increased compared to control in
both sexually -naive and -experienced rats. This result is hard to interpret, firstly because
the level of Fos expression in control animals was high and therefore it limited the
visualization of a putative increase of activation at intromission, and secondly because
only a few cell bodies in the arcuate nucleus were immunostained for a-MSH. Thus, the
activation of a-MSH -containing cells during male sexual behaviour requires further
investigation.
Influence ofprevious sexual experience on male sexual behaviour and on neuronal
activation during male sexual behaviour:
Rats with previous sexual experience were more successful at mating than naive
rats, and presented significantly lower intromission latency than naive rats. We
hypothesized that previous sexual experience might facilitate sexual behaviour by
inducing long-term changes in the neuronal organization of specific brain areas. In the
present study, we investigated the neuronal activity in the PVN, SON and arcuate
nucleus between rats mating for the first time and rats with previous sexual experience.
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Although the activation of the arcuate nucleus was similar at intromission between
experienced and naive rats, the neuronal activation was greater in the SON and in
oxytocin neurones in the PVN of rats with previous sexual experience than in rats with
no sexual experience. This illustrates that sexual experience influences the neuronal
activity in brain areas involved in the regulation of male sexual behaviour but also that
these brain areas are differently influenced by previous sexual experience. Oxytocin
neurones appear to be sensitive to previous sexual experience as their activity increased
in experienced rats compared to naive rats. The facilitation of sexual behaviour could
result from the facilitation of the motivation period or /and the sexual performance.
Indeed, several sexual experiences might enhance the responsiveness of the cells
towards the signals induced by sexual stimulation and might also lead to an increase in
neuronal networking improving, for instance, the rat's ability to perceive sensory
information from the receptive female or to develop the physical aptitudes required to
perform.
The present study firstly confirmed that the experimental conditions used were
adequate to undergo behavioral studies to investigate the neuronal regulation of sexual
behaviour. Secondly, we have shown that previous sexual experience facilitated the
display of male sexual behaviour. However, further investigation is required to extent
this study to other brain areas and other neuronal populations, and to understand why
some areas or neuronal populations are influenced by previous sexual behaviour and
some areas are not. More importantly, we confirmed that parvocellular oxytocin
neurones in the PVN were activated during male sexual behaviour and described that
during male sexual behaviour magnocellular oxytocin neurones from the PVN and from
the SON were activated during male sexual behaviour. The increase in neuronal activity
in magnocellular oxytocin neurones from the PVN and the SON might reflect the
stimulation of oxytocin secretion into the blood occurring at intromission (Chapter 3).
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Finally, we have shown for the first time that, as well as the PVN and the SON, the
arcuate nucleus was also activated during male sexual behaviour. Although, the
activation of a-MSH -containing cells in the arcuate nucleus during male sexual
behaviour needs further investigation, we reported, anatomical evidences in the PVN, of
a-MSH fibres at the vicinity of cells activated during male sexual behaviour. This
indicates that a-MSH can interact with another neuronal system to regulate male sexual
behaviour, and this system could be the oxytocin system.
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g-MSH modulation of neuronal activity in the
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a-MSH and neuronal activity in SON, PVN & Arcuate nucleus Chapter 5
5.1. Introduction:
Previous studies have shown that Fos expression is increased in the SON and
in the PVN after central administration of a-MSH or agonists, suggesting that a-
MSH has excitatory effects on oxytocin neurones (Thiele et al., 1998; McMinn et al.,
2000; Olszewski et al., 2001). Thus, it may be expected that a central administration
of a-MSH or agonists will induce secretion of oxytocin into plasma. However, as
described in Chapter 3, injection of an MC4 receptor agonist led to a reduction in
oxytocin secretion, suggesting inhibitory effects of a-MSH. To understand the action
of a-MSH on oxytocin neurones, these discrepancies needed to be clarified. In a first
experiment, we studied the effects of i.e.v. administration of a-MSH on oxytocin
secretion into blood, and in the same rats on Fos expression in oxytocin neurones in
the SON. We compared the results to those obtained from a positive control group:
rats i.v.-injected with CCK, known to induce oxytocin secretion into blood and to
induce Fos expression in oxytocin neurones (Verbalis et al., 1986; Renaud et al.,
1987).
The PVN is a very heterogeneous nucleus, with different subdivisions where
specific populations of oxytocin neurones are located. Previous studies of Fos
expression in the PVN after a-MSH administration did not distinguish between the
parvocellular oxytocin neurones and the magnocellular oxytocin neurones. These
two types of oxytocin neurones project to different areas, and are involved in
different regulatory functions. Because parvocellular oxytocin neurones project
within the brain, they are the only oxytocin system that is generally recognized to be
involved in central regulation of oxytocin-dependent behaviours. Thus, if a-MSH
interacts with oxytocin neurones to mediate its central effects, we would expect to
see an increase in Fos expression in parvocellular oxytocin neurones after i.e.v.
injection of a-MSH. To investigate if a-MSH modulates specific populations of
oxytocin neurones, especially parvocellular neurones, and so to see if a-MSH has a
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specific role in the regulation of oxytocin neuronal activity, Fos expression in
oxytocin neurones in each subdivisions of the PVN was studied.
In Chapter 4, we found that the arcuate nucleus was activated at intromission.
To investigate whether the increase in neuronal activity in the arcuate nucleus
observed during male sexual behaviour was also stimulated by a-MSH, Fos
expression in the arcuate nucleus was studied.
Finally, in a second experiment, to identify if the effect of a-MSH on Fos
expression in oxytocin neurones was direct or via other type of neurone, Fos
expression in the SON was investigated after local administration of a-MSH.
5.2. Methods:
5.2.1. Experiment 1: Fos expression in the SON, PVN and arcuate nucleus in
conscious rats after i.c.v injection of a-MSH:
To clarify the apparent discrepancies observed between the effects of a-MSH on Fos
expression and on oxytocin secretion, any experimental artefacts or faults needed to
be excluded:
a. Previous Fos expression studies used conscious rats, whereas our
previous study of oxytocin secretion used urethane-anaesthetised rats
(Chapter 3). Although urethane anaesthetic does not impair the
physiological reflexes of oxytocin neurones, we used conscious rats
throughout this experiment to ensure that the anaesthesia process could
not influence the actions of a-MSH.
b. Rats injected intravenously with CCK were used as a positive control
group. CCK induces Fos expression in oxytocin neurones and induces
oxytocin secretion into the general circulation (Verbalis et al., 1986;
Renaud et al., 1987).
5.2.1.1) Surgery:
Male rats were fitted with an i.v. and an i.c.v. cannulae under brief halothane
anaesthesia (sections 2.4.1; 2.4.4). They were then placed in individual cages for two
days of recovery.
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5.2.1.2.) Experimental design:
Sixty minutes after the cannulae (i.v. and i.e.v.) were connected to drug-
administration and blood-sampling tubes, rats were divided into 4 groups: Rats from
the first two groups received a single i.e.v. 5 pl-injection of a-MSH (lpg / 5pi) or
isotonic saline. Rats that had not been equipped with an i.e.v. cannula were injected
intravenously with CCK (20pg/kg/ml) or isotonic saline. Four blood samples (300
pi) were taken for each rat (a basal sample 10 min before the drug injection and 3
samples 10, 15 and 80 min after). Blood samples were kept in ice and centrifuged 3
min at 6500 r.p.m.; plasma samples were aliquoted and kept in freezer -20°C until
they could be processed for radioimmunoassay for oxytocin (section 2.7.3; the
oxytocin radioimmunoassay in this experiment were performed by Dr P. Bull).
Ninety minutes after drug injection, the rats were deeply anaesthetised with an
overdose of sodium pentobarbitone (50mg/kg, s.c.) and perfused transcardially with
heparinised physiological saline (0.9%) followed by 4% paraformaldehyde in 0.1M
phosphate buffer (section 2.8.1). The brains were removed, post-fixed overnight,
cryoprotected in 30% sucrose and stored at -70°C until processed for
immunocytochemistry. Coronal sections of the hypothalamus were cut at 44pm
using a freezing microtome. Only brains with a correct injection site were processed
for immunocyochemistry. Free-floating sections were processed for double
immunocytochemistry for Fos and oxytocin using standard procedures, described in
section 2.8.3. Fos-positive nuclei and the percentage of activation of oxytocin
neurones throughout the PVN and the SON were counted blind. Three sections /rat
were counted for each subdivisions of the PVN and for the dorsal SON. Fos-positive
nuclei in six arcuate nuclei/ rat were analysed throughout the arcuate nucleus.
5.2.2 Experiment 2: Fos expression in the SON after local administration of a-
MSH:
5.2.2.1 Surgery:
Rats, anaesthesised with sodium pentobarbitone (Sagatal, 60mg/kg, i.p.), were fitted
with an microdialysis probe adjacent to the right SON at the coordinates: 0 mm
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rostrocaudal to Bregma, 1.5mm lateral to Bregma and to a depth of 9.5mm from the
surface of the skull, (complete description of the procedure section 2.4.3.).
5.2.2.2. Experimental design:
Two hours after the end of surgery, probes in the SON were microdialysed with
aCSF at 1.5 pl/min. Thirty minutes later, the drug administration started: rats were
were dialysed with either vehicle aCSF or aCSF containing a-MSH (1.7 pg/pl) for
30 min and then with aCSF for the last 30 min. Sixty minutes after beginning the
drug injection, rats were killed with an overdose of pentobarbitone and transcardially
perfused as previously described (section 2.8.1). The brains were removed and
processed for Fos immunocytochemistry using standard procedures as detailed in
section 2.8.3. Three sections per rat through the SON were counted blind at the level
of maximal cross-sectional area.
5.3. Statistics:
Data presented are mean Fos -positive cells/ section or % of oxytocin
neurones Fos-positive/ section ± S.E.M.
5.3.1. Experiment 1:
A one -way repeated measures ANOVA test, followed by a multiple pairwise
comparion Student- Newman-Keuls ad hoc test was used to compare oxytocin
concentration at each time point with basal oxytocin concentration within each of the
four groups (i.v. vehicle, i.v. CCK, i.e.v. vehicle, i.e.v. a-MSH).
A one -way ANOVA test followed by a Student- Newman-Keuls ad hoc test test was
used to compare Fos expression in the SON between the 4 groups.
A t-test or a Mann Whitney rank sum test was used to compare Fos expression in the
PVN and in the arcuate nucleus between a-MSH -treated rats and vehicle -treated
rats.
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5.3.2. Experiment 2:
A paired t-test was used to compare the Fos-positive cells in the ipsilateral nucleus
with its contralateral nucleus within the same coronal section for the vehicle -treated
group and for the a-MSFI -treated group.
A t-test was used to compare the ipsilateral- contralateral difference in Fos-positive
cells between the vehicle -treated group and the a-MSH -treated group.
5.4. Results:
5.4.1. Experiment 1: Fos expression in the SON, PVN and arcnate nucleus in
conscious rats after Lc.v injection of cn-MSH:
i) Changes in oxytocin secretion and Fos expression in the SON after i.c.v.
injection of a-MSH:
In the same conscious rats we tested the effect of an i.c.v. injection of a-MSH
on oxytocin secretion and on Fos expression in oxytocin neurones. We compared the
results obtained with a-MSH to results obtained in conscious rats injected i.v. with
CCK.
As expected, rats i.v.-injected with CCK presented a significant increase in
plasma oxytocin concentration 10 min after injection (P<0.001, One -way RM
ANOVA; Fig 5.1), as well as a significant increase in Fos expression in the SON (55
±11 Fos-positive cells/section) compared to rats i.v -injected with vehicle (18 ± 6
Fos-positive cells/section) (Fig 5.2; 5.3). In the SON of rats injected with CCK, Fos
expression was predominantly dorsally distributed, and double
immunocytochemistry confirmed that this increase concerned oxytocin cells.
In rats injected with a-MSH, no significant changes in oxytocin concentration
were perceived (Fig 5.1). Note that the low circulating concentration of oxytocin in
conscious rats makes the inhibition of secretion by a-MSH undetectable in this
study. However, Fos expression was significantly higher in the SON of rats injected
with a-MSH (110 ± 19 Fos-positive cells/section) than in the SON of rats injected
with vehicle (42 ±18 Fos-positive cells/section; P=0.004, One way ANOVA,
Student-Newman-Keuls) or than in the SON of rats injected with CCK (P=0.005)
(Fig 5.2; 5.3).
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After double immunocytochemistry for Fos and oxytocin, the increase of Fos
expression in the SON induced by a-MSH proved to concern mainly oxytocin
neurones (Fig 5.4; 5.5). There was a significant increase in Fos expression in
oxytocin neurones after i.e.v. -injection of a-MSH (52 ± 5% Fos- positive oxytocin
cells) compared to vehicle (9 ± 3 %, P<0.001, One -way ANOVA), and this increase
in Fos expression in oxytocin neurones after a-MSH injection was even significantly
higher than after the CCK-injection (37 ± 6%, P= 0.025).
ii)Chanses in Fos expression in the paraventricular nucleus after i.e.v. injection
of a-MSH:
In the rats injected with a-MSH, Fos immunoreactivity was widespread in the
PVN. As expected, a-MSH injection increased the number of Fos-positive cells in
the whole PVN, supporting the study by Thiele et al, 1998; McMinn et al., 2000;
Olszewski et al. 2001. To investigate whether a-MSH specifically modulates
different populations of oxytocin neurones, we studied Fos expression in oxytocin
neurones in all the subdivisions of the PVN:
In the parvocellular subdivisions of the PVN:
No significant changes between the rats injected with vehicle and the rats
injected with a-MSH were observed in the four parvocellular subdivisions of the
PVN (Figs 5.6; 5.7; 5.8.). In the anterior parvocellular PVN (Fig 5.8), the increase in
Fos expression in rats injected with a-MSH was noticeable although not significant
(,P=0.122, t-test). Due to the small number of rats per group (4 for vehicle and 3 for
a-MSH), the non-significant values from the lateral posterior PVN should be
interpreted cautiously (Fig 5.8).
After double immunocytochemistry for Fos and oxytocin, activation of oxytocin
neurones by a-MSH was perceptible in the selected subdivisions:
In the anterior parvocellular PVN, rats injected with a-MSH presented 11 ± 3% of
oxytocin neurones expressing Fos, while rats injected with vehicle had 1 ± 3% of
oxytocin neurones which were Fos-positive (Fig 5.9; 5.11). Thus, a-MSH produced
a small but significant increase in Fos expression in oxytocin neurones in the anterior
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parvocellular PVN (P=0.041, t-test). In the ventral parvocellular PVN (Fig 5.9; 5.11),
there was no significant difference in the percentage of oxytocin neurones that
express Fos between rats injected with vehicle (19 ± 7%) and rats injected with a-
MSH (33 ± 6%). In the dorsal parvocellular PVN (Fig 5.10; 5.11), the percentage of
oxytocin neurones that contain Fos was not significantly different in the rats injected
with a-MSH (10 ± 4%) than in the rats injected with vehicle (4 ± 3%). In the lateral
posterior parvocellular PVN(Fig 5.10; 5.11), there was no significant difference in
the percentage of oxytocin neurones that expressed Fos between the rats injected
with a-MSH rats (13 ± 8%) and the rats injected vehicle (12 ± 4%).
In the magnocellular subdivisions of the PVN:
The injection of a-MSH significantly increased the number of Fos-positive
cells in the magnocellular subdivisions of the PVN (Fig 5.12; 5.13): from 12 ± 2 cells
in rats injected with vehicle to 28 ± 3 cells in rats injected with a-MSH (P<0.001, t-
test).
Double immunocytochemistry for Fos and oxytocin, confirmed that
magnocellular oxytocin neurones were activated after i.c.v injection of a-MSH:
In the posterior magnocellular PVN (Fig 5.14; 5.15), no oxytocin neurones expressed
Fos in the vehicle-injected rats. By contrast, in a-MSH- treated rats, the percentage
of oxytocin neurones that expressed Fos was 21± 5%. Thus, the injection of a-MSH
significantly increased Fos expression in oxytocin neurones in the posterior
magnocellular PVN (PcO.OOl, Mann -Whitney rank sum test).
Hi) Changes in Fos expression in the arcuate nucleus after i.c.v. injection of
a-MSH:
In rats injected with a-MSH, 38 ± 3 cells/ arcuate nucleus were Fos-positive,
whereas in rats i.e.v.-injected with vehicle 30 ± 2 cells/ arcuate nucleus were Fos-
positive (Fig 5.16; 5.17). Thus, a-MSH injection significantly increased Fos
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Emure 5.1: Effect of a-MSH i.c.v injection on plasma oxytocin
secretion in conscious rats.
A: Changes in plasma concentration of oxytocin after i.v. injection of
CCK (20pg/kg) or vehicle. B: Changes in plasma oxytocin after i.c.v.
injection of a-MSH (1pg/5pl) or vehicle. CCK induced an 180%
increase in oxytocin secretion whereas a-MSH had no significant effect
(*P<0.05, One way RM ANOVA). The number of rats per group is in
parentheses.
Figure 5.2: Photomicrographs illustrating Fos immunoreactivity in the
SON after i.v. injection of vehicle (A) or CCK(C) or after i.e.v. injection
of vehicle (B) or a-MSH (D).
OC: Optic chiasm, (arrow: Fos protein: black nuclear stain). Scale bar: 50pm.
Figure 5.3: Fos immunocytochemistry in the SON after i.v. injection of
vehicle or CCK or after i.e.v. injection of vehicle or a-MSH.
Values are means ± SEM. The number of rats per group is in parentheses. *P=0.004
versus i.v. vehicle, #P=0.005 versus i.v. CCK (one way ANOVA followed by Student-
Newman-Keuls method).
Figure 5.4: Photomicrographs illustrating Fos immunoreactivity (Black
nuclear stain) in oxytocin neurones (Brown cytoplasmic stain, arrow) in
the SON after i.e.v. injection of vehicle (A) or a-MSH (B).
OC: Optic chiasm. Scale bar: 50pm.
Figure 5.5: Fos expression in oxytocin neurones in the SON after i.c.v
administration of a-MSH.
Values are mean % oxytocin neurones Fos-positive/ section ± SEM. n=8. *P<0.001
versus vehicle treated group, #P=0.025 versus CCK treated group (One way ANOVA
foolwed by Student-Newman-Keuls method).
Figure 5.6: Photomicrographs illustrating Fos immunoreactivity
(arrow) in the anterior parvocellular PVN (A, B) and in the ventral
parvocellular PVN (C, D) after i.c.v injection of vehicle (A, C) or a-MSH
(B, D).
Scale bar: lOO^m.
Figure 5.7: Photomicrographs illustrating Fos immunoreactivity
(arrow) in the dorsa parvocellular PVN (A, B) and in the lateral
posterior parvocellular PVN (C, D) after i.c.v injection of vehicle (A, C)





















































































□ Vehicle ■ a-MSH
Figure 5.8: Fos expression in the parvocellular subdivisions of the PVN after
i.c.v. injection of a-MSH.
A: apPVN: anterior parvocellular PVN; B: vpPVN: ventral parvocellular PVN; C: dpPVN:
dorsal parvocellular PVN; D: IppPVN: lateral posterior parvocellular PVN. Values are means
± SEM. The numbers of rats per group is in parentheses.
Figure 5.9: Photomicrographs illustrating Fos-immunoreactivity (Black
nuclar stain) in oxytocin neurones (Brown cytoplasmic stain, arrows) in the
anterior parvocellular PVN after i.c.v. injection of vehicle (A) or ot-MSH (B)
and in the ventral parvocellular PVN after i.c.v. injection of vehicle (C) or a-
MSH (D).
Figure 5.10: Photomicrographs illustrating Fos immunoreactivity (Black
nuclear stain) in oxytocin neurones (Brown cytoplasmic stain, arrows) in
the dorsal parvocellular PVN after i.e.v. injection of vehicle (A) or a-
MSH (B) and in the lateral posterior parvocellular PVN after i.e.v.
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Figure 5.11: Fos expression in oxytocin neurones in the
parvocellular PVN after i.e.v. administration of a-MSH.
A: apPVN: anterior parvocellular PVN; B: vpPVN: ventral parvocellular PVN;
C: dpPVN: dorsal parvocellular PVN; D: IppPVN: lateral posterior
parvocellular PVN. Values are mean % oxytocin neurones Fos-positive/ PVN
± s.e.m. The number of rats per group is in parentheses. *P=0.041 versus
vehicle treated group, t-test.
Figure 5.12: Photomicrographs illustrating Fos
immunoreactivity (arrow) in the magnocellular PVN after
i.c.v injection of vehicle (A) or after i.c.v injection of a-
MSH (B).
Scale bar: "lOOnm.
Figure 5.13: Fos expression in the magnocellular subdivisions of the PVN
after i.e.v.injection of a-MSH.
Values are means ± SEM. *p<0.001 versus 'vehicle' treated group, t-test. The number of
rats per group is in parentheses.
Figure 5.14: Photomicrographs illustrating Fos immunoreactivity (Black
nuclear stain) in oxytocin neurones (Brown cytoplasmic stain, arrow) in

































Figure 5.15: Fos expression in oxytocin magnocellular neurones in the PVN
after i.c.v administration of a-MSH.
Values are mean % oxytocin neurones Fos-positive/ section ± SEM. n=7. *P<0.001
versus vehicle treated group, Mann-Whitney rank sum test.
Figure 5.16: Photomicrographs illustrating Fos immunoreactivity
(arrow) in the arcuate nucleus after i.c.v injection of vehicle (A) or
after i.c.v injection of a-MSH (B).
Scale bar: 100|u.m.
Vehicle a-MSH
Figure 5.17: Fos expression in the arcuate nucleus after i.e.v.injection of
a-MSH.
Values are means ± SEM. *P=0.020 versus vehicle treated group, t-test. The number




Figure 5.18: Photomicrographs illustrating Fos immunoreactivity (arrow)
in the SON after local retrodialysis of isotonic saline (A: contralateral
side, B: ipsilateral side) or a-MSH (C: contralateral side, D: ipsilateral
side, E: Coronal hypothalamic section with the two SON).
OC: Optic chiasm. 3V: Third ventricle.
Figure 5.19: Fos expression in the SON after local retrodialysis of a-
MSH.
Values are mean ipsilateral-contralateral difference in Fos-positive cells ± SEM. n=6.
*P=0.01, t-test.
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5.4.2. Experiment 2: Changes in Fos expression in the SON after local
administration of a-MSH:
In rats dialysed with vehicle aCSF, there was no significant difference
between the two supraoptic nuclei: the supraoptic nucleus adjacent to the
microdialysis probe (ipsilateral nucleus) contained 10 ± 7 Fos-positive cells/ SON
while the control supraoptic nucleus (contralateral nucleus) contained 10 ± 7 Fos-
positive cells/ SON (Fig 5.18). In rats dialysed with aCSF containing a-MSH, the
ipsilateral nucleus contained 14 ± 5 Fos-positive cells/ SON while the contralateral
nucleus contained 8 ± 3 Fos-positive cells/ SON. Thus, Fos expression in the
ipsilateral nucleus was significantly higher than in the contralateral nucleus
(P=0.005, paired t-test). The mean ipsilateral-contralateral difference in rats dialysed
with vehicle was 0.4 ± 2 Fos-positive cells/ section but was significantly higher in
rats dialysed with a-MSH (7 ± 2 Fos-positive cells/ section; P=0.011, t-test) (Fig
5.19). This indicates that the increase in Fos expression observed in the ipsilateral
supraoptic nucleus is not related to the insertion of the microdialysis probe, but is
induced by administration of a-MSH.
5.4.Discussion
The present study illustrates the modulatory effects of a-MSH on oxytocin
neurones in the PVN and SON. Surprisingly, we found that the modulation of
oxytocin neurones by a-MSH was remarkably selective as a-MSH injection
activated especially magnocellular oxytocin neurones and had little effect on
parvocellular oxytocin neurones. We also found that a-MSH had modulatory effects
on neurones from the arcuate nucleus. These two main findings are discussed in the
following sections:
I. a-MSH and Fos expression in the arcuate nucleus:
i.c.v. administration of a-MSH significantly increased Fos expression in the
arcuate nucleus. The arcuate nucleus is a heterogeneous nucleus that contains
different neuronal populations with specific neurotransmitters that mediate particular
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effects. So, the increase of Fos expression by a-MSH could reflect the modulation of
activity of POMC neurones such as endorphin-, corticotropin- or melanotropic
peptide -containing neurones. a-MSH could also interact directly or indirectly with
a-MSH -containing neurones as an auto-control of its own release. Although MC3
and MC4 receptors are expressed in the arcuate nucleus, the presence of
melanocortin receptors on a-MSH neurones still needs to be investigated. Thus, this
result could reflect the role of a-MSH in the regulation of a vast number of
biological functions and behaviours. For instance, the arcuate nucleus is one of the
regulation centres of feeding behaviour and because a-MSH is a potent anorexic
peptide, an increase of Fos expression in the arcuate nucleus after i.e.v. a-MSH
could reflect neuronal interactions involved in the regulation of feeding. Another
possible candidate with whom a-MSH could interact is the neuropeptide Y (NPY,
from the pancreatic polypeptide family). The arcuate nucleus is the major source of
NPY expression in the hypothalamus, and amongst other physiological functions,
NPY is known to stimulate feeding. Growing evidence suggests that a-MSH and
NPY systems interact to regulate each other's activity. Hansen et al. (2002) have
shown that a-MSH i.c.v administration (1 - 4nmol) attenuates NPY-induced food
intake.
II. a-MSH modulates directly and selectively magnocellular oxytocin neurones:
We found that a-MSH modulates directly and selectively the activity of
oxytocin neurones. Unexpectedly a-MSH had no or little effect on parvocellular
oxytocin neurones, but predominantly activated magnocellular oxytocin neurones.
Nonetheless, a-MSH had no effect on oxytocin secretion into the plasma. These
results place the relationship between Fos and neuronal electrical activity, and the
interaction between a-MSH and the magnocellular oxytocin system into question:
• Relationship between Fos and neuronal depolarization:
Since its discovery in stimulated neurones by Sagar and colleagues (1988),
Fos, the protein product of the immediate early gene c-fos, has been widely used as
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an anatomical marker of neuronal activation. It has been generally accepted that the
presence of Fos in a neurone reflects the electrical neuronal excitation, and is
consequential to a stimulus -induced depolarization. However, the present study of
the effects of a-MSH on the oxytocin system contradicts this general assumption. To
try to clarify the real meaning of Fos, it needs to be understood why the presence of
Fos in a stimulated neurone led to the assumption that this neurone was excited, and
some evidence countering this general assumption, including a brief description of
the main signaling pathways that lead to the transcription of the c-fos gene, needs to
be examined.
1. Why has Fos been assumed to reflect neuronal excitation?
In numerous neuronal systems, the presence of Fos is associated with an increase
in the neuronal electrical activity in various conditions:
Parvocellular and magnocellular oxytocin neurones when stimulated
generally express the protein Fos. Numerous stimuli, for instance stress (Sharp et al.,
1991), osmotic stimulation (Giovannelli et al., 1990), peripheral injection of CCK
(Verbalis et al., 1991) and behaviours like parturition (Douglas et al., 1995) induce
Fos expression in magnocellular oxytocin neurones. In each of these examples, Fos
expression is associated with an increase of the neuronal firing rate andI or with an
increase in plasma oxytocin secretion. For instance, osmotic stimuli such as a
systemic injection of hypertonic saline and water deprivation induce strong Fos
expression in magnocellular oxytocin neurones (Giovannelli et al., 1990), and
increase oxytocin secretion in the general circulation (Strieker & Verbalis, 1986).
Shibuki et al., (1988) showed that hypertonic saline injection also induced an
increase in the firing rate of oxytocin neurones. Another example of stimulus
inducing Fos expression is a peripheral injection of CCK. CCK induces secretion of
oxytocin but has no effect on vasopressin secretion (Verbalis et al., 1986), increases
the electrical activity of oxytocin neurones but has no effect on vasopressin neuronal
activity (Renaud et al., 1987), and induces Fos expression in oxytocin neurones but
not in vasopressin neurones (Verbalis et al., 1991). These studies suggested that Fos
expression reflects an increase in neuronal activity in magnocellular neurones.
Compared to an injection of hypertonic saline, systemic injection of CCK induces a
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mild and transient increase in electrical activity of magnocellular oxytocin neurones,
but nonetheless, it also induces Fos expression in magnocellular oxytocin neurones,
suggesting that Fos expression does not only reflect a strong and sustained neuronal
activation. This was illustrated in a study by Hamamura et al. (1991), in which they
compared the degree of c-fos mRNA expression with the electrical activation of
oxytocin neurones after systemic injection of CCK using an i.p injection of
hypertonic saline as a positive control. Injection of hypertonic saline induced an
intense increase in neuronal activity and strong c-fos mRNA expression in
magnocellular oxytocin neurones. Although, CCK injection induced a brief increase
in neuronal activity of magnocellular oxytocin neurones, it induced a detectable
increase in c-fos mRNA expression. This illustrated that a brief and small electrical
activation was sufficient to induce c-fos mRNA expression in magnocellular
oxytocin neurones. Thus, these results suggested that the Fos was a specific and
precise marker of increased neuronal electrical activity associated with stimulated
secretion.
Taking these observations together, it has been deduced that a neurone
containing Fos was an excited neurone and led to the general assumption that Fos
was a marker of neuronal excitation.
2. Contradicting evidence
Firstly, Fos expression is not always associated with increased neuronal
activity. Indeed, previous studies have shown that a-MSH induced Fos expression in
vasopressin neurones (Olszewski et al., 2001). If Fos reflects neuronal
depolarization, a-MSH should also induce an increase in firing rate of vasopressin
neurones. However, Sabatier et al. (2003) showed that a-MSH i.e.v. had no effect on
the electric activity of vasopressin neurones.
Conversely, there are examples were depolarization (and/ or secretion) is not
associated with Fos expression:
i). LHRH neurones contain NMDA (N-methyl-D-aspartate) receptors. An
injection of a NMDA receptor agonist increases the secretion of GnRH and hence the
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secretion of LH, but fails to induce Fos expression in LHRH neurones (Hoffman,
1993).
ii). Excitatory efferents from the cerebral cortex project to regions in the basal
ganglia including the striatum. Fu & Beckstead (1992) reported that electrical
stimulation of the cerebral cortex induces Fos expression in striatal neurones.
However, Sgambato et al. (1997) reported that electrophysiological activation of
striatal cells was not systematically accompanied by Fos expression. They
electrically stimulated different cortical areas in the rat and looked at the Fos
induction in the striatum and measured the electrical activity of striatal cells.
Whereas electrical stimulation of the motor or auditory cortex induced increase in
neuronal activity and Fos expression in the striatum, electrical stimulation of the
somatosensory facial area (visual and orbital cortices) increased electrical activity in
the striatum but failed to induce Fos expression in the striatal areas receiving these
cortical excitatory inputs. They therefore suggested that Fos induction does not
accurately reflect neuronal activity.
The present study of a-MSH effect on the Fos expression in oxytocin
neurones and on oxytocin secretion, also illustrates dissociation between Fos
expression and neuronal electrical activity. While i.e.v. injection of a-MSH
increased Fos expression in magnocellular oxytocin neurones in the SON and in the
PVN, it did not stimulate the secretion of oxytocin into plasma. In addition, we
previously described that an i.e.v. injection of MC4 receptor agonist inhibited plasma
oxytocin secretion (Chapter 3). Positive control CCK-injected rats presented, as
expected, an increase of Fos expression in the SON as well as an increase in oxytocin
secretion, demonstrating that the apparent contradictory results obtained for a-MSH
-injected rats were not due to an experimental artifact. This would suggest that a-
MSH increases Fos expression and inhibits oxytocin secretion from the nerve
terminals in the posterior pituitary and therefore inhibits oxytocin electrical activity.
An inhibition of secretion might result either from a reduction in electrical activity of
the neurones, or from an inhibitory action at the nerve terminals analogous to the
actions of opioid peptides (Bicknell and Leng, 1982). Sabatier et al. (2003) showed
an inhibition of electrical activity of oxytocin neurones by a-MSH. They tested the
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effect of a-MSH and MC4 receptor agonist on oxytocin neurone electrical activity.
a-MSH produced a rapid inhibition of oxytocin cells and MC4 receptor agonist
inhibited oxytocin neurones in a dose-dependant manner; Thus, these results
strikingly suggest that Fos expression does not necessarily reflect excitation of the
neurones, and can be associated with the inhibition of electrical activity; whether a-
MSH also inhibits oxytocin secretion by an action at the nerve terminals is not
established.
3. Intracellular signaling pathways regulating c-fos transcription:
c-fos gene transcription is controlled by two major promoter sequences
CaCRE (Ca2+/ cAMP responsive element) occupied by CREB (CRE -binding
proteins) regulated by phosphorylation, and SRE (serum responsive element) to
which TCF (ternary complex factors) and SRF (SRE -binding factors) binds (Fig
5.20). Various complex signaling pathways lead to the activation of these two
promoter sequences. CREB, for instance, can be phosphorylated by several kinases,
which are themselves activated by changes in intracellular calcium or cAMP
concentration.
The fact that calcium is a major second messenger in the c-fos transcription
signaling pathways and that an increase in intracellular calcium concentration can
induce Fos expression confirmed the assumption that Fos induction was related to
depolarization, as the opening of voltage -dependent Ca 2+ -channels by
depolarization would result in an entry of calcium. However, an entry of calcium by
depolarization is not sufficient to induce Fos expression. Indeed, Luckman et al.
(1994) demonstrated that an increase in spike activity of suproptic neurones was not
sufficient to induce Fos expression in the same neurones. They compared the effect
of i.c.v. carbachol (a muscarinic receptor agonist) and antidromic stimulation on Fos
expression and firing rate of magnocellular neurones in the SON. Carbachol
increased the firing rate of both oxytocin and vasopressin neurones as well as
increased the Fos -immunoreactivity in the SON. However, Fos expression in the




















Figure 5.20: Schematic illustration of the main signalling pathways
leading to Fos expression, (adapted from Hoffman & Lyo 2002)
There are two major promoter sequences controlling c-fos gene transcription: CaRE/ CRE
(calcium / cAMP responsive element) and SRE (serum responsive element). In the first main
pathway, an increase of either intracellular calcium or cAMP induces, by activation of specific
kinases, the phosphorylation of transcription factor CREB (CRE binding proteins). The
binding of numerous neurotransmitters to their receptors can induce an increase of
intracellular cAMP or intracellular calcium. Depolarisation, via activation of voltage-dependent
Ca2+ channels or relargage of Ca2+ from the reticulum endoplasmic store (RE) can also
increase the level of intracellular calcium. In a second pathway, the binding of growth factors
or mitogens on their receptors induces the activation of kinases (e.g.: MAPkinases) which
induces the phosphorylation of the transcription factors SRF (serum response factors) and
TCF (ternary complex factor) which bind to SRE.
AC: Adenylate cyclase; cAMP: cyclic adenosine monophosphate; CaM: Calmodulin; G: G-
protein.
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This suggests that Fos is not induced by the influx of Ca2+ resulting from the spike
activity but requires some additional intracellular signal.
In addition, changes in intracellular Ca2+ can result from a release of Ca2+
from the endoplasmic reticulum stores (ER). Gissel et al. (1997) used thapsigargin
(an irreversible inhibitor of Ca2+-ATPase of the ER) to deplete the Ca2+ ER store of
primary neurones in culture, and measured changes of c-fos mRNA. Thapsigargin
induced an increase in c-fos mRNA expression. Thus, a surplus of Ca2+ ions from
depolarization is not the only source of changes of intracellular Ca2+ that induce c-fos
transcription, Ca2+ from ER store intervenes too.
As indicated by its name, CaCRE (Ca2+/ cAMP responsive element) is also
under the regulation of intracellular cAMP levels. Indeed, an increase in intracellular
cAMP concentration activates various kinases that then phosphorylate CREB, which
in turn activates CaCRE. The production of cAMP results from activation of
metabotropic receptors by a variety of neuropeptides and neurotransmitters (Hoffman
& Lyo, 2002).
Thus, the presence of Fos in a neurone can result from the activation of
various signaling pathways that can be independent from any changes in intracellular
Ca2+. This illustrates that considering Fos expression as a reflection of depolarization
and neuronal excitation is inadequate. The complex cellular mechanisms and
signaling cascades that induce Fos still need to be clarified and until then, no
assumption about Fos significance should be made. The presence of Fos in a neurone
after stimulation indicates that some changes in the intracellular signaling pathways
have been induced by the stimulus used: the neurone is 'activated'; but these changes
can be associated either with an excitation, an inhibition or with no modification of
the neuronal electrical activity.
• a-MSH and the magnocellular oxytocin system:
1. Direct action of a-MSH onto magnocellular oxytocin neurones:
In the second experiment, we found that a local infusion of a-MSH onto the
SON induced an activation of oxytocin magnocellular neurones, and so confirmed
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that this modulation was direct on the oxytocin neurones and not through other types
of neurones. This result corroborates the study of Sabatier et al. (2003) who tested
the effect of a-MSH directly administrated onto the SON by retrodialysis. They
measured the changes in the firing rate of five oxytocin neurones during retrodialysis
of a-MSH (concentrations from 1 to 3.4pg/pl) and found that the oxytocin neurones
were inhibited by a-MSH. Two types of melanocortin receptors MC3 and MC4
receptors, are involved in the central effects of a-MSH. No MC3 receptors or MC3
receptor mRNA has been located in the SON or PVN but high levels of MC4
receptor mRNA have been found (Mountjoy et al., 1994). Furthermore, Sabatier et
al. (2003) demonstrated that i.e.v. administration of a MC4 receptor agonist
significantly decreased oxytocin firing rate. Taken together, these results indicate
that the direct effect of a-MSH on oxytocin neurones is mediated via MC4 receptors.
2. Magnocellular oxytocin system and central regulation ofoxytocin-dependent
behaviours:
Generally, oxytocin is limited in its ability to cross the blood -brain barrier
and so very little of the oxytocin that is secreted in the blood can reenter in the brain.
Because magnocellular oxytocin neurones project to the pituitary gland (where
oxytocin is released in the blood) and have very few axon collaterals terminating
within the central nervous system, it has been assumed that the magnocellular
oxytocin system was not involved in central regulation of behaviours. Instead, it has
been assumed that the parvocellular oxytocin neurones, which project to different
brain areas where functional oxytocin receptors have been located, were the only
oxytocin system involved in the central regulation of oxytocin-dependent behaviours.
Since a-MSH and oxytocin are thought to interact centrally to modulate their
central effects, an i.c.v injection of a-MSH was expected to activate parvocellular
oxytocin neurones with no major effect on magnocellular oxytocin neurones.
However, we found the opposite: although a-MSH had little effect on parvocellular
oxytocin neurones, as it activated only oxytocin neurones from the anterior
parvocellular PVN; a-MSH predominantly activated magnocellular oxytocin
neurones in both the PVN and the SON. We also found that a-MSH administration
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induced no significant changes in oxytocin secretion. These results place the role of
magnocellular oxytocin neurones into question:
If the only role of the magnocellular oxytocin system is to control the secretion of
oxytocin into the systemic circulation, why does a-MSH, which has no effect on
oxytocin secretion, induce changes in the intracellular pathways of magnocellular
oxytocin neurones (reflected by the presence of Fos)?
Could magnocellular neurones be involved in the central regulation of oxytocin-
dependent behaviours? Perhaps, oxytocin released from the dendrites of
magnocellular neurones could act as a neurohormone by diffusing to distant brain
areas and interact with other neuronal systems to regulate various functions and
behaviours. Several lines of evidence support this hypothesis:
i). As mentioned in chapter 1, oxytocin fibres and oxytocin receptors have
been located in many areas throughout the CNS. Their distribution is well
documented (see Buijs et al, 1978, 1979, 1985; Yoshimura et al., 1993; Elands et
al., 1998; Vaccari et al., 1998; Gimpl & Fahreholz, 2001; Table 1.3). Going through
the literature, discrepancies within the distribution of oxytocin fibres and receptors
become apparent. Although, several authors mentioned the existence of mismatches
between the localization of oxytocin fibres and the localization of oxytocin receptors
(Yoshimura et al. 1993), no study ever precisely detailed or listed those mismatches.
In brief, by comparing areas where both oxytocin innervation and oxytocin receptors
distribution have been investigated, it is noticeable that the distribution of oxytocin
axon terminals and oxytocin receptors does not follow any 'rules of organisation'
(Table 1.3): Some areas are highly innervated with oxytocin fibers and possess
numerous oxytocin receptors (e.g.: hypothalamus); conversely, some areas are
weakly innervated and possess a small number of oxytocin receptors (e.g.: SFO,
hippocampus). But interestingly, in some areas, while oxytocin innervation is weak,
oxytocin receptors are disproportionately abundant (e.g.: olfactory system,
subiculum, amygdala, BNST).
The functionality of these receptors has been confirmed by electrophysiological
studies (DeKloet et al., 1990). It seems unlikely that the existence of receptors
independent from any oxytocin axon terminals is due to a redundant expression of
oxytocin receptors in these brain areas.
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ii) In many brain areas, the content of oxytocin in extracellular fluid is much
higher than what should be expected by local release from axon terminals only.
Oxytocin release from different micro-dissected brain areas has been measured in
basal and 'stimulated' (high levels of K+induced depolarization) (Moos et al., 1984;
Buijs et al., 1985). Even in conditions where the release is stimulated, the levels of
oxytocin released represent only around 3% of the local tissue content. Landgraf et
al. (1992) performed push-pull perfusion studies in vivo and measured the amount of
oxytocin release from different brain areas in basal conditions. They found that the
quantity of oxytocin release from the axon terminals was not substantial enough to
explain the large amount of oxytocin found in many brain areas. The cerebrospinal
fluid (CSF) also contains oxytocin (from 0.5 to 0.7pg/ml at basal levels), of which
the source is unclear. The oxytocin present in both CSF and extracellular fluid in
many brain areas could derive from the diffusion from magnocellular neurones as the
major source of oxytocin in the brain is the magnocellular system and dendrites from
the magnocellular neurones are packed with oxytocin neurosecretory granules.
Hi) Pow and Morris (1989) have demonstrated that oxytocin can be released
from the dendrites of magnocellular neurones by exocytocis. Numerous stimuli are
known to induce dendritic release of oxytocin (Fudwig, 1998). Central dendritic
release of oxytocin and peripheral secretion of oxytocin from axons terminals are
regulated by different mechanisms and dendritic release is semi- independent from
the electrical activity. Oxytocin itself has been reported to induce dendritic release of
oxytocin without any oxytocin secretion into the plasma (Ludwig, 1998). In a similar
way, a-MSH could trigger oxytocin release from magnocellular neurones without
inducing peripheral secretion.
Thus, some central effects of a-MSH could be mediated via dendritic release of
oxytocin from magnocellular neurones rather than via oxytocin release from the axon
terminals of the parvocellular neurones.
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Taken together, these results illustrate the fact that central a-MSH could
interact with the oxytocin system to regulate some physiological functions and
behaviours. Indeed, a-MSH modulates the activity of specific subpopulations of
oxytocin neurones: it predominantly modulates the activity of oxytocin
magnocellular neurones and does not modulate the activity of oxytocin parvocellular
neurones, except the anterior parvocellular neurones. a-MSH may act directly on
oxytocin magnocellular neurones via MC4 receptors to trigger oxytocin release from
the dendrites. Thus, some behavioural effects of a-MSH that are mediated by
oxytocin may reflect central dendritic release of oxytocin from magnocellular
neurones, rather than from parvocellular neurones.
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Oxytocin and a-MSH interaction during male sexual behaviour Chapter 6
6.1. Introduction:
Magnocellular oxytocin neurones in the PVN and in the SON are activated at
intromission (Chapter 4). In conscious rats, i.e.v. administration of a-MSH increased
Fos expression in magnocellular oxytocin neurones but had no effect on parvocellular
oxytocin neurones (Chapter 5). We concluded that a-MSH modulated magnocellular
oxytocin neurones specifically, probably via MC4 receptors. In the present study, we
investigated whether the activation of magnocellular oxytocin neurones observed at
intromission is induced by a-MSH via MC4 receptors.
We studied whether blocking the central effects of a-MSH that are mediated by
MC4 receptors would attenuate the Fos expression in magnocellular oxytocin neurones
observed at intromission. The goal of this study was to confirm a plausible interaction
between a-MSH and oxytocin in the regulation of their central effects and, at the same
time, to clarify the involvement of the MC4 receptors in the mediation of male sexual
behaviour. Rats were injected i.e.v. with a MC4 receptor antagonist or vehicle. The Fos
expression induced at intromission was then analyzed in all the subdivisions of the PVN
and in the SON.
Finally, to clarify the previous results that a-MSH induced Fos expression in the
arcuate nucleus (Chapter 5); a nucleus that is activated at intromission (Chapter 4), we
measured changes in Fos expression in the arcuate nucleus after i.c.v administration of
MC4 receptor antagonist. This study contributes to investigate a putative action of a-
MSH on the arcuate nucleus and to discuss the involvement of the arcuate nucleus in the
regulation of male sexual behaviour.
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6.2. Methods:
6.2.1. Preparation of the females: Induction ofsexual receptivity:
A month before the beginning of the experiment, 12 female rats were
ovariectomised under brief halothane anesthesia (section 2.9.1.2) and then placed into
single cages for recovery. Sexual receptivity was induced by s.c. injection of 3-(3-
estradiol monobenzoate (30pig/ 300pi; 48h before the test or experiment) and
progesterone (lmg/ lOOpl; 5 to 6h before the test or experiment) (section 2.9.1.2). A
week before the experiment, each female was tested with a sexually-experienced male
(stud male) to ensure that the doses used were sufficient to induce receptivity in all the
females injected; and the timing of injection was adjusted to ensure the females were
receptive at the starting time of the experiment i.e.: 13:00h.
6.2.2. Reverse light cycle:
Two weeks before the beginning of the experiment, rats were placed in reverse
light cycle (dark from 10:00h to 22:00h). All the following tests and experiments were
performed in the dark phase under dim red light illumination.
6.2.3. Preparation of the males:
6.2.3.1.) Test ofmale sexual visor:
Sexually-experienced rats were used in this experiment. To ensure that males
were physically-capable of mating, male sexual vigor was tested one week before the
experiment. Each male was placed with a receptive female for 15 min. Only males that
successfully mated were used for the experiment.
6.2.3.2) Surgery:
Three days before the experiment, males were fitted with an i.e.v. cannula under
brief halothane anaesthesia (section 2.4.4) and then placed in a single cage for recovery
until the beginning of the experiment.
108
Oxytocin and CX-MSII interaction during male sexual behaviour Chapter 6
6.2.4. Experimental design:
6.2.4.1. Injection ofMC4 receptor antagonist:
The selective MC4 receptor antagonist L-863224 (Merck Laboratories, USA)
(also named MBP10) was used.
i.c.v injections of MC4 receptor antagonists have been reported to have effects on sexual
behaviour at doses from 5pg/ rat to lOjLig/ rat (Vergoni et al., 1998 & 2000; Martin et al.,
2002). It was important to ensure that the injection of MC4 receptor antagonist would
not block male sexual performance, as the objective was to compare neuronal activation
during intromission with vehicle-injected rats. Therefore, a low dose of 5.5pg/ 2pl/ rat
of MC4 receptor antagonist was used, as used by Martin et al. (2002).
Dilution for 1 ml of MC4 receptor antagonist solution:
2.75 mg MC4 R antagonist (Merck)
400 pi Polyethylene glycol 6000 (BDH)
100 pi EtOH (BDH)
500 pi saline
The timing of the drug injection was important, as the effect of the antagonist
needed to be synchronized with the rat behaviours. If the injection was too early before
the test, then the drug effects would have disappeared long before the rat become
aroused, and so the mating would then happen as normal. If the injection was too late,
again the injection would have no effect on the mating process. In previously published
studies related to male sexual behaviour, melanocortin receptor antagonists were
injected before pairing the male and the female together (Vergoni et al., 1998 & 2000;
Martin et al., 2002). Unfortunately, no more precise time of injection was described. In
one study about the role ofmelanocortin receptors in sexual behaviour in female rats,
sexual activity was tested 10 min after the i.c.v. administration of a central melanocortin
receptor antagonist (Cragnolini, 2000). As described in chapter 3, i.c.v. injection of
MC4 receptor agonist induced a significant decrease in plasma oxytocin concentration
15 min after the injection. In our laboratory conditions, intromission, the behaviour
reference chosen, happened around 4 min after pairing a male with a receptive female.
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The timing of injection chosen was 10 min before pairing to ensure that the expected
duration of drug action would cover the time period during which rats would have mated
in normal conditions (injection time + 14 min).
6.2.4.2. Protocol:
Ten minutes after connecting the drug administration tubes to the i.e.v. cannula,
rats were injected with 2 |al of MC4 receptor antagonist (5.5 |lg) or vehicle (saline). Ten
min later, each injected-rat was paired with a receptive female in the female's cage.
Sexual behaviours were recorded for 15 min or until the intromission reference
behaviour had occurred. Males were then put back in their own cage. Rats were killed
with an overdose of pentobarbitone (50mg/kg, s.c.), 95 min after being paired with a
female for the control non-mating rats, or 90 min after intromission for the mating rats.
Rats were perfused transcardially with heparinised physiological saline (0.9%) followed
by 4% paraformaldehyde in 0.1M phosphate buffer (section 2.8.1). The brains were
removed, post-fixed overnight, cryoprotected in 30% sucrose and stored at -70°C until
processed for immunocytochemistry. Coronal sections of the hypothalamus were cut at
44/xm using a freezing microtome. Only brains with a i.e.v.-injection site confirmed
were processed for immunocyochemistry. Free-floating sections were processed for
double immunocytochemistry for Fos and oxytocin as described in section 2.8.3. Fos-
positive nuclei and the percentage of activation of oxytocin neurones throughout the
PVN and the SON were counted blind. Four SON/ rat were counted for the dorsal SON;
two profiles/ rat were counted for each subdivisions of the PVN. Fos-positive nuclei in
six arcuate nuclei/ rat were analysed throughout the arcuate nucleus (posterior arcuate
nucleus excluded).
6.3. Statistics:
A t-test was used to compare the mount and intromission latencies between
vehicle-treated rats and MC4 receptor antagonist-treated rats.
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Against expectations, a few rats injected with the MC4 receptor antagonist did not mate,
creating a third experimental group with a small n number. A one-way ANOVA test was
performed to compare Fos expression between the three groups (vehicle-treated mating
rats, MC4 receptor antagonist-treated mating rats, MC4 receptor antagonist-treated
control (non-mating) rats), followed by a pairwise multiple-comparison post hoc test
(Student-Newman-Keuls Method). In a case of a failure of the equal test of variance, a
one-way ANOVA on ranks followed by a pairwise multiple-comparison procedure
(Dunn's Method) was performed instead. A P value < 0.05 was considered as
statistically significant.
Statistical differences between data from the vehicle-injected mating rats and the MC4
receptor antagonist-treated non-mating rats were not taken into account, as the rats from
these two groups have different treatment and experimental status.
6.4. Results:
i)Changes in sexual behaviour parameters after i.e.v. injection ofMC4 receptor
antagonist:
While all rats injected with vehicle mated when paired with a receptive female, only
5 out of 8 rats injected with MC4 receptor antagonist mated in the same conditions (Fig.
6.1.A). In the rats that did mate, injection of the MC4 receptor antagonist slowed down
the mating process (Fig. 6.1.B):
After 78 ± 24s since pairing with a female, vehicle-injected rats displayed the first
intensive mount whereas an average of 188 ± 94s were required for the MC4 receptor
antagonist-injected rats (P=0.059, t-test). The reference behaviour (intromission)
occurred after 127 ± 29s in vehicle-treated rats and after 274 ± 137s in rats treated with
MC4 receptor antagonist (P=0.052, t-test). The time between the first intensive mount
observed and intromission also increased in the MC4 receptor antagonist-treated group
(87 ± 43s against 49 ± 9s for vehicle-treated rats).
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iiiChanses in Fos expression in the PVN after i.c.v injection ofMC4 receptor
antagonist:
In the parvocellular subdivisions of the PVN:
Due to technical issues no sections with the lateral posterior parvocellular PVN
were available for analysis for Fos alone.
In all the other subdivisions of the parvocellular PVN, no significant changes in the Fos
expression were measured between the vehicle-treated rats and the MC4R antagonist-
treated rats (Fig. 6.2; 6.3; 6.4). Nonetheless, in all parvocellular subdivisions, Fos
expression in MC4R antagonist-treated rats that did not mate was generally lower than
in the mating rats, verifying that the injection of MC4 receptor antagonist itself did not
induce Fos expression.
The same observations were obtained after double immunocytochemistry for Fos and
oxytocin: no significant changes in the Fos expression in parvocellular oxytocin
neurones were noticed between the vehicle-treated rats and the MC4R antagonist-treated
mating rats (Fig. 6.5, 6.6, 6.7).
In magnocellular subdivisions of the PVN:
No significant changes in Fos expression at intromission were noticed between
the vehicle-treated rats and the MC4R antagonist-treated rats (Fig. 6.8; 6.9). However,
after double immunocytochemistry for Fos and oxytocin, attenuation in Fos expression
in magnocellular oxytocin neurones in MC4R antagonist-treated group was significant
(Fig. 6.10; 6.11). Indeed, at intromission, 14 ± 6% of magnocellular oxytocin neurones/
PVN were Fos-positive in vehicle-treated rats against 5 ± 3% of magnocellular oxytocin
neurones/ PVN in MC4R antagonist-treated rats (P=0.015, One-way ANOVA). No
oxytocin neurones were Fos-positive in the MC4R antagonist-treated rats that did not
mate, verifying that the injection itself did not induce any Fos (Fig. 6.11).
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iii)Changes in Fos expression in the SON after i.c.v injection ofMC4 receptor
antagonist:
In the SON (Fig. 6.12; 6.13), i.c.v injection of MC4R antagonist had no effect on
Fos expression induced at intromission. The MC4R antagonist-treated rats that didn't
mate showed a significantly lower level of Fos expression in the SON, verifying that the
injection of MC4R antagonist itself did not induce Fos expression.
Double immunocytochemistry for Fos and oxytocin confirmed that intromission
increases Fos expression in oxytocin neurones in the SON as Fos expression in oxytocin
neurones was significantly higher in MC4 receptor antagonist-treated rats that mate than
in MC 4 receptor antagonist -treated non-mating rats (P=0.036, One-way ANOVA on
ranks, Dunn's method). Moreover, Fos expression induced at intromission in oxytocin
neurones was significantly attenuated by injection of MC4 receptor antagonist (Fig.
6.14; 6.15). Indeed, in vehicle-treated rats, 26 ± 4% oxytocin neurones/ SON were Fos -
positive at intromission compared with 11 ± 3% oxytocin neurones Fos-positive / SON
in MC4R antagonist -treated rats (P<0.05).
iv)Changes in Fos expression in the arcuate nucleus after i.c.v injection ofMC4
receptor antagonist.
In the arcuate nucleus (Fig. 6.16; 6.17), i.c.v injection of MC4 receptor
antagonist had no significant effect on Fos expression induced at intromission. The MC4
receptor antagonist-treated/ Control group presented a similar level of Fos expression to

































latency (t1) latency (t2)
t2-t1
Figure 6.1: Changes in behavioural parameters after i.e.v. injection
of MC4 receptor antagonist
A: Success of mating. Values are percentage of rats that mated. B: Time to onset
of mating behaviours after i.c.v injection of MC4 receptor antagonist.Values are
means ± SEM. Mount latency: Time (s) to first intensive mount; Intromission
latency: Time (s) to intromission; t2-t1: Time between the first mount and the first
intromission.
apPVN vpPVN
Figure 6.2: Photomicrographs illustrating Fos immunoreactivity
(arrow) in the anterior parvocellular PVN (A, C, E) and in the ventral
parvocellular PVN (B, D, F) at intromission after i.c.v injection of
vehicle (A, B) or i.c.v injection of MC4 receptor antagonist (C, D) or in
control rats after i.c.v injection of MC4 receptor antagonist (E, F).
Photomicrographs illustrating the increase in Fos expression in the apPVN and in
the vpPVN at intromission (A, B, C, D) compared to control conditions (E, F).
However, there is no difference in Fos expression present at intromission between
vehicle -injected rats (A, B) and MC4 receptor antagonist -injected rats (C, D).
3V: Third ventricle. Scale bar: 100p.m.
c
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Figure 6.3: Photomicrographs illustrating Fos immunoreactivity (arrow)
in the dorsal parvocellular PVN at intromission after i.c.v injection of
vehicle (A) or i.c.v injection of MC4 receptor antagonist (B) or in control
rats after i.c.v injection of MC4 receptor antagonist (C).
Photomicrographs illustrating the increase in Fos expression in the dpPVN at
intromission (A, B) compared to control conditions (C). However, there is no difference
in Fos expression present at intromission between vehicle -injected rats (A) and MC4
receptor antagonist -injected rats (B).











I I Vehicle/ Intromission
Hi MC4 R antagonist/ Intromission
[\\1 MC4 R antagonist / Control
Figure 6.4: Fos expression in the parvocellular subdivisions of the PVN
after i.c.v injection of MC4 receptor antagonist.
Values are means Fos-positive cells/ section ± SEM. A: apPVN: anterior
parvocellular PVN. B: vpPVN: ventral parvocellular PVN. C: dpPVN: dorsal
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Figure 6.5: Photomicrographs illustrating Fos in oxytocin neurones
(arrow) in the anterior parvocellular PVN (apPVN; A, C, E) and in the
ventral parvocellular PVN (vpPVN; B, D, F) at intromission after i.c.v
injection of vehicle (A, B) or i.c.v injection of MC4 receptor antagonist
(C, D) or in control rats after i.c.v injection of MC4 receptor antagonist
(E, F).
3V: Third ventricle. Scale bar: 100(.im.
dpPVN LppPVN
Figure 6.6: Photomicrographs illustrating Fos in oxytocin neurones
(arrow) in the dorsal parvocellular PVN (dpPVN; A, C, E) and in the
lateral posterior parvocellular PVN (LppPVN; B, D, F) at intromission
after i.c.v injection of vehicle (A, B) or i.c.v injection of MC4 receptor
antagonist (C, D) or in control rats after i.c.v injection of MC4 receptor
antagonist (E, F).
















































































































HI MC4 R antagonist/ Intromission
MC4 R antagonist / Control
Figure 6.7: Changes in Fos expression in oxytocin neurones in the
parvocellular subdivisions of the PVN after i.e.v. injection of MC4 receptor
antagonist.
Values are means % of oxytocin neurones Fos-positive/ section ± SEM. The number of rats
per group is in parentheses. A: apPVN: anterior parvocellular PVN. B: vpPVN: ventral
parvocellular PVN. C: dpPVN: dorsal parvocellular PVN. D: Lpp: Lateral posterior
parvocellular PVN.
Figure 6.8: Photomicrographs illustrating Fos immunoreactivity
(arrow) in the magnocellular PVN at intromission after i.c.v
injection of vehicle (A) or MC4receptor antagonist (B) or in non-

























MC4 R antagonist/ Intromission
MC4 R antagonist / Control
Figure 6.9: Fos expression in magnocellular subdivisions in the PVN
at intromission after i.e.v. injection of MC4 receptor antagonist.
Values are mean Fos-positive/ section ± SEM. The number of rats per group is in
parentheses.
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Figure 6.10: Photomicrographs illustrating Fos immunoreactivity
in oxytocin neurones (arrow) in the magnocellular PVN at
intromission after i.c.v injection of vehicle (A) or MC4receptor































MC4 R antagonist/ Intromission
MC4 R antagonist / Control
Figure 6.11: Fos expression in magnocellular oxytocin neurones in the
PVN at intromission after i.e.v. injection of MC4 receptor antagonist.
Values are mean % oxytocin neurones Fos-positive/ section ± SEM. *P=0.015
versus vehicle-treated group, #P=0.038 versus MC4 R antagonist / Control group (One
way ANOVA, Student-Newman-Keuls method). The number of rats per group is in
parentheses.
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Figure 6.12: Photomicrographs illustrating Fos immunoreactivity
(arrow) in the SON at intromission after i.c.v injection of vehicle
(A) or MC4 receptor antagonist (B) or in control rats after i.c.v
injection of MC4 receptor antagonist (C).
























WM MC4 R antagonist/ Intromission
IS3 MC4 R antagonist / Control
Figure 6.13: Changes in Fos expression in the SON after i.e.v. injection
of MC4 receptor antagonist.
Values are means Fos-positive cells/ section ± SEM. The number of rats per group is in
parentheses. #P=0.034 versus MC4 R antagonist / Control group (One way ANOVA,
Student-Newman-Keuls method).
Figure 6.14: Photomicrographs illustrating Fos immunoreactivity in
oxytocin neurones (arrow) in the SON at intromission after i.c.v
injection of vehicle (A) or MC4 receptor antagonist (B) or in control
rats after i.c.v injection of MC4 receptor antagonist (C).
OC: Optic chiasm. Scale bar: 100pm.
Vehicle/ Intromission
MC4 R antagonist/ Intromission
MC4 R antagonist / Control
Figure 6.15: Fos expression in oxytocin neurones in the SON at
intromission after i.c.v injection of MC4 receptor antagonist.
Values are mean % oxytocin neurones Fos-positive/ section ± SEM. *P=0.014
versus vehicle-treated group (One way ANOVA, Dunn's Method), #P=0.014 versus
MC4 R antagonist / Control group (One way ANOVA, Student-Newman-Keuls method). The
number of rats per group is in parentheses.
dpPVN LppPVN
Figure 6.6: Photomicrographs illustrating Fos in oxytocin neurones
(arrow) in the dorsal parvocellular PVN (dpPVN; A, C, E) and in the
lateral posterior parvocellular PVN (LppPVN; B, D, F) at intromission
after i.c.v injection of vehicle (A, B) or i.c.v injection of MC4 receptor
antagonist (C, D) or in control rats after i.c.v injection of MC4 receptor
antagonist (E, F).
3V: Third ventricle. Scale bar: lOOpm.
□ Vehicle/ Intromission
!■ MC4 R antagonist/ Intromission
MC4 R antagonist / Control
Figure 6.17: Fos expression at intromission in the arcuate
nucleus after i.c.v injection of MC4 receptor antagonist.
Values are means ± SEM. The number of rats per group is in parentheses.
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6.5. Discussion:
The present study investigated whether blocking the central effects of a-MSH
mediated by MC4 receptors would attenuate the Fos expression in oxytocin neurones
induced at intromission. The data indicate that i.e.v. MC4 receptor antagonist injection
specifically reduced Fos expression in magnocellular oxytocin neurones, but had no
effect on the parvocellular oxytocin neurones. This study highlights the controversial
role of MC4 receptors in the regulation of male sexual behaviour, and provides evidence
of an interaction between a-MSH and the magnocellular oxytocin system during male
sexual behaviour. Finally, the lack of effect ofMC4 receptor antagonist on the neuronal
activity in the arcuate nucleus during sexual behaviour will be discussed.
Methodology and experimental issues:
A few rats injected with MC4 receptor antagonist did not mate within the 15 min
period of behavioural recording; this created a third experimental group of rats. This was
not expected, as the dose of MC4 receptor antagonist used was small and not previously
reported to block mating behaviours. Splitting the MC4 receptor antagonist -treated rats
in two groups (i.e.: non-mating and intromission), reduced the number of rats in the
MC4 receptor antagonist/ intromission group. Consequently, the statistical comparisons
between the three groups were limited and inconclusive for some brain areas. However,
the MC4 receptor antagonist/ control group gave precious information about the effect
of the drug itself on the Fos expression. In all subdivisions of the PVN, in the SON, Fos
expression in the control group was lower than in the MC4 receptor antagonist/
intromission group. Thus, the MC4 receptor antagonist injection did not induce Fos; and
the Fos expression observed was linked to intromission.
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Are MC4 receptors involved in the modulation ofmale sexual behaviour?
In the present study, we found that i.c.v - injection of MC4 receptor antagonist
delays mating. Indeed, the rats injected with the antagonist took more time to mate than
the vehicle -injected rats, the mounting and intromission latencies increased, and even
three rats did not mate within the observation period. These results support the
involvement of the MC4 receptors in the mediation of sexual behaviour and are in line
with previous findings:
Martin et al. (2002) investigated the erectogenic role of the MC4 receptor by
studying changes in intracavernosal pressure (ICP) during penile erection 'ex copula'
(out of the context of copulation). They tested the effect of systemic and central
injections of the MC4 receptor agonist THIQ, and observed that THIQ increased ICP
and the number of penile erections. They suggested that the activation of MC4 receptors
was sufficient for pro-erectile activity. Studies in mice showed that i.v. injection of
THIQ enhanced penile erection initiated by stimulation of the cavernous nerve in wild
type but not in MC4 receptor knock -out mice (Van der Ploeg et al., 2002). They also
reported that i.v. -injection of THIQ reduced mounting and intromission latencies.
These results suggest that MC4 receptors participate in the modulation of the erectile
activity and thus in the regulation of sexual behaviour. However, these results conflict
with other finding in which MC4 receptors were excluded from the regulation of sexual
activity. Vergoni (1998) reported that in rats, i.c.v. -injection of a MC4 receptor
antagonist (HS014), could block the yawning-stretching reflex and the grooming
behaviour induced by a-MSH; but failed to block penile erection induced by a-MSH
(Vergoni 1998, Argiolas et al., 2000). Even if stretching, yawning and grooming
behaviours have often been associated with penile erection, they concluded that MC4
receptors were mediating stretching, yawning and grooming behaviours but that, in
contrast, the penile erection was mediated by another MC receptor type. They suggested
that MC3 receptors were likely to be the main MC receptors involved in the regulation
of penile erection, as MC 3 receptors are located in brain areas that modulate sexual
behaviours including the hypothalamus (Roselli-Rehfuss et al., 1993).
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The interpretation of the results from previous studies is difficult: most of the
MC4 receptor antagonists or agonists that have been used (e.g.: HS014, THIQ), bind to
MC3 receptors as well. Indeed, although THIQ is more selective for MC4 receptors over
MC3 receptors by -3000 fold, HS014 selectivity for MC4 receptors over MC3 receptors
is only modestly stronger (~ 17 fold) (Schioth et al., 1998; Martin et al., 2002 Van der
Ploeg et al., 2002). As the doses of drugs used in these studies are large (range from 5 to
20p,g/rat), it is likely that they also have effects on the MC3 receptors. Thus, no
definitive conclusion refuting the involvement of one type of MC receptor in the
regulation of male sexual behaviour should have been made.
Are two independent a-MSH-related pathways involved in the regulation ofmale
sexual behaviour?
MC3 and MC4 receptors are the two types of MC receptors present in the brain,
and therefore the only types of MC receptors that can mediate central effects of a-MSH.
No studies have directly demonstrated the role of MC3 receptors in male sexual
behaviour. It has been speculated that MC3 receptors could mediate sexual behaviour
because some studies refuted the involvement of MC4 receptors (Vergoni 1998,
Argiolas et al., 2000). But growing evidence, as well as the present study, demonstrates
that MC4 receptors are part of the mediation of the sexual behaviour.
Perhaps these discrepancies cannot be reconciled, and trying to distinguish whicli
one of the two MC receptors is involved is a mistake. Involvement of both MC3 and
MC4 receptors in the mediation of male sexual behaviour is plausible. Martin and
colleagues (2002) suggested that the induction of penile erection by a-MSH could
require activation of both MC3 and MC4 receptors. Indeed, both MC3 and MC4
receptors could be activated during sexual behaviour: a-MSH could activate two
independent pathways, one mediated by MC3 receptors and the other one mediated by
MC4 receptors, whose activations would lead to increased erectile activity and enhanced
sexual behaviour, and each pathway could be sufficient to facilitate and enhance sexual
activity as shown for the MC4 receptor-related pathway. The MC4 receptor-related
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pathway may interact with the oxytocin system while the MC3 receptor-related pathway
may involve different independent systems other than oxytocin system. This suggestion
is supported by the study by Vemulapalli et al., (2001), in which SHU 9119, a
nonselective MC3 and MC4 receptor antagonist, abolished the increase in ICP induced
by Melanotan-II (melanocortin receptor agonist) in anaesthetized rabbits.
Whether this suggestion is correct needs to be investigated. Testing the effects of true
selective agonist or antagonist towards either MC4 or MC3 receptors on sexual activity
could clarify the discrepancies observed.
a-MSH and oxytocin interact to drive male sexual behaviour:
We found that injection of a MC4 receptor antagonist did not affect Fos
expression in parvocellular oxytocin neurones at intromission but significantly reduced
Fos expression in magnocellular oxytocin neurones. It is unlikely that the attenuation of
Fos expression in the magnocellular oxytocin neurones in MC4R antagonist -injected
mated rats is an indirect result from the disruption of the mating, as it would had been
expected to see the same effect on the parvocellular oxytocin neurones.
Nonetheless, these results conflict with the study by Mizusawa et al. (2002), who
reported that central administration of a-MSH induced penile erections in anaesthetized
rats but that these effects were not blocked by a central injection of the oxytocin
antagonist CAP.
However, Martin et al. (2002) mentioned the importance of oxytocin pathways in the
modulation of penile erection mediated by MC4 receptors in 'ex copula' studies. They
found that central administration of another oxytocin receptor antagonist (L-368899)
blocked penile erections induced by MC4 receptor agonist THIQ. Therefore, these
results illustrate the possibility that some of the central effects of a-MSH involved in the
regulation of male sexual behaviour and mediated via MC4 receptors could be
modulated by magnocellular oxytocin neurones. Thus, activation of magnocellular
oxytocin neurones by a-MSH would then induce changes in sexual behaviour.
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a-MSH and magnocellular vasopressin neurones at intromission:
In the SON, i.c.v injection of the MC4 receptor antagonist had no effect on the
overall Fos expression induced at intromission. However, double immunocytochemistry
for Fos and oxytocin showed that i.c.v. injection of MC4R antagonist attenuated the Fos
expression in oxytocin neurones at intromission. These results could suggest that Fos
expression in magnocellular vasopressin neurones was increased at intromission in
MC4R antagonist -injected rats. It is unlikely that the injection of MC4R antagonist
itself induced Fos expression in vasopressin neurones as the level of Fos expression in
MC4R antagonist rats that did not mate was significantly lower than for rats that did
mate (Fig 6.13; P=0.034). The increase in Fos expression in magnocellular vasopressin
neurones could be related to intromission. However, since vasopressin has strong
vasoconstrictor effects, it is difficult to distinguish whether the activation seen in
vasopressin neurones is correlated to vascular events indirectly related to the behaviour,
or whether the activation is associated with sexual behaviour itself.
This also leads to the discussion of whether a-MSH may also modulate vasopressin
neurones activity, i.c.v injection of a-MSH induces Fos expression in vasopressin
neurones in the SON and in the PVN (Abdel-Malek, 2001; Starowicz eta/, 2003; Adan et al,
1997). Sabatier et al. (2003) showed that i.c.v MC4R agonist had no effect on the firing
rate of vasopressin neurones, and thus on vasopressin secretion. They also reported that
neither MC4R agonist nor a-MSH had any effect on [Ca2+]i in vasopressin neurones in
vitro. These results could suggest that a-MSH modulates vasopressin neural activity via
MC3R rather than MC4R; however, no evidence so far has shown MC3R localized in
the SON and PVN. Taken together, these results suggest that the increase in Fos
expression in vasopressin neurones seen after i.c.v injection of a-MSH is likely to be an
indirect effect.
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a-MSH and the arcuate nucleus at intromission:
In the arcuate nucleus, i.c.v injection of the MC4 receptor antagonist had no
effect on Fos expression induced at intromission. However, the Fos expression in non-
mated rats injected with MC4 receptor antagonist was as large as the Fos expression
induced at intromission. It is difficult to distinguish whether this Fos expression was
induced by the injection of the drug, or whether this Fos expression is the basal level of
Fos expression in normal conditions. Therefore, the activation of the arcuate nucleus
during intromission should be discussed. In Chapter 4, 30 ± 2 cells were Fos-positive in
the arcuate nucleus from mating rats, significantly higher than in the non-mating rats. In
the present study, the two mating rats groups showed between 28 and 33 cells Fos-
positive/ section. The level of Fos expression in the arcuate nucleus at intromission
observed in the present study coincides with our previous results. In that case, it could be
said that the injection may have induced the increase of Fos expression in the non-
mating rats. However, it is difficult to determinate whether the antagonist itself or the
vehicle, in which the antagonist has been dissolved, induced Fos expression. The MC4
receptor antagonist used has been prepared in 50% saline / 50% polyethylene glycol/
ethanol solution (as described in section 6.2.4.1). In our laboratory Dr Louise Johnstone
have noticed large levels of Fos expression in the arcuate nucleus in rats injected with a
vehicle solution containing 50% saline / 50% polyethylene glycol/ ethanol. She reported
that modifying the vehicle solution to 25% polyethylene glycol/ ethanol / 75% saline,
significantly reduced the level of Fos expression in the arcuate nucleus (data not
published, personal communication). Thus, the large Fos expression observed in the
arcuate nucleus in MC4 receptor antagonist/ non-mating rats may have been induced by
the vehicle rather than by the antagonist itself. Obviously, this suggestion needs further
experimental investigations to be validated or refuted.
Numerous findings still need to be reconciled to better understand the regulatory
mechanisms of male sexual behaviour in which a-MSH and oxytocin are involved. In
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the present study, we have given further evidence that MC4 receptors are involved in the
regulation of sexual activity, and we have demonstrated that a-MSH and oxytocin
interact to drive male sexual behaviour. As hypothesized in the previous chapter,
magnocellular oxytocin neurones activated by a-MSH via MC4 receptors, could release
oxytocin. Thus, this central (dendritic) release of oxytocin could induce changes in the
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The present study aimed to investigate a putative interaction between oxytocin
and a-MSH during male sexual behaviour to lead to a better understanding of how these
two peptides facilitate copulation, and in particular, to establish whether one mediates
the central effects of the other. The following sections will summarize the main
conclusions of the experimental studies and critically review their interpretation.
Consequently, a new hypothesis, as well as suggestions for its investigation, will be
proposed.
• Oxytocin and a-MSH characteristics during copulation:
During male sexual behaviour, oxytocin is secreted into the general circulation
especially during the consummatory phase; and centrally, oxytocin neuronal activity is
increased. Both parvocellular and magnocellular oxytocin neurones are activated during
male sexual behaviour (Chapters 3 & 4). Although, these findings are supported by
numerous studies that have reported an increase in oxytocin secretion, and an increase in
neuronal activity of parvocellular oxytocin neurones in all subdivisions of the PVN, this
is the first description of the activation of magnocellular oxytocin neurones in both the
PVN and the SON at intromission. This major finding highlights the underestimated role
of the magnocellular neurones in the central regulation of sexual behaviour, or even of
any behaviour.
In parallel to the study of the oxytocin system during copulation, changes in a-MSH
secretion and neuronal activity were investigated. The plasma concentration of a-MSH
was measured before, during and after copulation, and the activity of a-MSH -
containing neurones was studied using immunocytochemistry for Fos. We found that,
during male sexual behaviour, a-MSH is secreted into the blood with a large increase at
intromission, and evidence suggests that a-MSH -containing neurones in the arcuate
nucleus are also activated. These findings demonstrate that both central and peripheral
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a-MSH might play a role in the regulation of male sexual behaviour. Centrally,
modulatory effects of a-MSH on male sexual behaviour are likely to be mediated via
MC4 receptors, as central injection of a MC4 receptor antagonist delayed the onset of
copulation (Chapter 6). Thus, oxytocin and a-MSH not only induce similar effects when
injected centrally, they are both secreted peripherally during copulation, and both
oxytocin neurones and a-MSH -containing neurones are activated at intromission.
These similarities reinforced the initial hypothesis that oxytocin and a-MSH interact to
regulate male sexual behaviour, and that oxytocin could mediate the central effects of a-
MSH or vice versa.
• Peripheral or central interaction?
Sexual behaviour, like any complex behaviour, depends upon the modulation of
many physiological systems, which are orchestrated at both central and peripheral levels.
As central and systemic oxytocin and a-MSH are involved in the regulation of male
sexual behaviour, the two peptides could interact peripherally and/ or centrally.
Oxytocin might modulate the a-MSH secretion or alternatively a-MSH might modulate
oxytocin secretion. We firstly hypothesized that central and peripheral oxytocin
modulate a-MSH secretion during copulation, but, as reported in chapter 3, systemic or
central oxytocin had no effect on the peripheral secretion of a-MSH during copulation,
as a central injection of oxytocin or a systemic injection of oxytocin antagonist had no
effect on the a-MSH plasma concentration. Therefore, the alternative was tested: that
central a-MSH modulates oxytocin systemic secretion and central release during
copulation.
Previous studies have reported that MC4 receptor mRNA is expressed in the
SON and in the PVN, and that central injection of a-MSH stimulates neuronal activity
in the SON and in the PVN. It has thus been assumed that a-MSH has excitatory effects
on oxytocin neurones. It was therefore surprising that, as shown in chapter 3, central a-
MSH did not stimulate systemic secretion of oxytocin as expected, but reduced it.
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Investigating these discrepancies confirmed, that while a-MSH modulates oxytocin
neuronal activity (as a-MSH induces Fos expression in oxytocin neurones), it does not
stimulate peripheral secretion of oxytocin (chapter 5). These findings lead to two main
conclusions: Firstly, Fos is a marker of neuronal activation rather than neuronal
excitation: although the presence of Fos is, in some cases, associated with an excitation
of the neurone, the presence of Fos is independent of the electrical activity, and so is
independent of the secretion from the axon terminal. The second conclusion is that the
interaction between oxytocin and a-MSH is central rather than peripheral: central a-
MSH might regulate central release of oxytocin as it modulates oxytocin neuronal
activity but it has no effect on (or inhibits) oxytocin systemic secretion.
• What are the characteristics of the interaction between oxytocin and a-MSH?
The modulation of oxytocin neurones by a-MSH has three features:
- This modulation is direct, and does not involve any other populations of
neurones. In chapter 5, infusion of a-MSH onto the SON by retrodialysis induced a
widespread distribution of Fos in the SON neurones.
- This modulation is specific to the type of oxytocin neurone. a-MSH modulates
selectively magnocellular oxytocin neurones rather than parvocellular oxytocin
neurones, as central injection of a-MSH has little effect on oxytocin parvocellular
neuronal activity but strikingly increases the neuronal activity of magnocellular oxytocin
neurones in both the SON and PVN in conscious rats (Chapter 5).
- This modulation occurs during male sexual behaviour. In chapter 6, central a-
MSH selectively modulates the oxytocin magnocellular neurones via the MC4 receptors,
as central injection of MC4 receptor antagonist selectively attenuated magnocellular
oxytocin neuronal activity in the SON and in the PVN at intromission while delaying the
onset of copulation.
123
General Discussion Chapter 7
These results, taken together, demonstrate that, during male sexual behaviour,
central oxytocin and a-MSH interact to drive male sexual behaviour. a-MSH centrally
released during sexual behaviour, stimulates magnocellular oxytocin neurones directly
via MC4 receptors without influencing the parvocellular oxytocin neurones. This is an
exciting conclusion as it not only confirms our initial hypothesis that a-MSH and
oxytocin interact during male sexual behaviour, but it also highlights the underestimated
role of the magnocellular neurones in the central regulation of sexual behaviour and
probably of any behaviour. If the only role of magnocellular oxytocin neurones was the
secretion of oxytocin into the systemic circulation, why would a-MSH modulate
magnocellular oxytocin neuronal activity without stimulating oxytocin secretion from
the axon terminals? As discussed in chapter 5, oxytocin can be released from the
dendrites of the magnocellular neurones. Therefore, magnocellular oxytocin neurones
could intervene in the central regulation of the male sexual behaviour via the dendritic
release of oxytocin stimulated by a-MSH.
However, a few points in the present study need to be clarified or require further
investigations:
Firstly, the activation of a-MSH- containing neurones in the arcuate nucleus or
the dorsomedial hypothalamus during male sexual behaviour has not been directly
proved, nor has it been shown that a-MSH is released centrally. Nonetheless, strong
evidence was given supporting that a-MSH -containing neurones are activated at
intromission in the arcuate nucleus.
Secondly, the role of systemic oxytocin and a-MSH has not been clarified.
Although, oxytocin and a-MSH are secreted into the general circulation during male
sexual behaviour, with maximal secretion during the consummatory phase, the exact role
of peripheral oxytocin and a-MSH and their physiological consequences remain unclear.
Once secreted, oxytocin and a-MSH could act on distant targets directly involved in the
male sexual behaviour (oxytocin receptors have been found in the testis and in the
prostate, and MC4 receptors have been located in the penis) but could also act on other
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physiological systems, whose activity need to be adapted to enable the sexual behaviour
to occur.
Finally, a degree of uncertainty exists: direct evidence that a-MSH stimulates
dendritic release of oxytocin from the magnocellular neurones during male sexual
behaviour has not been given. However, previous findings support this postulation:
- Sabatier et al. (2003), reported that a-MSH can induce an increase in
intracellular calcium concentration, as infusion of a-MSH onto isolated supraoptic
neurones induced a transient increase in [Ca2+]i. They suggested that a-MSH induced a
release of calcium from intracellular stores rather than via an entry of Ca2+ through
voltage- gated channels, as even in absence of extracellular calcium, a-MSH still
induced an increase in [Ca2+]i. in supraoptic neurones. They also reported that a-MSH
was acting on oxytocin neurones via MC4 receptors, as the effects of a-MSH on [Ca2+]i
were blocked by a MC4 receptor antagonist.
- Ludwig et al. (2002), reported that changes in [Ca2+]i trigger dendritic release
of oxytocin and this dendritic release is independent from the secretion of oxytocin from
the axon terminals (Ludwig, 1998).
-Sabatier et al. (2003), showed that a-MSH stimulates, in vitro, the dendritic
release of oxytocin in isolated supraoptic nuclei, and that the effect of a-MSH can be
blocked by an MC4 receptor antagonist. They also reported that the stimulatory effect of
a-MSH on dendritic release of oxytocin was not blocked by a lower concentration of
extracellular calcium, confirming that the stimulation of oxytocin dendritic release by a-
MSH is induced by changes in [Ca2+]i caused by mobilization of calcium from
intracellular store rather than via depolarization.
Thus, a-MSH can stimulate the release of oxytocin from the dendrites of
magnocellular neurones in vitro, supporting the hypothesis that a-MSH could have the
same effect in vivo during male sexual behaviour.
In conclusion, from the present findings, a new hypothesis can be proposed:
During male sexual behaviour, a-MSH released centrally stimulates, via MC4 receptors,
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the dendritic release of oxytocin from magnocellular neurones without influencing the
release of oxytocin from the axon terminals of either magnocellular or parvocellular
oxytocin neurones. Once released oxytocin modulates other neuronal systems to enhance
male sexual behaviour. Thus, some of the central effects of a-MSH in the regulation of
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Fiqure7. 2: Stimulation of oxytocin dendritic release from magnocellular oxytocin
neurones by a-MSH during male sexual behaviour (Newhypothesis)
Once centrally released, a-MSH acts via MC4R to activate the dendritic release of oxytocin by
increasing intracellular Ca2+ concentration. Oxytocin then diffuse to distant areas where
oxytocin receptors are located to induce changes in the behaviours.
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Further studies:
The present study was a starting point in the investigation of the interaction
between oxytocin and a-MSH during male sexual behaviour. The new hypothesis that
some of the central effects of a-MSH are mediated via oxytocin released from the
dendrites ofmagnocellular neurones will require further investigation.
New experiments would have to be designed to be able to answer the main questions
raised by the new hypothesis, and to test whether oxytocin released from the dendrites
plays an important role in the regulation of male sexual behaviour. However, it is
necessary to keep in mind that oxytocin knockout mice, which both lack of oxytocin,
successfully reproduce and mate. This suggests that although oxytocin is important to
facilitate the behaviour, oxytocin itself is not necessary to induce the behaviour; thus,
blocking oxytocin released from the dendrites to expect to block the behaviour might be
an inappropriate approach to prove the role dendritically released oxytocin.
1. Is oxytocin dendritically released during male sexual behaviour?
There is evidence of central release of oxytocin during copulation, but no studies
have yet investigated whether some of this central oxytocin comes from dendrites of
magnocellular neurones. This could be studied by measuring the release of oxytocin
from magnocellular neurones during male sexual behaviour. Using a microdialysis probe
placed onto the SON, samples of extracellular fluid would be collected before, during
and after copulation. These samples would be then assayed for oxytocin concentration.
This experiment could be extended to the PVN, keeping in mind that the release of
oxytocin could reflect the release of oxytocin from axon terminals of parvocellular
neurones.
2. Does a-MSH trigger dendritic release of oxytocin during male sexual
behaviour?
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Using a similar experimental design, rats could be centrally injected with a MC4
receptor antagonist or vehicle before being placed with a receptive female. Dialysates
would be then collected via the probe throughout the sexual behaviours, and assayed for
oxytocin concentration. We would expect to see an increase in oxytocin concentration in
the copulating control rats, reflecting the dendritic release of oxytocin; and no significant
changes or an attenuated response in MC4 receptor antagonist -injected rats. Another
possibility could be to infuse the antagonist directly onto the SON via the microdialysis
probe. To minimize technical issues, the effect of a-MSH on dendritic release could be
firstly tested in conscious rats but without mating (i.e.: Infusions of a-MSH or aCSF
onto the SON and measure oxytocin concentration in dialysates).
3. What is the role of dendritically released oxytocin in male sexual
behaviour?
Investigating the role of oxytocin released from the dendrites will require
overcoming the problem that magnocellular oxytocin neurones are also involved in the
peripheral regulation of male sexual behaviour by the systemic secretion of oxytocin.
The dendritic release from magnocellular oxytocin neurones from both the SON and the
PVN will have to be selectively blocked without influencing the systemic secretion of
oxytocin, which also plays a role in the behaviour and when blocked, would interfere
with the behavioral process. Thus, to be able to study the behavioral changes induced by
a lack of oxytocin released from the dendrites, experiments should be selective of the
magnocellular neurones without interfering with the parvocellular neurones and be
selective of the oxytocin release from the dendrites without disturbing the oxytocin
secretion from the axon terminals.
For now, it is difficult to obtain an adequate experimental design, but the development
of research on the difference in exocytosis mechanisms at the dendrites and at the axon
terminals should produce new tools for investigating selectively the release from the
dendrites. Hopefully, understanding what these differences are will allow to selectively
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block the exocytosis mechanisms at the dendrites without interfering with the axonal
secretion.
4. When does the interaction between a-MSH and magnocellular oxytocin
neurones occur during male sexual behaviour?
Investigating when the interaction occurs will give precious information about
the role of oxytocin released from the dendrites in the regulation of male sexual
behavior. If a-MSH stimulates the release of oxytocin at the beginning of the sexual
process, during or at the result of the sexual motivation phase, this could indicate that the
release oxytocin facilitates the establishment of the following consummatory behaviour;
whereas if a-MSH stimulates oxytocin release during the second phase, the role of
oxytocin could be to maintain the behaviour. This could be tested by measuring the
concentration of a-MSH and oxytocin in extracellular fluid in the SON and in the PVN,
in parallel with a precise recording of the behaviour.
5. How does a-MSH stimulate the dendritic release of oxytocin while at the
same time, inhibiting the electrical activity of the same magnocellular neurones?
The cellular mechanisms of the activation of the dendritic release of oxytocin
and the inhibition of the electrical activity by a-MSH will have to be clarified.
It could be possible that the increase in [Ca2+]i induced by a-MSH, could activate, in
parallel to the release of oxytocin from the dendrites, some Ca2+-dependent K+ -
channels, whose activation leads to a hyperpolarisation and so to the inhibition of the
electrical activity.
Another possibility is that the increase in [Ca2+]i also stimulate the release of
endogenous cannabinoids from the phospholipid membrane (Wilson & Nicoll, 2001).
Endogenous cannabinoids could then act on the pre-synaptic terminals to stimulate the
liberation of GABA or to inhibit the liberation of glutamate, which will lead to the
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electrical inhibition of the oxytocin neurone. Studies have reported that dendritically
released oxytocin stimulates the release of endogenous cannabinoids which can inhibits
the glutamate release from pre-synaptic terminals (Hirasawa et al., 2004).
How does dendritic release ofoxytocin influence male sexual behaviour or indeed
any behaviour?
Answering this question relies upon a new concept of neuronal communication:
The diffusion of neuromodulators from their sites of release to distant sites of action
within the brain. In our example, oxytocin once secreted from the dendrites could act
locally, or diffuse unselectively to distant brain areas where it could interact with any
neuronal populations that express the oxytocin receptor. The mechanisms of diffusion of
oxytocin itself would be not orientated towards a brain area or neuronal population; but
the pattern of distribution of oxytocin receptors in some areas and the presence of
oxytocin receptors on some neuronal populations that would determine the selectivity of
action. Once bound to its receptors, oxytocin might induce a cascade of intracellular
events leading to a modulation of the neuronal activity. The primed neurones would be
then prepared to be activated (excitated or inhibited) by the subsequent stimuli.
Consequently, this increase in responsiveness would facilitate the neuronal
communication and therefore enhances behavioral processes.
For now, it is difficult to demonstrate how oxytocin, or neuromodulators in
general, can diffuse within the brain; but as already mentioned in chapter 5, there is
evidence supporting this concept. These include, for instance, the mismatch between the
distribution of oxytocin receptors and the terminals endings of oxytocin fibres; the fact
that in the SON, oxytocin is predominantly located within neurosecretory granules in the
dendrites rather than in the axons; and especially the fact that, when injected centrally,
without reproducing any spatio-temporal pattern of any endogenous stimulus, oxytocin
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(or peptides in general) induces an organized behavioral response rather than a
disorientated and random response. Investigating the diffusion mechanisms will require
the possibility to switch on demand and selectively the dendritic release of oxytocin, and
measure precisely the quantity of oxytocin released in selected brain areas (where the
density of oxytocin receptors is high, for instance), or be able to selectively tag the
oxytocin release from the dendrites at a precise time and visualize the distribution of the
tagged protein within the brain.
The present study not only gives precious information about how two of the most
potent erectogenic peptides interact to drive male sexual behaviour, it also gives
persuasive evidence for an important role of the magnocellular oxytocin neurones in the
central regulation of behaviours via dendritic release of oxytocin. These findings not
only open new areas of research for a better understanding of male sexual behaviour
with a hope of obtaining results that will lead to therapeutic schemes; they are also
evidence for a new concept in neuronal communication, whose investigation will lead to
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Behavioral terms and parameters definitions
Terms:
Pre-copulatory, appetitive or non-consummatory behaviours: behaviours reflecting
rat's sexual motivation (sniffing, vocalizations, penile erection).
Motivation: search for sexual contact.
Arousal: motivational state during which rat seeks sexual contact.
Copulatory, consummatory behaviours: behaviours reflecting rat's sexual performance
(penile erection, mounts, intromission, ejaculation).
Performance: ability to complete copulation.
Penile erection: Penile erection that occurs in the context of copulation, results from two
aspects: the rat being sexually aroused and the rat having the physical abilities to have an
erection. Therefore, penile erection does not just reflect sexual motivation but also sexual
performance. It is important to make a distinction with the following terms:
• Non -contact penile erection (NCE): Spontaneous erection in isolated rats, ex
copula. A male and a receptive female are kept separated in a special apparatus;
the male can see and detects cues from the female but cannot have any contact
with her. NCE is defined as being initiated by chemosensory, visual, auditory or
imaginative stimuli.
• Reflexive erection: Penile erection induced ex copula by the "erection generating
center" in the spinal cord, independently from any environmental sexual
stimulation or brain influences.
• Drugs-induced penile erection: it is not possible to distinguish whether the drug
induces penile erection by mimicking a arousal state or by directly activating
motor pathways leading to the erection.
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Parameters:
Mount latency (ML): Time (s) from the introduction of the female until the first mount.
ML reflects rat's sexual motivation.
Intromission latency (IL): Time (s) from the introduction of the female until the first
intromission.
Ejaculation latency (EL): Time (s) from the beginning of the first intromission to the
beginning of the first ejaculation.
Inter-intromission intervals (III): Time (s) from the end of one mount with
intromission until the beginning of the next.
IL, EL and III reflect rat's motivation and ability to perform.
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